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ABSTRACT
Cancer-related cachexia is a complex metabolic syndrome that involves the
unintentional loss of skeletal muscle mass that cannot be reversed by standard nutritional
intervention. Skeletal muscle mass depletion directly impacts patient survival and life
quality, and therefore treatments that preserve muscle mass and function may have
significant implications for cancer patient treatment and survival. Systemic and muscle
inflammation has been implicated in the regulation of skeletal muscle homeostasis, and the
cytokine interleukin-6 (IL-6) and muscle gp130 receptor signaling have established roles
in cancer-induced muscle wasting. Resistance exercise is a nonpharmacological treatment
that can improve physical function and metabolic health in many disease conditions, and
has proven beneficial outcomes during cancer patient treatment and survival.
Unfortunately, no studies to date have examined the effects of exercise in the cachectic
cancer patient, and significant gaps remain in our understanding of the interaction between
exercise and the systemic cachectic environment during cancer. Therefore, the purpose of
this dissertation was to determine how cancer-induced inflammation affects wasting
muscles ability to respond to eccentric contractions (ECC). We hypothesized that chronic
muscle inflammatory signaling would attenuate the anabolic response to acute ECC. In
experiment 1, we determined if muscle inflammatory signaling regulated the cachectic
muscle’s acute anabolic response to ECC. We found that muscle inflammatory signaling
regulated basal and ECC-induced protein synthesis. In experiment 2, we determined if
systemic IL-6 and muscle gp130 signaling regulated basal and ECC- induced protein
v

synthesis and mTORC1 signaling. We found that systemic IL-6 signaling regulated basal
and ECC-induced protein synthesis. In addition, muscle gp130 could regulate ECCinduced protein synthesis. In experiment 3, we determined if altering muscle inflammatory
signaling by training improved basal and ECC-induced protein synthesis and mTORC1
signaling. We found that training could improve basal and ECC-induced protein synthesis.
These findings provide initial evidence that cachectic muscle is responsive to acute
responses and training adaptations induced by exercise. Additionally, we provide evidence
for a potential interaction between muscle inflammation, protein synthesis, and oxidative
metabolism, which can be influenced by exercise during cancer cachexia.
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CHAPTER 1
INTRODUCTION
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1.1 INTRODUCTION
Cachexia, a complex metabolic syndrome that involves the unintentional loss of
bodyweight that cannot be reversed by nutritional intervention, directly impacts patient
survival and life quality (K. Fearon et al., 2011). Cachexia development does not occur
with all cancers, but is most prevalent in pancreatic, lung, colorectal, and gastrointestinal
cancers (Dodson et al., 2011). The progression of cachexia is directly associated with
cancer patient morbidity and mortality. Cancer cachexia accounts for approximately 20%
of all cancer related deaths and about 40% of deaths related to colon cancer (Bruera, 1997;
Tisdale, 2002). The prevention and treatment of cancer cachexia will have a major impact
on cancer patient survival and life quality. While cachexia results in the loss of both
skeletal muscle and adipose tissue, maintenance of skeletal muscle mass has proven to be
of importance. Given that the maintenance of skeletal muscle mass and metabolic function
are critical for health (Wolfe, 2006b), the loss of skeletal muscle mass loss is directly
associated with increased mortality.
Skeletal muscle mass depletion associated with cancer cachexia contributes to
increased patient morbidity and mortality (K. C. Fearon, 1992; Tisdale, 2009). This muscle
wasting is accompanied by the suppression of muscle protein synthesis and the activation
of muscle protein breakdown (Samuels et al., 2001; Smith & Tisdale, 1993; White, Baynes,
et al., 2011). Skeletal muscle size can be highly plastic and influenced by the dynamic
balance between the rates of protein synthesis and breakdown (Murton & Greenhaff, 2010).
While our understanding of basal protein breakdown and synthesis has dramatically
increased (Bonaldo & Sandri, 2013; Sandri, 2013; Schiaffino & Mammucari, 2011), we
have a limited understanding of how the cachectic environment affects wasting muscles
2

ability to respond to anabolic stimuli, which is clinically important in the treatment of the
cachectic cancer patient.
Protein synthesis control involves the regulation of both translational efficiency and
capacity, which can be directed by the mechanistic target of rapamycin complex 1
(mTORC1). The activation of ribosomal protein 6 protein kinase 1 (S6K1), a direct
mTORC1 downstream target, participates in cap-dependent translation and ribosomal
biogenesis (Bentzinger et al., 2013; Bentzinger et al., 2008; Kimball, Farrell, & Jefferson,
2002; Laplante & Sabatini, 2009). We have previously reported that muscle protein
synthesis and mTORC1 signaling is suppressed during the initiation of cachexia, and
further decreased during severe cachexia (Bentzinger et al., 2013; Bentzinger et al., 2008;
Kimball et al., 2002; Laplante & Sabatini, 2009; White, Baynes, et al., 2011). Muscle 5’adenosine monophosphate-activated protein kinase (AMPK), a negative regulator of
mTORC1, is activated in pre-clinical models of cancer cachexia (Hardee et al., 2016;
Puppa, Murphy, Fayad, Hand, & Carson, 2014; White, Baynes, et al., 2011; White, Puppa,
Gao, et al., 2013). Additionally, activation of AMPK and signal transducer and activator
of transcription 3 (STAT3) by IL-6 overexpression coincides with suppressed muscle
protein synthesis and mTORC1 signaling in tumor bearing mice (White, Puppa, Gao, et
al., 2013). While these studies highlight a potential role of muscle AMPK and IL-6/STAT3
signaling in the dysregulation of muscle mTORC1 signaling during cachexia, it is currently
unknown if suppressed muscle protein synthesis and mTORC1 signaling can be activated
in the present of the cachectic environment.
Resistance exercise, consisting of concentric and eccentric contractions, is a potent
stimulator of mTORC1 signaling and protein synthesis, and repeated bouts can lead to
3

muscle hypertrophy in healthy adults (Charette et al., 1991; Chesley, MacDougall,
Tarnopolsky, Atkinson, & Smith, 1992; Eliasson et al., 2006). Moreover, resistance
exercise has also been demonstrated to attenuate skeletal muscle mass loss associated with
various muscle wasting conditions (Alberga et al., 2012; Hardee, Porter, Sidossis, et al.,
2014; Sharif et al., 2011). Eccentric contractions (ECC) induced by high-frequency
electrical stimulation (HFES) have been used to examine signaling associated with muscle
hypertrophy (Baar & Esser, 1999; Y. W. Chen et al., 2002; Nader & Esser, 2001;
Witkowski, Lovering, & Spangenburg, 2010).

A single bout of ECC can increase

mTORC1-dependent signaling related to translational efficiency and ribosomal biogenesis
(Jacobs et al., 2013; Nader & Esser, 2001; O'Neil, Duffy, Frey, & Hornberger, 2009; West
et al., 2016), and multiple bouts can induce muscle and myofiber growth (Baar & Esser,
1999; Hardee et al., 2016). Related to cancer cachexia, initial evidence suggests skeletal
muscle can initiate growth in response to increased loading by synergist ablation or ECC
in tumor-bearing mice (al-Majid & McCarthy, 2001; Hardee et al., 2016; Norton, Lowry,
& Brennan, 1979; Otis, Lees, & Williams, 2007). Repeated ECC bouts started at the time
of C26 tumor implantation can prevent mouse extensor digitorum longus (EDL) muscle
protein loss (al-Majid & McCarthy, 2001). While these initial findings suggest cachectic
skeletal muscle is responsive to exercise training, further is work is needed to determine if
single and repeated ECC bouts can modulate suppressed mTORC1 activity in cachectic
skeletal muscle.
Despite the clinical significance of maintaining muscle mass during cancer and the
known benefits of exercise, there is currently limited information related to exercise
training in the cachectic cancer patient. We have previously found that tumor derived
4

cachectic factors blocked the mechanical activation of protein synthesis in vitro (Gao &
Carson, 2016), but whether this occurs in vivo has not been examined. Further, the
interaction between inflammatory signaling and ECC on muscle mass regulation could
have important ramifications in future treatments. Therefore, the mechanistic basis of
acute exercise responses and training adaptations are being examined in preclinical models
of cancer cachexia. The ApcMin/+ (MIN) mouse is an established pre-clinical model of
colorectal cancer that develops a slow progression of cachexia, which allows treatments to
be performed after significant muscle wasting has occurred (Baltgalvis et al., 2010; Hardee
et al., 2016; Narsale et al., 2016; White, Baynes, et al., 2011). We previously found that
repeated bouts of ECC after the initiation of cachexia induced myofiber growth despite the
presence of a systemic cachectic environment (Hardee et al., 2016).

Interestingly,

improvements were accompanied by the suppression of muscle inflammatory signaling and
chronically activated AMPK. However, the activation of mTORC1 signaling and protein
synthesis by ECC was not investigated.
Overall Premise: Cancer cachexia is a severe wasting condition associated with
chronic inflammation and muscle atrophy. Muscle wasting is accompanied by altered
proteostasis and oxidative metabolism, which have been associated with enhanced muscle
inflammatory signaling (STAT3, NFkB). Protein breakdown activation through FOXO
signaling and protein synthesis suppression by Akt/mTORC1 are thought to be critical for
this regulation. While attenuating protein breakdown can attenuate muscle mass loss
during cachexia progression, the ability of anabolic stimuli to activate cachectic muscle
protein synthesis is not well understood. ECC can produce growth through protein
synthesis activation. However, the effect of the cancer-induced cachectic environment on
5

the anabolic response to muscle contractions has not been well described. Furthermore,
cachectic skeletal muscle’s capacity to stimulate protein synthesis and Akt/mTORC1
signaling has not been established.
The overall purpose of this study is to determine how cancer-induced
inflammation affects wasting muscles ability to respond to ECC. The central hypothesis
is that chronic muscle inflammatory signaling will attenuate the anabolic response to acute
ECC. Our working model is that muscle gp130 receptor signaling will be required for the
suppression of ECC-induced protein synthesis through altered mTORC1 activation. First,
this study will examine if systemic IL-6 and muscle inflammatory signaling regulate
cachectic muscle’s acute anabolic response to ECC. Next, this study will examine if
systemic IL-6 and muscle gp130 signaling independent of the cachectic environment can
regulate basal and ECC-induced protein synthesis through mTORC1 signaling. Lastly, this
study will examine if altering muscle inflammatory signaling by training improves the
acute anabolic response to ECC. The MIN mouse, an established preclinical model of
colorectal cancer that develops cachexia, will be used to examine the anabolic response to
acute ECC during cancer cachexia. Plasma cytokine levels and muscle inflammatory
signaling will be manipulated using non-pharmacological (exercise), pharmacological
(systemic inhibitors), molecular (plasmid electroporation), and genetic (knock-out)
approaches.
Specific Aim 1 will determine if cachectic muscle inflammatory signaling
disrupts the anabolic response to a single ECC bout in MIN mice. Aim 1.1 will
determine cachectic muscle regulation of ECC-induced mechano-sensitive pathways in
MIN mice. Aim 1.2 will determine cachectic skeletal muscle regulation of ECC-induced
6

protein synthesis and mTORC1 signaling in MIN mice. Aim 1.3 will determine muscle
STAT3/NFkB regulation of ECC-induced mTORC1 signaling in MIN mice.
Specific Aim 2 will determine if IL-6 signaling through muscle gp130
independent of the cachectic environment can regulate basal and ECC-induced
protein synthesis and mTORC1 signaling. Aim 2.1 will determine if IL-6 regulates basal
and ECC-induced mTORC1 signaling and protein synthesis in B6 mice. Aim 2.2 will
determine if IL-6 regulates basal and ECC-induced mTORC1 signaling and protein
synthesis in MIN mice. Aim 2.3 will determine if IL-6 signaling through muscle gp130
regulates basal and ECC-induced protein synthesis regulation in tumor-free mice.
Specific Aim 3 will determine if training regulates ECC-induced protein
synthesis in MIN mice. Aim 3.1 will determine if ECC training alters cachectic skeletal
muscle regulation of protein synthesis and mTORC1 signaling in MIN mice. Aim 3.2 will
determine if ECC training alters cachectic skeletal muscle regulation of oxidative capacity
in MIN mice. Aim 3.3 will determine if training alters cachectic skeletal muscle regulation
of ECC-induced protein synthesis and mTORC1 signaling in MIN mice.
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Figure 1.1. Overall Working Model. The overall purpose of this study is to determine
how cancer-induced inflammation affects wasting muscles ability to respond to ECC. The
central hypothesis is that chronic muscle inflammatory signaling will attenuate the anabolic
response to acute ECC. Our working model is that muscle gp130 receptor signaling will
be required for the suppression of ECC-induced protein synthesis through altered mTORC1
activation. First, this study will examine if muscle inflammatory signaling regulates
cachectic muscle’s acute anabolic response to ECC. Next, this study will examine if
systemic IL-6 and muscle gp130 signaling can regulate basal and ECC-induced protein
synthesis and mTORC1 signaling. Lastly, this study will examine if altering muscle
inflammatory signaling by training improves the acute anabolic response to ECC. The
MIN mouse, an established preclinical model of colorectal cancer that develops cachexia,
will be used to examine the anabolic response to acute ECC during cancer cachexia.
Plasma cytokine levels and muscle inflammatory signaling will be manipulated using nonpharmacological (exercise), pharmacological (systemic inhibitors), molecular (plasmid
electroporation), and genetic (knock-out) approaches.
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CHAPTER 2
REVIEW OF LITERATURE1

1

Hardee JP, Wang X, Goldsmith EC, Koh HJ and JA Carson. Resistance Exercise Rescues
Skeletal Muscle Anabolic Resistance During Cancer Cachexia. To be submitted to Exerc
Sport Sci Rev.
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2.1 CANCER CACHEXIA
Cancer cachexia is defined as a multifactorial syndrome characterized by an
ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully
reversed by conventional nutritional support and leads to progressive functional
impairment (K. Fearon et al., 2011). Cachexia development does not occur with all
cancers, but is most prevalent in pancreatic, lung, colorectal, and gastrointestinal cancers
(Dodson et al., 2011). The progression of cachexia is directly associated with cancer
patient morbidity and mortality. Additionally, cachexia is associated with reduced physical
function and tolerance to anticancer therapy. Given that cancer cachexia accounts for
approximately 20% of all cancer related deaths and about 40% of deaths related to colon
cancer (Bruera, 1997; Tisdale, 2002). The prevention and treatment of cancer cachexia
will have a major impact on cancer patient survival and life quality.
Systemic disruption induced by cachexia include systemic inflammation, anorexia
or reduced food intake, increased energy expenditure, insulin resistance, anemia, and
hypogonadism (K. Fearon et al., 2011; Tisdale, 2010). Physical activity levels are also
reduced in cancer patients, and may contribute to systemic wasting processes (Eheman et
al., 2012; Irwin et al., 2008; Michaud et al., 2001). These systemic disruptions can promote
whole-body wasting through altered metabolism and physical function. While treatments
that impede cachexia are important to reduce morbidity and mortality in cancer patients,
there are currently no FDA approved treatments for cancer cachexia. This is in part due to
the complex nature of the disease and the severity of cachectic symptoms varying between
patients (Baracos, 2013). Significant progress has been made in our understanding of
cellular pathways regulating wasting during cancer.
10

However, many studies have

examined cachexia prevention in preclinical models, and far fewer studies have been
designed to treat the cachectic condition by initiating treatments after the development of
cachexia, which has clinical significance since many cancer patients are cachectic at the
time of diagnosis (Tisdale, 2009; Wigmore, Plester, Richardson, & Fearon, 1997). Thus,
it remains to be determined if cachexia can be prevented or reversed after significant
wasting has occurred.
Loss of skeletal muscle is a hallmark of cancer cachexia, and muscle mass loss is
directly related to increased morbidity and mortality. Given that the maintenance of
skeletal muscle mass and metabolic function are critical for health (Wolfe, 2006b),
understanding the regulation of muscle wasting is critical for the development of
preventative and therapeutic strategies for the proper treatment of cancer cachexia. Muscle
mass is regulated through an intricate balance between the rates of protein synthesis and
breakdown, termed protein turnover (Kimball et al., 2002; Schiaffino & Mammucari,
2011).

While significant progress has been made in our understanding of protein

breakdown during wasting, much less is known related to protein synthesis suppression
during cancer cachexia. It is currently unknown if the cachectic phenotype related to
disrupted protein turnover and oxidative metabolism can be modulated while the cachectic
environment is present.

2.2 MUSCLE MASS REGULATION
In healthy adults, skeletal muscle about 40% of total body weight and represents
the largest protein reservoir (Wolfe, 2006b). The maintenance of skeletal muscle mass is
critical for metabolic health and physical function (Wolfe, 2006b), and the loss of skeletal

11

muscle mass is associated with increased morbidity and mortality (Levy & Welch, 2015).
Skeletal muscle is a highly plastic tissue in which its size can be influenced by the balance
between the rates of protein synthesis and degradation, termed protein turnover (Maddocks,
Murton, & Wilcock, 2011; Murton & Greenhaff, 2010). The rates of protein synthesis and
degradation can be regulated by nutrient status/energy balance, mechanical loading, and
growth factors (Kimball et al., 2002). In general, skeletal muscle mass is maintained due
to equal rates of muscle protein synthesis and degradation. While circadian fluctuations in
the rates of protein synthesis and degradation occur, sustained alterations to either
component can lead to alterations in muscle mass (Horstman, Olde Damink, Schols, & van
Loon, 2016). Given the importance of skeletal muscle to overall health, understanding the
mechanisms regulating protein synthesis and breakdown are critically important for
improving cancer cachexia treatments.

2.3 MUSCLE PROTEIN SYNTHESIS REGULATION
2.3.1 Protein synthesis and Akt/mTORC1 signaling
Skeletal muscle protein synthesis is regulated by several factors such as nutrient
status, activity level, and inflammation. Protein kinase B (PKB, also known as Akt) and
the mechanistic target of rapamycin complex 1 (mTORC1) have established roles for the
integration of anabolic signaling initiated by growth factors, nutrients, and mechanical
loading to regulate protein synthesis (Kimball et al., 2002; Laplante & Sabatini, 2009;
Schiaffino & Mammucari, 2011). In mammals, the mTORC1 complex is composed of
four known subunits: raptor (regulatory associated protein of mTOR), PRAS40, mLST8,
and mTOR. Raptor acts as a scaffold to recruit downstream substrates such as 4EBP1 and
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ribosomal S6 kinase (p70S6K1), to the mTORC1 complex (Nojima et al., 2003; Schalm,
Fingar, Sabatini, & Blenis, 2003). Growth factors such as insulin and insulin-like growth
factor 1 (IGF1) stimulate mTORC1 signaling through the activation of Akt (Kimball et al.,
2002; Schiaffino & Mammucari, 2011). Binding of insulin/IGF1 to its respective cell
surface receptor initiates tyrosine kinase activity and phospho-inositide 3-kinase (PI3K)dependent activation of Akt T308 through phosphoinositide-dependent kinase 1 (PDK1).
The rapamycin-insensitive mTOR complex 2 (mTORC2) has also been implicated in
growth factor signaling through the phosphorylation of Akt S473 (Fayard, Tintignac,
Baudry, & Hemmings, 2005). Subsequent downstream targets of activated Akt which can
control muscle protein synthesis include tuberous sclerosis 2 (TSC2), glycogen synthase
kinase-3B (GSK3B), and proline-rich Akt substrate 40 kDa (PRAS40) (Laplante &
Sabatini, 2009; Schiaffino & Mammucari, 2011). Akt phosphorylates and inhibits GSK3B,
which leads to the activation of eukaryotic translation initiation factor 2B (eIF2B) and
protein synthesis initiation (P. Cohen & Frame, 2001; Rommel et al., 2001; Schiaffino &
Mammucari, 2011). Inactivating eIF2B stops the initiation of protein synthesis (Proud &
Denton, 1997).

In addition, Akt can indirectly activate mTORC1 through the

phosphorylation of TSC2, which relieves the inhibitory effects of TSC1/2 complex on the
Ras homologue enriched in brain (Rheb) activation of mTORC1 (Kimball et al., 2002;
Zoncu, Efeyan, & Sabatini, 2011). Mechanical signaling and amino acids can also
stimulate mTORC1 through PI3K-independent, but Rheb-dependent mechanisms.
Upstream signaling pathways implicated in the mechanical activation of mTORC1 include
phospholipase D and extracellular signal-regulated kinases 1/2 (ERK1/2) (Hornberger et
al., 2006; Miyazaki, McCarthy, Fedele, & Esser, 2011). While it has long been recognized
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that amino acids stimulate protein synthesis in skeletal muscle (Preedy & Garlick, 1986),
the precise signaling molecules or interactions responsible for this activation remained
elusive. Recently, the localization of mTORC1 to the lysosome has emerged as a critical
regulatory point in the activation of mTORC1 by amino acids (Bar-Peled & Sabatini,
2014). While mTORC1 can be found throughout the cytoplasm during amino acid
deprivation, the Ragulator-Rag complex can target mTORC1 to the lysosomal surface
where it can interact with and be activated by the small GTPase Rheb upon amino
stimulation (Sancak et al., 2010).

Regardless of the upstream activator, mTORC1

promotes protein synthesis by phosphorylating the eukaryotic initiation factor 4E (4E-BP1)
and the p70 ribosomal S6 kinase (S6K1). The hyperphosphorylation of 4E-BP1 prevents
binding to eukaryotic initiation factor 4E (eIF4E) and the formation of 4E-BP1-eIF4E
complex, resulting in the assembly of the eIF4F complex and translation initiation (Kimball
et al., 2002). In addition, S6K1 activation by mTORC1 has been implicated in capdependent translation, translation elongation, and ribosomal biogenesis (Bentzinger et al.,
2013; Bentzinger et al., 2008; Laplante & Sabatini, 2009). Collectively, these studies
highlight the unique role of Akt/mTORC1 signaling in the regulation of muscle protein
synthesis.
2.3.2 Protein Synthesis and Cancer Cachexia
While it is well established that muscle protein breakdown is activated during
wasting, whether suppressed protein synthesis regulation contributes to muscle mass loss
during cachexia is not well known (Combaret, Ralliere, Taillandier, Tanaka, & Attaix,
1999; Llovera et al., 1998). To date, only a few studies have examined muscle protein
synthesis and breakdown rates in cancer patients (Deutz et al., 2011; Dillon et al., 2012;
14

Dillon et al., 2007; Emery, Edwards, Rennie, Souhami, & Halliday, 1984; Williams et al.,
2012). Despite a lack of human studies, it has been concluded that changes in both basal
and postprandial muscle protein synthesis and breakdown rates contribute to the muscle
wasting observed in cachectic cancer patients (Horstman et al., 2016). While cancer
patients demonstrate a muscle protein synthetic response to protein ingestion (Deutz et al.,
2011; Dillon et al., 2012; Dillon et al., 2007; Horstman & Sheffield-Moore, 2015; Williams
et al., 2012), there is evidence to support that the responsiveness to protein administration
is strongly reduced during cancer cachexia (Deutz et al., 2011; Horstman & SheffieldMoore, 2015; Williams et al., 2012). Thus, this anabolic resistance to feeding attenuates
the postprandial rise in muscle protein synthesis and may contribute to the loss of muscle
mass observed in cancer cachexia. To circumvent the issues with performing tracer studies
in cachectic cancer patients, the majority of data related to muscle protein synthesis has
been collected in rodent models of cancer cachexia. Indeed, basal protein synthesis rates
are reduced in preclinical models of cancer (Smith & Tisdale, 1993). Our laboratory has
routinely demonstrated suppressed muscle protein synthesis throughout the progression of
cachexia in the MIN mouse (Narsale et al., 2016; White, Baynes, et al., 2011). During the
natural progression of cachexia, muscle protein synthesis is reduced during the initial
stages of weight loss (<5% loss) and is further suppressed with the severity of cachexia
progression (White, Baynes, et al., 2011). The suppression of muscle protein synthesis
corresponds to a reduction in muscle IGF1 expression and mTORC1 signaling, however
these alterations in mTORC1 signaling are independent of Akt (White, Baynes, et al.,
2011). Interestingly, muscle AMPK activity was not changed during the initiation of
cachexia, but was increased during late-stages of cachexia progression (White, Baynes, et
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al., 2011). While the administration of the IL-6 receptor antibody was sufficient to
attenuate muscle mass loss and AMPK activity, it did not alter the suppressed muscle
protein synthesis, mTORC1 signaling, or IGF-1 mRNA expression (White, Baynes, et al.,
2011).

In contrast to specific IL-6 receptor antibody, short-term pyrrolidine

dithiocarbamate (PDTC) treatment improved disrupted protein turnover regulation through
the activation of protein synthesis and suppression of protein breakdown (Narsale et al.,
2016). To further examine the role of systemic IL-6 on muscle protein synthesis during
cachexia, we have also examined protein synthesis regulation by IL-6 in prior to the
initiation of cachexia in pre-cachectic MIN mice.

Systemic IL-6 overexpression is

sufficient to suppress muscle protein synthesis and mTORC1 signaling in pre-cachectic
MIN mice (White, Puppa, Gao, et al., 2013). Interestingly, treadmill exercise training was
sufficient to block IL-6 suppression of mTORC1 signaling (White, Puppa, Gao, et al.,
2013).

It is currently unknown whether systemic IL-6 overexpression can reduce

Akt/mTORC1 signaling in healthy skeletal muscle independent of cancer. Long-term IL6 exposure can decrease myotube diameter and mTORC1 signaling in C2C12 cells, and
inhibition of AMPK can also relieve IL-6 inhibition of protein synthesis (White, Puppa,
Gao, et al., 2013). In the Lewis lung carcinoma (LLC) tumor model, cachexia suppressed
the phosphorylation of the mTORC1 substrates 4EBP-1 and S6RP, and this suppression
was not affected by skeletal muscle gp130 receptor loss (Puppa, Gao, Narsale, & Carson,
2014). We have also examined C2C12 myotube protein synthesis suppression by LLC
tumor-derived factors. We have found that LLC-derived media decreased basal mTORC1
activity and protein synthesis, which coincided with the activation of STAT3 and AMPK
(Gao & Carson, 2016; Puppa, Gao, et al., 2014). Interestingly, inhibition of AMPK, but
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not gp130 signaling, could restore basal protein synthesis suppression by LLC derived
factors (Gao & Carson, 2016). Collectively, these studies highlight that while IL-6/STAT3
signaling is associated with suppressed muscle protein synthesis and mTORC1 signaling,
singular inhibition inflammatory signaling pathways is not sufficient to restore basal
protein synthesis during the progression of cancer cachexia.

2.4 MUSCLE PROTEIN BREAKDOWN REGULATION
Muscle atrophy involves the reduction in size due to the coordinated loss of
proteins, cellular organelles, and cytoplasmic volume (Bonaldo & Sandri, 2013; Sandri,
2013). The ubiquitin-proteasome system and the autophagy-lysosome pathway are the two
main proteolytic systems involved in the muscle atrophy process (Sandri, 2013). Other
proteolytic systemic implicated in muscle proteostasis include calpains and caspasemediated proteolysis. Calpains are Ca2+-dependent cysteine proteases which can cleave
cytoskeletal proteins for further breakdown at the proteasome (Huang & Zhu, 2016). In
contrast, caspases (cysteine-aspartic proteases) are a family of proteolytic enzymes that are
most commonly known for their role in initiating apoptosis (Bell, Al-Khalaf, & Megeney,
2016). The following section will highlight the role of the ubiquitin-proteasome and
autophagy-lysosomal systems in protein breakdown.
2.4.1 Ubiquitin-proteasome pathway
The bulk of intracellular proteins are degraded by the ubiquitin-proteasome
pathway (Lecker, Solomon, Mitch, & Goldberg, 1999). The ubiquitin–proteasome system
includes 3 enzymes that conjugate ubiquitin to intracellular proteins that are then
recognized and degraded in the proteasome (Lecker et al., 1999; Sandri, 2013). The
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enzymatic components that link ubiquitin chains onto proteins include the E1 (Ubactivating enzyme) and E2 proteins (Ub-carrier or conjugating proteins), which prepare
ubiquitin for conjugation. E1 enzymes activate ubiquitin proteins after the cleavage of
ATP. The ubiquitin is then moved from E1 to members of the E2 enzyme class. The third
enzyme, E3 Ub-protein ligase, is a key factor in terms of the specificity of proteolysis
because specific E3 enzymes will recognize a specific protein substrate. E3 enzymes
catalyze the transfer of activated ubiquitin to the substrate until a chain of 4–5 Ub's are
attached. E3 binds to E2 and the protein substrate, inducing the transfer of ubiquitin from
E2 to the substrate. The conjugation reactions form Ub-conjugated proteins which can be
recognized by the 26S proteasome. The proteasome removes ubiquitin and degrades the
substrate protein into smaller peptides (Bonaldo & Sandri, 2013; Rajan & Mitch, 2008),
which can then be used to resynthesize new proteins.
In wasting conditions, two muscle-specific E3 Ub-conjugating enzymes, Atrogin1 (also known as MAFbx) and MuRF-1, are thought to be critical for the breakdown of
muscle proteins (Bodine, Latres, et al., 2001). Indeed, in cultured muscle cells Atrogin-1
mRNA expression correlates closely with rates of protein breakdown (Sacheck, Ohtsuka,
McLary, & Goldberg, 2004; Sandri et al., 2004; Stitt et al., 2004). We have also found that
IL-6 can modulate Atrogin-1 expression in C2C12 cells (White, Puppa, Gao, et al., 2013).
In several models of muscle wasting, Atrogin-1 and MuRF-1 gene expression are
dramatically increased and corresponds to periods of rapid muscle atrophy (Bodine, Latres,
et al., 2001). Thus, it commonly thought that these E3 mRNAs might prove useful as
biomarkers of excessive proteolysis in muscle. Two upstream transcription factors that
regulate Atrogin-1 and MuRF-1 expression have been identified, which include FOXO and
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NFkB (Sandri et al., 2004; C. L. Wu, Cornwell, Jackman, & Kandarian, 2014). These
transcription factors stimulate their expression, and evidence from both human cancer
patients and preclinical models support their involvement in atrogene transcriptional
regulation associated with muscle wasting (Cai et al., 2004; W. A. He et al., 2013; Judge
et al., 2014).
2.4.2 Lysosomal/autophagy
Autophagy plays a crucial role in the turnover of cell components during normal
homeostasis and in response to various stimuli such as cellular stress, nutrient deprivation,
and muscle contraction (Mizushima, Levine, Cuervo, & Klionsky, 2008). Indeed, there is
emerging evidence that the lysosomal-autophagy system plays a critical role during muscle
wasting conditions (Asp, Tian, Wendel, & Belury, 2010; McClung, Judge, Powers, & Yan,
2010).

Autophagy, specifically macroautophagy in skeletal muscle, is primarily

considered to be a non-selective degradation pathway, however more selective removal of
specific organelles such as mitochondria by mitophagy is becoming increasingly evident
(Bonaldo & Sandri, 2013). Unlike the ubiquitin proteasome, this is an ATP-independent
process. Several genes have been identified as autophagy-related which include LC3B,
Gabarpl1, Atg12l, PI3kIII, Ulk2, Atg4b and Beclin-1 (Sandri, 2013). Disruption in the
expression of these genes can cause deleterious effects, as deletion of Atg7, a critical gene
involved in autophagy, results in skeletal muscle atrophy, abnormal mitochondria and
disorganization of sarcomeres (Masiero et al., 2009). There is evidence to suggest that the
lysosomal/autophagy system is disrupted during cancer cachexia (Asp et al., 2010; Lecker
et al., 2004).

Moreover, while the molecular components of autophagy/lysosomal

pathways have been described, their regulation is not well known.
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2.4.3 Upstream signaling regulating protein breakdown
In addition to protein synthesis regulation, Akt can also regulate protein breakdown
processes through the phosphorylation and inhibition of the forkhead box O (FOXO)
transcription factor. Skeletal muscle expresses three FOXO family members, including
FOXO1, FOXO3 and FOXO4, with both FOXO1 and FOXO3a significantly upregulated
in cachectic muscles from LLC and C26 tumor-bearing mice (Cornwell, Mirbod, Wu,
Kandarian, & Jackman, 2014; Reed, Sandesara, Senf, & Judge, 2012). Moreover, FOXO1
is also upregulated in skeletal muscle of human cancer patients, and was recently identified
as a cachexia-associated gene (Skorokhod, Bachmann, Giese, Martignoni, & KrakowskiRoosen, 2012). Akt can phosphorylate FOXO at Thr24, Ser256, and Ser319, which
prevents nuclear entry and activation of gene expression (Latres et al., 2005). FOXO has
been shown to regulate gene expression related to the ubiquitin proteasome and lysosomalautophagy systems (Milan et al., 2015; Sandri et al., 2004). AMPK can also stimulate
protein breakdown through the regulation of FOXO signaling. AICAR has been shown to
increase the mRNA expression of Atrogin-1 and MuRF-1, and the nuclear localization of
FOXO in C2C12 myotubes (Tong, Yan, Zhu, & Du, 2009).

Additionally, AICAR

treatment increased FOXO1 and FOXO3 mRNA expression, and stimulated protein
degradation in vitro (Nakashima & Yakabe, 2007). Nonetheless, it is still unclear how
AMPK activation can lead to FOXO activation and ubiquitin proteasome protein
degradation.
mTORC1 has also been implicated in the regulation of autophagy. Activation of
mTORC1 inhibits autophagy through the phosphorylation of multiple autophagy-related
proteins that promote autophagy initiation and autophagosome nucleation. mTORC1
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inhibits the autophagy-initiating UNC-5 like autophagy activating kinase (ULK) complex
by phosphorylating complex components including autophagy related gene 13 (ATG13)
and ULK1/2 (C. H. Jung et al., 2009; C. H. Jung, Ro, Cao, Otto, & Kim, 2010).
Additionally, mTORC1 can regulate lysosomal and autophagy gene expression by
modulating localization of the transcription factor EB (TFEB), as phosphorylation of S142
and S211 results in cytoplasmic sequestration of TFEB, thereby inhibiting transcriptional
activity (Roczniak-Ferguson et al., 2012).

Thus, it appears modulating suppressed

Akt/mTORC1 activity can have significant implications on protein turnover regulation
during cancer cachexia.
2.4.4 Protein Breakdown and Cancer Cachexia
It is well established that protein breakdown is elevated during cancer cachexia,
which results from both the activation of the ubiquitin proteasome and lysosomalautophagy systems. We have found strong associations between systemic IL-6, myofiber
cross-sectional area, and muscle Atrogin-1 mRNA expression in tumor bearing mice
(Baltgalvis et al., 2009). More specifically, systemic IL-6 overexpression is sufficient to
decrease myofiber cross-sectional area, which is associated with the induction of Atrogin1 gene expression in MIN mice (Baltgalvis et al., 2009). Other preclinical models have
also observed increased Atrogin-1 expression during severe muscle wasting (Toledo et al.,
2016; Toledo, Penna, Busquets, Lopez-Soriano, & Argiles, 2014). Related to the natural
progression of cancer cachexia, total protein degradation was increased in mice with initial
weight loss, and was further increased throughout cachexia progression (White, Baynes, et
al., 2011). The initial activation of protein degradation corresponds to increased ATP
dependent degradation, while an increase in both ATP-dependent and –independent protein
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degradation activity occurs during severe cachexia (White, Baynes, et al., 2011). During
the initiation of cachexia muscle there was an increase in total muscle ubiquitination, E3
ligase expression, and proteasomal subunit expression, which was further increased as
cachexia severity increased. In contrast to the ubiquitin proteasome system, autophagy
related protein expression (Beclin-1, Atg7, LC3B) was not increased until late-stage
cachexia in MIN mice (>5% loss) (White, Baynes, et al., 2011). These findings highlight
differential expression related to the ubiquitin and lysosomal-autophagy systems during
the progression of cachexia. Interestingly, both of these proteolytic systems could be
attenuated with IL-6 receptor antibody treatment (Fujita et al., 1996; White, Baynes, et al.,
2011), further establishing a role for IL-6 in the regulation of muscle protein breakdown.
In addition to the MIN mouse, we and others have demonstrated enhanced ubiquitin
proteasome and lysosomal-autophagy systems in cachectic muscle of C26 and LLC tumor
bearing mice (Pin et al., 2015; Toledo et al., 2016; Toledo et al., 2014). Indeed, the
expression of a dominant negative FOXO inhibited the cachexia induction of atrogin-1,
MuRF1, cathepsin L, and/or Bnip3 gene expression, and inhibited muscle fiber atrophy in
LLC tumor bearing mice (Reed et al., 2012). Collectively, these results demonstrate that
while the proteolytic systems may be activated during different degrees of cachexia
severity in MIN mice, both systems are activated in cachectic skeletal muscle regardless of
tumor model.

2.5 MUSCLE OXIDATIVE METABOLISM
Mitochondria oxidative capacity and function are important for the maintenance of
muscle mass. The maintenance of healthy mitochondria, which can directly affect muscle
oxidative capacity, involves the coordinated processes related to biogenesis, fission, fusion,
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and mitophagy (Yan, Lira, & Greene, 2012), and the disturbance to any of these processes
can disrupt muscle metabolism and function. Mitochondrial biogenesis is required for the
maintenance of newly synthesized mitochondria. The peroxisome-proliferator gammaactivated receptor (PGC-1) family of co-activators has been described as the ‘master
regulators’ of muscle oxidative metabolism. PGC-1α regulates mitochondrial biogenesis
by nuclear translocation and activation of oxidative gene transcription (Z. Wu et al., 1999),
and is a critical regulatory step of mitochondrial biogenesis through the transcriptional
control involves mitochondrial proteins, mitochondrial transcription factor A (TFAM), and
nuclear respiratory factor-1 (NRF-1) and NRF-2 (Hood, Irrcher, Ljubicic, & Joseph, 2006;
Z. Wu et al., 1999). Emerging evidence suggest the fission and fusion of mitochondria, a
process known as mitochondrial dynamics, plays a critical role in mitochondrial function
(Ding et al., 2010). Mitochondrial fusion proteins Mitofusin-1 and -2 (Mfn1/2) promote
mitochondrial elongation and activity, whereas the mitochondrial membrane protein
fission-1 (Fis1) promotes mitochondrial fragmentation (James, Parone, Mattenberger, &
Martinou, 2003). Maintaining mitochondrial quality requires the removal of damaged
mitochondria (Yan et al., 2012), and the selective removal of damaged or dysfunctional
mitochondria is known as mitophagy. AMPK/FOXO and mTORC1 signaling have been
implicated in the control of several autophagy-lysosomal pathway components (Bonaldo
& Sandri, 2013; Sandri, 2013). For example, the transcription factor FOXO can control
the expression of autophagy-lysosomal proteins LC3 and Bnip (Bonaldo & Sandri, 2013).
Additionally, activation of AMPK induces stimulatory phosphorylation of ULK1 for
induction of autophagy, whereas mTORC1 inhibits autophagy through ULK1
phosphorylation (D. Egan, Kim, Shaw, & Guan, 2011). Thus, perturbations to any of these
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aforementioned mitochondrial quality control points could lead to the accumulation of
damaged mitochondrial, which would ultimately impair muscle oxidative capacity and
function.
2.5.1 Muscle Oxidative Metabolism During Cancer Cachexia
Skeletal muscle oxidative capacity is disrupted during the progression of cancer
cachexia (White, Baltgalvis, et al., 2011; White et al., 2012). Indeed, several aspects of
mitochondrial quality control related to biogenesis, content, fission/fusion, and dynamics
are altered during the progression of cachexia (White et al., 2012). We have found a strong
relationship between the degree of muscle wasting and the loss of muscle oxidative
capacity (White, Baltgalvis, et al., 2011). The suppression of PGC-1α precedes the loss of
mitochondrial content (mtDNA) and protein expression (Cytochrome C and COXIV)
during the progression of cachexia (White, Baltgalvis, et al., 2011; White et al., 2012). The
loss of muscle oxidative capacity parallels skeletal muscle mass atrophy and the disruption
of protein turnover (Puppa, Murphy, et al., 2014; White et al., 2012). However, systemic
IL-6 receptor inhibition in MIN mice can increase mitochondrial content, PGC-1α
expression, and mitochondrial protein expression while attenuating the progression of
cancer cachexia (White et al., 2012). Similar effects have also been observed in response
to exercise training during systemic IL-6 overexpression in MIN mice (White et al., 2012).
Reductions in PGC-1α and mitochondrial fusion proteins Mfn1 and 2 precede the loss of
mitochondria during the initial stages of cachexia, while the induction of Fis1 occurs in
late cachexia (White, Baltgalvis, et al., 2011; White et al., 2012). In contrast, mitochondrial
fission is not induced until severe cachexia (White, Baltgalvis, et al., 2011). Nonetheless,
evidence suggest that both mitochondrial fusion and fission are IL-6 sensitive processes.
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Systemic IL-6 over-expression decreases Mfn1/2 protein expression and increases Fis1
protein expression in MIN mice (White et al., 2012). Additionally, long-term IL-6
exposure to C2C12 myotubes induces Fis1 protein expression (White et al., 2012). During
the natural progression of cachexia, IL-6 receptor (IL-6r) antibody administration after the
initiation of cancer cachexia can improve disrupted fusing and fission protein expression
in MIN mice (White et al., 2012). Although we have made dramatic progress in the
understanding of the regulation of muscle oxidative metabolism during the progression of
cachexia, whether skeletal muscle retains the plasticity to improve mitochondrial quality
control, and ultimately function, after the initiation of cachexia is still unclear. Given the
ability of PGC-1α and mTORC1 signaling axes to regulate muscle oxidative capacity and
protein turnover, treatment strategies that can modulate these pathways, such as exercise
training, are of potential interest for the attenuation or reversal of skeletal muscle atrophy
occurring with cancer.
2.5.2 Muscle Oxidative Metabolism and Exercise During Cancer Cachexia
Exercise training is a potential non-pharmacological treatment to attenuate muscle
wasting with cancer, and the metabolic responses to endurance and resistance exercise are
distinct. Endurance training is associated with increased mitochondrial density, capillary
supply, and key metabolic enzymes in muscle (Holloszy & Booth, 1976). After an acute
bout of exercise PGC-1α is rapidly upregulated leading to mitochondrial-associated gene
transcription and mitochondrial biogenesis (Baar et al., 2002; Pilegaard, Saltin, & Neufer,
2003). Repeated bouts of exercise increase several mitochondrial proteins such as PGC1α, mitochondrial transcription factor A (TFAM), and nuclear respiratory factor (NRF),
leading to improved muscle oxidative capacity (J. W. Gordon, Rungi, Inagaki, & Hood,
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2001). Additionally, endurance exercise can increase Mfn1/2 and Fis1 mRNA, which
positively regulates mitochondrial function (Ding et al., 2010). The two primary protein
kinases involved in the regulation of PGC-1α in skeletal muscle are AMPK and p38γ
mitogen-activated protein kinase (p38γ MAPK) (Akimoto et al., 2005; Yan et al., 2012).
Paradoxically, AMPK activity is increased during late-stage cachexia which coincides with
the loss of PGC-1α expression and mitochondrial content (White, Baltgalvis, et al., 2011;
White, Baynes, et al., 2011). Treadmill exercise training could increase basal PGC-1α and
mitochondrial protein expression, suppress the activation of AMPK and FOXO, and reduce
autophagy related proteins (Puppa et al., 2012; White et al., 2012). Additionally, we
recently found that a single bout of concentric contractions could stimulate PGC-1α
expression in cachectic skeletal muscle (Puppa, Murphy, et al., 2014). However, despite
the contraction-induced increase of PGC-1α, there was not a corresponding induction in
downstream PGC-1α targets NRF1 and TFAM in cachectic muscle (Puppa, Murphy, et al.,
2014). These data suggest cachexia disrupts the muscle metabolic response a single bout
of concentric contractions. Whether repeated bouts of concentric contractions increase
basal PGC-1α expression and improve the suppression of mitochondrial oxidative
metabolism has yet to be examined.
Resistance exercise is associated with increased muscle mass, fiber hypertrophy,
and strength (B. Egan & Zierath, 2013). Resistance exercise consisting of ECC can induce
muscle protein synthesis through the activation of mammalian target of rapamycin complex
1 (mTORC1) and downstream substrates p70S6K and 4EBP-1 (Hornberger & Esser,
2004). In rodents, a single bout of ECC elicits a rapid and sustained activation of p70S6K
(Baar & Esser, 1999; Nader & Esser, 2001), and is sufficient to induce muscle hypertrophy
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when repeated ECC bouts are performed (Baar & Esser, 1999). In addition to its role in
mTORC1 signaling and protein synthesis, recent evidence suggests that mTORC1 can
work in concert with YY1 and PGC-1α to stimulate mitochondrial gene expression and
improve oxidative function (Cunningham et al., 2007). PGC-1α protein expression is
induced following an acute bout of resistance exercise (Ydfors et al., 2013), and improved
mitochondrial respiratory capacity and mitochondrial complex protein expression have
been observed in hypertrophic muscle following 12 wks. of resistance exercise training in
humans (Porter, Reidy, Bhattarai, Sidossis, & Rasmussen, 2015).

We also have

demonstrated that repeated ECC bouts can induce myofiber growth that is associated with
improved oxidative capacity during cachexia progression (Hardee et al., 2016), however
the effects of ECC on the regulation of mitochondrial quality control and mTORC1
signaling in cachectic muscle has not been investigated.

2.6 MUSCLE INFLAMMATORY SIGNALING
Muscle signaling pathways related to inflammation are disrupted with cachexia
progression and appear to have regulatory roles in the wasting process (K. Fearon et al.,
2011; Narsale & Carson, 2014). We and others have demonstrated the importance of
systemic IL-6 and muscle gp130/STAT3 signaling pathways in the regulation of protein
turnover during cancer cachexia (Bonetto et al., 2012; Bonetto et al., 2011; Puppa, Gao, et
al., 2014; Seto, Kandarian, & Jackman, 2015). Interestingly, many of these same pathways
are regulated by both acute and repeated bouts of exercise (B. Egan & Zierath, 2013). The
interaction between the systemic cachectic environment, muscle inflammatory signaling,
and muscle contraction has not been well established.
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2.6.1 Interleukin-6 / glycoprotein 130 receptor signaling
Interleukin 6 (IL-6) is a pleiotropic cytokine expressed throughout the body. While
IL-6 is a 26 kDa protein mainly secreted from T cells and macrophages to produce an
immune response, it can be secreted by a variety of cell types including muscle. Depending
on the context and duration of exposure, IL-6 has been shown to have both proinflammatory and anti-inflammatory properties.

IL-6 binds to its specific receptor

(interleukin-6 receptor, IL-6R), which then heterodimerizes with the membrane gp130
receptor, forming an active complex to initiate intracellular signaling (Schwantner,
Dingley, Ozbek, Rose-John, & Grotzinger, 2004). The glycoprotein 130 (gp130) receptor
is a transmembrane receptor for the IL-6 family of cytokines. The interleukin-6 signal
transducer (IL6ST) gene, also known as the gp130 receptor, is found on chromosome 5q11,
and gp130 protein is ubiquitously expressed in all tissues throughout the body (Rodriguez,
Grosgeorge, Nguyen, Gaudray, & Theillet, 1995). Systemic deletion of the receptor is
embryonic lethal (Saito, Yoshida, Hibi, Taga, & Kishimoto, 1992; Yoshida et al., 1996).
Several different cytokines signal through the gp130 receptor forming either a heterodimer
or homodimer with the cytokine, its receptor and gp130. Cytokines within the IL-6 family
of cytokines that signal through gp130 receptor include IL-6, IL-11, IL-27, IL-30, IL-31,
oncostatin M (OSM), leukemia inhibitory factor (LIF), cardiotrophin-1 (CT-1),
cardiotrophin-like cytokine (CLC) and ciliary neurotrophic factor (CNTF) (Heinrich et al.,
2003; Kishimoto, Akira, Narazaki, & Taga, 1995). The gp130 receptor is composed of an
Ig-like binding domain and five fibronectin type III (FNIII) repeats on the extracellular
portion of the receptor. The first two FNIII repeats form the cytokine binding module. The
transmembrane domain is followed by the box1 and box2 regions and the leucine motif
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where JAK/STAT3 activation occurs on tyrosine residues (Heinrich et al., 2003).
Mutations in the intracellular region of the gp130 receptor leads to inactivation of the
JAK/STAT pathway and IL-6 receptor signaling (Haan, Heinrich, & Behrmann, 2002;
Stahl et al., 1994). Downstream signaling pathways activated by IL-6/IL-6R/gp130
include JAK/STAT, RAS/ERK, and PI3K/Akt (Sims & Walsh, 2010). In response to
ligand binding and receptor dimerization, constitutively bound Janus family kinases,
JAK1, JAK2 or Tyk2, phosphorylate tyrosine residues in the distal cytoplasmic domain of
gp130. Phosphorylated gp130 then acts as docking sites for the SH2 domains of the Signal
Transducer and Activator of Transcription (STAT) family of transcription factors
(typically STATs 1, 3 and 5). Subsequent phosphorylation of STATs then induces STAT
dimerization and translocation to the nucleus where they activate gene transcription
(Hirano, Ishihara, & Hibi, 2000). Recent evidence also suggests that STAT3 can also enter
the mitochondria and regulate oxidative phosphorylation through protein-protein
interactions (Gough et al., 2009). In addition to STAT signaling, dimerization of gp130
receptor cytokine receptors can also lead to the activation of MAPK signaling cascades
which include ERK1/2, JNK1/2, and p38. The activation of MAPKs by gp130 receptor is
mediated through the recruitment of the protein tyrosine phosphatase SHP2 to the gp130
Y759 phosphorylation site, which its recruitment and phosphorylation by JAK.
Phosphorylated SHP-2 then interacts with growth-factor receptor bound protein 2 (Grb2),
which leads to the activation of the Ras-Raf-ERK1/2 cascade (Heinrich et al., 2003). While
IL-6 family of cytokines through gp130 can also induce the phosphorylation and activation
stress-activated MAPKs (P38 and JNK), their activation remains poorly understood.
Cytokine signaling through gp130 can also lead to the activation of PI3K/Akt. While not
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completely understood in skeletal muscle, activation of PI3K signaling has been reported
to be involved in the regulation of gp130-dependent hypertrophic signaling in cardiac
myocytes (Oh et al., 1998). Interestingly, LIF cytokines stimulation induced JAK1 binds
to PI3K, which resulted in enhanced p70 S6 kinase activation and protein synthesis, which
would be inhibited by wortmannin and rapamycin (PI3K and mTORC1 inhibitor,
respectively). It is currently unknown whether gp130 cytokines can induce PI3K/Akt
signaling activation in skeletal muscle cells.
2.6.2 IL-6/gp130/STAT3 Signaling During Cancer Cachexia
Plasma IL-6 levels are elevated in many cachectic conditions associated with
wasting. In the MIN mouse model of colorectal cancer, the initiation and progression of
cachexia is directly related to tumor burden and circulating IL-6 levels (Baltgalvis, Berger,
Pena, Davis, Muga, et al., 2008; Baltgalvis et al., 2009; White, Baltgalvis, et al., 2011).
Our laboratory has shown that cachexia severity is directly related to IL-6 and that the
inhibition of IL-6 signaling through use of an IL-6 receptor antibody or IL6 knockout mice
attenuates/prevents the development of cachexia (Baltgalvis, Berger, Pena, Davis, Muga,
et al., 2008; White, Baynes, et al., 2011). IL-6 can suppress muscle protein synthesis and
activate degradation in vivo and in vitro (White, Puppa, Gao, et al., 2013). Plasma IL-6
levels are elevated during the natural progression of cachexia, and systemic IL-6
overexpression can induce cachexia in pre-cachectic MIN mice (Baltgalvis, Berger, Pena,
Davis, Muga, et al., 2008; Puppa et al., 2012; White, Puppa, Gao, et al., 2013). Moreover,
long-term IL-6 exposure is sufficient to induce atrophy in C2C12 myotubes (White, Puppa,
Gao, et al., 2013). The activation muscle STAT3 has been implicated in many preclinical
models of cachexia. For example, IL-6 and subsequent muscle signal transducer and
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activator of transcription 3 (STAT3) signaling through the gp130 receptor are activated
during the progression of cachexia (Baltgalvis, Berger, Pena, Davis, Muga, et al., 2008;
Bonetto et al., 2012; Bonetto et al., 2011; White, Baltgalvis, et al., 2011), and either STAT3
inhibition (Bonetto et al., 2012) or gp130 loss can attenuate muscle wasting in some mouse
models of cachexia (Puppa, Gao, et al., 2014). During the natural progression of cachexia,
inhibition muscle STAT3 signaling can attenuate muscle mass loss in animal models of
cancer cachexia (Bonetto et al., 2012; Bonetto et al., 2011). Muscle STAT3 signaling
induced by IL-6 overexpression can induce muscle wasting (Baltgalvis, Berger, Pena,
Davis, Muga, et al., 2008; Baltgalvis et al., 2009; Bonetto et al., 2012), and the inhibition
of muscle protein synthesis signaling (White, Puppa, Gao, et al., 2013). STAT3 inhibition
can improve myofiber cross-sectional area in C26 tumor bearing mice (Bonetto et al., 2012;
Seto et al., 2015). Furthermore, STAT3 inhibition can block IL-6 induced myotube atrophy
in vitro (Bonetto et al., 2012).

Additionally, reducing muscle signaling pathways

associated with IL-6 can improve protein turnover regulation (Narsale et al., 2016; Puppa,
Gao, et al., 2014; Puppa, Murphy, et al., 2014). These studies indicate a need for further
investigation of IL-6/STAT3 signaling on protein synthesis during cancer cachexia.
2.6.3 STAT3 and Muscle Contraction
While muscle inflammatory signaling and its link to protein degradation regulation
have established roles in cancer cachexia-induced muscle wasting (S. Cohen, Nathan, &
Goldberg, 2015), these same pathways can also be regulated by muscle contraction or
exercise, and have a regulatory role in overload-induced hypertrophy (B. Egan & Zierath,
2013; Schiaffino, Dyar, Ciciliot, Blaauw, & Sandri, 2013). While muscle IL-6/STAT3
signaling has an important role in the regulation of muscle mass loss with some types of
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cancer cachexia (Baltgalvis, Berger, Pena, Davis, Muga, et al., 2008; Baltgalvis et al.,
2009; Bonetto et al., 2012; Bonetto et al., 2011; White, Baynes, et al., 2011; White et al.,
2012), this pathway has also been implicated in functional overload-induced muscle
growth (Serrano, Baeza-Raja, Perdiguero, Jardi, & Munoz-Canoves, 2008; White et al.,
2009). However, global IL-6 knockout impedes both myofiber growth and extracellular
remodeling in functionally overloaded plantaris muscle (White et al., 2009). Additionally,
muscle contraction and functional overload induce IL-6 mRNA expression which may be
important for both metabolic and growth processes (Keller et al., 2003; White et al., 2009).
However, the IL-6-independent regulation of STAT3 signaling in muscle growth
regulation has not yet been clearly established. Functional overload and resistance exercise
can increase muscle STAT3 phosphorylation (Begue et al., 2013). Muscle IL-6 mRNA
expression is transiently induced by acute exercise (Keller et al., 2003), and treadmill
exercise disrupts IL-6-induced regulation of muscle mass loss in MIN mice (Puppa et al.,
2012; White et al., 2012). We have previously found that repeated ECC bouts attenuated
the cachexia-induced increase in muscle STAT3 phosphorylation in severely cachectic
muscle (Hardee et al., 2016), which extends our previous findings that treadmill exercise
training can improve muscle mass in the presence of chronically elevated STAT3 signaling
(Puppa et al., 2012). Since STAT3 signaling pathways can be induced by both catabolic
cachectic stimuli and anabolic muscle contraction, further work is needed to identify the
role of contraction-induced regulation of STAT3 signaling during the progression of
cachexia.
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2.6.4 Adenosine Monophosphate-activated Protein Kinase (AMPK)
5’-AMP-activated protein kinase (AMPK) regulates energy homeostasis (Hardie,
2007), which can be influenced by inflammatory cytokines, energy stress, and muscle
contraction. AMPK is a highly conserved heterotrimeric kinase complex composed of a
catalytic α-subunit (α 1 and α 2) and two regulatory (β- and γ-) subunits (Ruderman et al.,
2010). Further, the β subunit contains a glycogen-binding domain (GBD) and the γ subunit
contains four repeat sequences (CBS) that form a pair of Bateman domains responsible for
nucleotide binding (Kemp, Oakhill, & Scott, 2007). AMPK containing α 1 subunit is
exclusively cytoplasmic; however, AMPK containing α 2 subunit is also found in the
nucleus (Ruderman et al., 2010). Several upstream kinases that regulate AMPK activity
have been identified: serine-threonine liver kinase B1 (LKB1) and calcium/calmodulin
kinase kinase-β (CaMKKβ) (Ruderman et al., 2010). LKB1 is necessary for AMPK
activation by exercise in skeletal muscle (Sakamoto, Goransson, Hardie, & Alessi, 2004).
AMPK is activated under conditions of energy stress, when intracellular ATP levels decline
and intracellular AMP increase (high intracellular AMP/ATP ratio). Increased binding of
AMP to specific domains of the γ-subunit trigger a conformational change that allows
upstream kinase to phosphorylate AMPK at threonine residue (Thr172) of the α-subunit to
promote ATP producing catabolic process (Hardie, 2007). Thus, AMPK is an energysensing protein that promotes processes that replenish ATP while concurrently inhibiting
pathways that consume ATP (Hardie & Sakamoto, 2006). In line with its role in muscle
protein turnover and metabolism, AMPK activation can regulate muscle protein synthesis
through mTOR inhibition (Bolster, Crozier, Kimball, & Jefferson, 2002), increased
muscle-specific ubiquitin ligase expression (Tong et al., 2009), autophagy processes (Kim,
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Kundu, Viollet, & Guan, 2011), and mitochondrial biogenesis (Jager, Handschin, St-Pierre,
& Spiegelman, 2007). AMPK inhibits mTORC1 through the phosphorylation of TSC2
and Raptor (Gwinn et al., 2008; Inoki, Zhu, & Guan, 2003; Shaw, 2009).

The

phosphorylation of TSC2 by AMPK inhibits mTORC1 and S6K1 activity (Inoki, Li, Zhu,
Wu, & Guan, 2002; Inoki et al., 2003). Moreover, phosphorylation of the mTORC1
binding partner raptor by AMPK at two highly conserved serine residues (S722 and S792)
leads to a suppression of mTORC1 kinase activity (Gwinn et al., 2008). Furthermore,
treatment with the AMPK activator 5-aminoimidazole-4-carboxamide-1–4-ribofuranoside
(AICAR) inhibits mTORC1-mediated signaling and protein synthesis in resting skeletal
muscle (Bolster et al., 2002), and protein translation in cultured myotubes (Williamson,
Bolster, Kimball, & Jefferson, 2006). AICAR activates AMPK as it is converted to the
AMP analog ZMP, thus mimicking an increase in intracellular AMP without disturbing the
actual energy status of the cell (Corton, Gillespie, Hawley, & Hardie, 1995). In addition
to mTORC1 signaling, AMPK can also activate atrogene expression in skeletal muscle
(Tong et al., 2009). The FOXO family of transcription factors regulate the expression of
genes related to autophagy and the ubiquitin-proteasome system (Romanello et al., 2010;
Sandri, 2013), and AMPK can directly activate FOXO3 independent from Akt (Greer et
al., 2007). Further, AMPK has been shown to directly phosphorylate PGC-1a to induce
PGC1-dependent gene expression related to glucose metabolism and mitochondrial content
(Jager et al., 2007). Collectively, these studies demonstrate that AMPK plays a critical role
in the regulation of energy metabolism.
While AMPK is a potent regulator of skeletal muscle metabolism (Jager et al.,
2007), its activation is disrupted during cancer cachexia progression. In skeletal muscle,
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the metabolic changes induced by AMPK activation are thought to either acute, through
direct phosphorylation of metabolic enzymes, or chronic, through control of gene
expression (Hardie & Sakamoto, 2006). However, several mouse models of cancer
cachexia demonstrate chronically elevated muscle AMPK activity in skeletal muscle
(Puppa, Gao, et al., 2014; Puppa, Murphy, et al., 2014; White, Baynes, et al., 2011; White,
Puppa, Gao, et al., 2013), which could negatively impact protein and metabolic
homeostasis. We have previously found that AMPK is activated during severe cachexia
(Hardee et al., 2016; White, Baynes, et al., 2011) or can be induced at earlier time-points
with IL-6 overexpression in MIN mice (White, Puppa, Gao, et al., 2013). This activation
coincides with the suppression of mTORC1 signaling and activation of ubiquitin
proteasome and lysosomal proteolytic systems (White, Baynes, et al., 2011). Interestingly,
AMPK inhibition, but not STAT3 inhibition, can rescue IL-6-induced suppression of
mTORC1 signaling in myotubes (White, Puppa, Gao, et al., 2013). Unlike healthy skeletal
muscle, AMPK activation by cachexia or IL-6 overexpression was not coupled to
mitochondrial biogenesis, where muscle oxidative metabolism was suppressed in cachectic
muscle (White, Baltgalvis, et al., 2011; White, Baynes, et al., 2011). In healthy muscle,
exercise can stimulate AMPK activity and subsequent induction of autophagy and
mitochondrial biogenesis (C. He et al., 2012; Hood, 2001). We have found that treadmill
exercise at the initiation of cachexia can attenuate AMPK phosphorylation independent of
reductions in elevated muscle STAT3 signaling (Puppa et al., 2012). Moreover, repeated
ECC bouts suppressed chronically activated AMPK and improved muscle oxidative
capacity, independent to STAT3 inhibition (Hardee et al., 2016). Further work is needed
to determine the relationship between AMPK and STAT3 signaling for the suppression of
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anabolic signaling and muscle oxidative metabolism in cachectic skeletal muscle. Given
the potential role of AMPK in muscle protein and metabolic homeostasis, further work is
required to determine if restoring AMPK activity may be a potential therapeutic target for
muscle wasting syndrome.

2.7 RODENT MODELS OF CANCER CACHEXIA
Approximately 50% of cancer patients will experience progressive wasting of
adipose or skeletal muscle tissue (Tisdale, 2002, 2010). However, there are currently
limited studies that have defined the cachectic response in cancer patients. This is in part
due to the difficulty related to obtaining patient samples, controlling for the type of tumor,
rate and duration of cachexia, and diverse treatment regimens used following diagnosis.
Therefore, several preclinical models have been developed to mechanistically examine the
initiation and progression of cancer cachexia. Genetic and tumor implantation rodent
models have been used to study muscle mass regulation with cancer. In vitro cell culture
models have also been developed to mechanistically define specific cachectic factors and
signaling pathways associated with wasting. While it is acknowledged that many different
preclinical models are available, the following section will highlight mouse and rat models
that have been commonly used by our laboratory and others for the examination of cancer
induced muscle wasting.
2.7.1 Injectable Models of Cancer Cachexia
Injection of cancer cells into mice has become one of the most frequently used
models to study cancer cachexia. The two most commonly used cancer cell lines to
produce cachexia include the colon tumor 26 (C26) and Lewis lung carcinoma (LLC). The
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development and utility of these tumor models are briefly discussed. The C26 cell line
originated as a chemically induced tumor, while the LLC model was observed naturally
occurring. First described in 1975, colon tumors were chemically induced by exposing
mice to carcinogens (Corbett, Griswold, Roberts, Peckham, & Schabel, 1975). Of the
colon tumors that developed across 82 mice, 4 survived the 1st passage and were serially
transplanted. The C26 tumor that developed in a female BALB/c mouse was classified as
an undifferentiated grade 4 carcinoma, and demonstrated high metastases to the lungs and
other tissues when transplanted. In contrast, the spontaneous LLC tumor cell line was first
isolated in 1951 by Dr. Margaret R. Lewis from B6 mouse lung. This model also displays
metastasis to the liver and lung tissues. In both models, tumor cells can be grown in culture
and then injected into the flank of a recipient mouse. While not commonly employed in
cachexia research, donor mice can also be used induce tumor growth and then tumor
fragments can be transplanted into the recipient mouse (Aulino et al., 2010). Regardless
of delivery method, significant wasting can be achieved within ~14-30 days depending on
the cell type (C26 vs LLC), cell culture conditions, and cell phenotype (moderate vs severe)
(Judge et al., 2014; Puppa, Gao, et al., 2014; Seto et al., 2015; Toledo et al., 2014). Key
features of cachexia observed in humans, which include anorexia, weight loss, adipose and
skeletal muscle wasting and increased energy expenditure (K. Fearon et al., 2011), can be
recapitulated throughout various time points following implantation.

However, the

cytokines or cachectic factors associated with cachexia initiation and progression can differ
between tumor cell lines. The cytokines IL-6 and LIF are elevated in C26 conditioned
culture media or mouse plasma (Pin et al., 2015), whereas increased TNFα and IL-6 levels
have been observed in LLC conditioned media or mouse plasma (J. A. Chen et al., 2015).
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It should be noted that culture conditions during tumor cell growth (i.e., serum vs serumfree) or tumor-host interactions can alter the cytokine profile in vitro or in vivo,
respectively. One common advantage of the LLC model is the utility of genetically
modified mice (e.g., knock-out) since B6 mice can be used (Pin et al., 2015; Puppa, Gao,
Narsale, & Carson, 2014). However, while BALB/c and CDF1 mice are commonly used
in the C26 model, this can be surpassed using molecular approaches such as plasmid
electroporation to overexpress or knock-down candidate proteins (Cornwell, Mirbod, Wu,
Kandarian, & Jackman, 2014; Judge et al., 2014; Seto, Kandarian, & Jackman, 2015). Both
tumor models have been utilized in exercise studies to examine potential effects of
endurance and resistance type exercise on muscle wasting processes (al-Majid &
McCarthy, 2001; Penna et al., 2011; Pin et al., 2015). Collectively, these two injectable
tumor models have greatly enhanced our current understanding of the potential regulators
of wasting during cachexia progression.
2.7.3 Genetically engineered mouse models
The MIN mouse is an established model of colorectal cancer and that develops
cachexia. This mouse is on a B6 (B6) background, and has a naturally occurring nonsense
germline mutation at codon 850 in the Adenomatous polyposis coli (Apc) gene which
predisposes mice to multiple intestinal neoplasia (Moser, Pitot, & Dove, 1990). Mutations
to the APC gene occurs in approximately 70% of familial adenomatous polyposis (FAP),
a dominant inherited syndrome that predisposes individuals to intestinal adenomas.
Therefore, this mouse model is commonly used in cancer biology to study the initiation
and progression of colon cancer. While the MIN mouse does not fully recapitulate the
observed cancer phenotype in humans (i.e., small intestinal polyps vs colon tumors), our
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laboratory and others have found this mouse develops a cachectic phenotype (i.e., muscle
wasting, high IL-6, hypogonadism) similar to that observed in the human cancer patient
(White, Baltgalvis, et al., 2011; White, Baynes, et al., 2011; White, Puppa, Narsale, &
Carson, 2013). Furthermore, this model can be advantageous due to the slow onset and
progression of cancer cachexia (discussed in detail below).
The MIN mouse develops intestinal polyps beginning as early as 4 weeks of age,
and total polyp formation is reached by approximately 12 weeks of age (McClellan et al.,
2012; Puppa et al., 2011). The majority of polyps are observed in all intestinal segments
(polyp segments), while only a few are observed in the colon.

The initiation and

progression of cachexia in this mouse is directly related to the intestinal tumor burden and
IL-6 levels.

Indeed, our laboratory has demonstrated an IL-6 dependent cachexia

phenotype between 3 and 6 months of age (Baltgalvis, Berger, Pena, Davis, Muga, et al.,
2008; Baltgalvis et al., 2009; White, Baynes, et al., 2011). During the natural progression
of cachexia, initial body weight loss occurs at approximately 14 weeks of age, and
progressive loss can continue over several weeks (Baltgalvis et al., 2010). This overall
wasting corresponds to both adipose and muscle tissue loss.

This slow cachexia

progression allows treatments to be initiated prior to or after significant wasting has
occurred (prevention versus treatment). Indeed, our laboratory has examined both exercise
in the prevention of wasting (Baltgalvis, Berger, Pena, Davis, & Carson, 2008; Puppa et
al., 2012; White, Puppa, Gao, et al., 2013; White et al., 2012), and the use of
pharmaceutical, nutritional, and exercise treatments in the attenuation of cachexia
progression (Hardee et al., 2016; Narsale et al., 2016; Velazquez et al., 2014; White,
Baynes, et al., 2011).
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We have observed strong relationships between tumor burden, circulating IL-6
levels, and cachexia severity during the progression of cachexia (Baltgalvis, Berger, Pena,
Davis, Muga, et al., 2008; Baltgalvis et al., 2009; White, Baltgalvis, et al., 2011). Our
laboratory has completed several studies demonstrating the importance of plasma IL-6 in
the development of cachexia in the male MIN mouse. In our initial studies, we found that
while MIN mice lacking IL-6 (MIN; IL-6-/-) did not develop cachexia, wasting could be
achieved in these mice when systemic IL-6 was reintroduced by muscle plasmid
overexpression (Baltgalvis et al., 2009). We have also found that systemic IL-6 inhibition
by a receptor antibody after the initiation of cachexia could attenuate muscle wasting
(White, Baynes, et al., 2011). Lastly, elevating systemic plasma IL-6 levels by muscle
plasmid electroporation can accelerate cachexia progression in young weight stable MIN
mice, which does not occur in polyp free wild-type littermates (i.e., B6). These studies
provided strong evidence for the use of the male MIN mouse as an IL-6-dependent model
of cancer cachexia. Interestingly, we have found sex differences in cachexia progression.
While female mice will eventually develop severe cachexia, the time course and IL-6
dependence on cachexia development differs from the male (Hetzler et al., 2015). For
example, IL-6 is not correlated to wasting during cachexia progression, and elevating
systemic IL-6 through muscle electroporation does not accelerate cachexia development.
We are currently examining the potential sex differences regulating IL-6 sensitivity and
cachexia development.
2.7.3 Rat models of cancer cachexia
Similar to mice, several rat models of cancer induced wasting have been developed.
Injectable tumor models include methylcholanthrene (MCA) sarcoma cells (Ekman et al.,
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1982; Ramos et al., 2004; Ramos et al., 2005), Yoshida AH-130 hepatoma (Busquets et
al., 2000; Busquets et al., 2004; Carbo et al., 1997; Muscaritoli et al., 2003; Tessitore,
Bonelli, & Baccino, 1987), and Walker 256 carcinosarcomas (Clark & Goodlad, 1975;
Goodlad & Clark, 1972, 1973; Goodlad, Tee, & Clark, 1981). These cell lines also
recapitulate the cachectic phenotype observed in humans (discussed above), however
cachexia initiation and progress is very rapid in these models. Body weight and muscle
mass loss can be observed after only seven days of tumor implantation depending on tumor
model.
2.7.4 In vitro Models
In vitro models have also been developed to examine alterations in protein turnover
and oxidative metabolism in response to various cytokines and tumor-derived cachectic
factors. This model employs exposing cultured myoblast and myotubes to individual
cytokines or media from cultured tumor cells (Gao & Carson, 2016; Seto et al., 2015). We
have found that long-term IL-6 exposure to C2C12 myotubes can recapitulate the cachectic
phenotype observed in MIN mice. For example, long-term IL-6 exposure can suppress
mTORC1 signaling, activate FOXO signaling, and reduce mitochondrial protein
expression (White, Puppa, Gao, et al., 2013). Long-term exposure of leukemia inhibitory
factor (LIF), another IL-6 family of cytokine, also induce myotube atrophy through STAT
activation in vitro (Seto et al., 2015). Additionally, we have found that C2C12 myotubes
preincubated in LLC-derived media promoted atrophy through the suppression of
mTORC1 signaling and protein synthesis, which coincided with the activation of muscle
inflammatory (STAT3, ERK1/2, P38, NFkB) and AMPK signaling (Gao & Carson, 2016).
Similar findings have also been observed using culture media from C26 cells.
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Interestingly, C2C12 myotubes treated with C26 conditioned medium induced myotube
atrophy that was associated with enhanced STAT transcriptional activation (Seto et al.,
2015). These important findings in vitro could be replicated in vivo, as STAT3 inhibition
in skeletal muscle has been shown attenuate myofiber atrophy in vivo (Bonetto et al., 2012;
Seto et al., 2015). Collectively, these studies highlight that key cytokine and intracellular
signaling pathways implicated in cancer induced wasting can be mechanistically
determined using this model system.

2.8 Rodent Models of Physical Activity, Exercise and Muscle
Contraction
2.8.1 Voluntary cage activity
It is well established that physical activity levels can have a significant role in the
etiology of cancer. While physical inactivity has been well documented with cancer
cachexia, it is often characterized as an outcome of wasting and not a contributor to the
process. The two most commonly employed methods to examine physical activity levels
in rodents include general cage monitoring and running wheels. Several customized
models of cage monitoring systems are available to examine daily spontaneous physical
activity.

In general, rodent cages are placed in fitted racks that contain infrared

photobeams. Spontaneous physical activity can be detected and measured by infrared
arrays in the x-, y-, and z-axis.

Physical activity across x- and y-axis allow the

determination of ambulatory (locomotor activity), while the z-axis allows for
determination of vertical movement (rearing or standing). The running wheel can also be
used to assess levels of physical activity. In general, healthy rodents with access to a wheel
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will engage in physical activity. Therefore, the running wheel has been used to study
spontaneous activity, but also to examine the effects of exercise training. It should be noted
that access to running wheel can alter physical activity and behavior patterns, which could
influence the study outcome and has been discussed elsewhere (Novak, Burghardt, &
Levine, 2012). Nonetheless, when the rodent is engaging in physical activity the number
and velocity of revolutions of the wheel can be simultaneously quantified through
computer or other devices. Regardless of method, physical activity patterns can be
monitored during specific times of day (light vs dark cycle) or across time (pre- and posttreatment). Therefore, careful monitoring of spontaneous cage activity over time could
help to reconcile the potential contribution of physical inactivity or muscle disuse as
contributing to the cancer-induced wasting.
2.8.2 Voluntary Cage Activity during Cancer Cachexia
As previously highlighted, the potential interaction between muscle use and the
systemic environment could have significant implications on muscle mass regulation
during cancer. Related to our previous discussion, access to a wheel could alter cachexia
progression through serving as a training stimulus compared to an animal without wheel
access. Indeed, several indices of cachexia progression are attenuated in rodents given
access to wheel. While voluntary wheel running increased over time in C26 tumor bearing
mice, it was reduced compared to non-tumor bearing controls (Coletti et al., 2013).
Nonetheless, wheel running has been shown to attenuate muscle mass loss and improve
myofiber cross sectional area across multiple studies in C26 mice (Coletti et al., 2016;
Pigna et al., 2016). Moreover, these studies have demonstrated improvements in ex vivo
force (Pigna et al., 2016) and reduced muscle inflammatory signaling related to NFkB
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activation (Coletti et al., 2016). More clinically relevant, there was a positive correlation
between running distance and survival days (Pigna et al., 2016). Thus, it appears that
participating in voluntary exercise can have significant clinical and functional
ramifications in tumor bearing animals.
2.8.3 Treadmill Exercise
Treadmill exercise is one of the most commonly used methods to increase physical
activity levels and induce exercise training adaptations in rodents. The overall concept of
treadmill exercise training in rodents is similar to humans in that varying speeds and
inclines during the exercise bout can be achieved. An advantage to this model is that a
specific, quantifiable dose can be delivered to the rodent. However, a disadvantage is that
the exercise is forced and can be stressful to the animal. Nonetheless, instrumental
information related to the mechanisms associated with the acute responses and chronic
adaptations to endurance exercise have been identified using this exercise model. In
addition to the acute response to exercise, treadmill run to fatigue test is also commonly
utilized to examine exercise capacity. Treadmills can also be coupled to respiratory
chambers that allow for the determination of oxygen consumption during exercise. These
systems have been used to examine resting, submaximal, and maximal oxygen
consumption.

Similar to spontaneous physical activity, this can provide valuable

information related to phenotype alterations throughout lifespan or treatment.
2.8.4 Treadmill Exercise During Cancer Cachexia
Treadmill exercise training is a potent stimulus to improve whole body metabolism.
Our laboratory has examined treadmill exercise training before (<12 wks. of age) or after
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(~12wks of age) intestinal polyp formation in MIN mice. We have found that treadmill
exercise training (6 days/wk., 9wks) decreased crypt depth: villus height ratio (CVR) in 13
wk. male and female MIN mice prior to body weight loss (Mehl, Davis, Clements, et al.,
2005). Additionally, training decreased total poly number and large size polyps (>1 mm)
in male MIN mice (Mehl, Davis, Clements, et al., 2005). The potential mechanisms for
reduced poly formation by exercise training include reductions in immune cell infiltration,
apoptosis, and beta-catenin signaling (Baltgalvis, Berger, Pena, Davis, & Carson, 2008).
In addition to polyp formation, exercise training prior to and during IL-6 overexpression
could prevent body weight and muscle mass loss, improved systemic glucose and fatty acid
metabolism, increased muscle oxidative metabolism, and restored mTORC1 signaling in
MIN mice (Puppa et al., 2012; White, Puppa, Gao, et al., 2013). Other laboratories have
also reported treadmill exercise prior to tumor injection and during treatment improved
survival rate and prevented/delayed muscle mass loss in metastatic C26 tumor model (Jee,
Chang, & Yang, 2016). However, not all studies have reported attenuated muscle mass
loss by exercise training in tumor implantation models (Pin et al., 2015), however training
was sufficient to improve muscle strength and oxidative capacity depending on the tumor
model (Pin et al., 2015). Collectively, there is sufficient evidence to suggest that exercise
training prior to and during cachexia progression can attenuate muscle mass and strength
loss, which may be related to improved oxidative metabolism and protein synthesis.
2.8.5 Synergist Ablation/Compensatory Hypertrophy
Compensatory overload of synergist muscles is commonly used to study muscle
growth and the mechanical signals activating transcription and translation. Two commonly
used models of compensatory overload include tenotomy of synergist and synergist
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ablation. Regardless of the model, the synergist muscle is inactivated by tenotomy or
removal and the remaining muscle compensate for the increased load, which leads to a
robust hypertrophic growth response. First described by Goldberg, tenotomy (i.e., severing
of tendon) of the gastrocnemius muscle redistributes load to the synergist soleus and
plantaris muscles and promotes rapid muscle growth (Goldberg, 1967, 1968).
Disadvantages to this model include rapid edema and inflammatory induction during the
initial phase of loading resumption, and tendon reattachment during long-term loading. In
contrast, the synergist ablation model places functional overload to the muscle by surgical
removal of the synergist muscle. The distal one-third of the gastrocnemius and soleus
muscles are removed leaving the plantaris to the bear load upon normalization of
ambulatory activity (McCarthy et al., 2011)). The soleus can also be left intact to examine
the loading responses in oxidative versus glycolytic muscle (Carson, Nettleton, & Reecy,
2002; Kilikevicius, Bunger, & Lionikas, 2016; W. J. Lee, McClung, Hand, & Carson,
2003). Similar to tenotomy, this model is associated with edema and inflammation
infiltration during reambulation, however significant muscle hypertrophy occurs following
this initial phase. The improvements in muscle mass are accompanied by increased
myofiber cross-sectional area and the accretion of protein and RNA content (Miyazaki et
al., 2011). While the compensatory overload model allows the mechanistic investigation
of a robust hypertrophic response, whether these findings directly reflect what occurs in
humans with resistance training should be considered.
2.8.6 Synergist Ablation/Compensatory Hypertrophy during Cancer Cachexia
While compensatory hypertrophy is an excellent model to examine muscle growth,
only a few studies have utilized this in tumor bearing animals. Of these studies, only two
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have examined them in cachectic conditions. One of the first pioneering studies found that
regardless of overall tumor burden, a comparable growth response was observed tumorand non-tumor bearing animals (Norton et al., 1979). Interestingly, this study utilized both
prevention and treatment perspectives (i.e., overload initiated at or 1-2 wks. post-tumor
inoculation), demonstrating that muscle growth could be achieved when loading was
initiated at varying tumor burdens. While the next study did not observe cachexia due to
the tumor utilized, the authors also found that increased muscle loading could promote
muscle growth in tumor-bearing animals (Jaweed, Herbison, Miller, & Ditunno, 1983).
These two studies demonstrated for the first time that muscle could respond to increased
workload despite the presence of a tumor. However, both studies only examined the initial
growth response following 1wk of tenotomy. Therefore, a more recent study examined if
long-term loading could prevent muscle wasting (Otis et al., 2007). The authors found that
muscle retained the plasticity to adapt to mechanical loading despite significant wasting
that occurred with cancer. Collectively, these studies demonstrated that tumor-bearing
rodents were responsive to increased loading, and that an initial growth response to
mechanical loading was maintained in a cachectic environment.
2.8.7 ECC-induced by High-Frequency Electrical Stimulation
When examining mechanisms related to severe cachexia, exercise feasibility
becomes an issue as severely cachectic mice are not capable of performing vigorous
exercise training. While not entirely exercise, skeletal muscle’s metabolic and growth
response to contraction has been examined using electrical muscle stimulation (Baar &
Esser, 1999; Nader & Esser, 2001; Puppa, Murphy, et al., 2014; Witkowski et al., 2010).
Electrical stimulation is performed in an unconscious animal, in which electrodes are used
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to stimulate a nerve at a specific frequency, thus resulting in contraction of the innervated
muscle. Low-frequency electrical muscle stimulation (LFES) has been used to examine
the acute responses and training adaptations to endurance like muscle contractions (Nader
& Esser, 2001; Patel, Cuizon, Mathieu-Costello, Friden, & Lieber, 1998; Puppa, Murphy,
et al., 2014). Related to growth promoting stimuli, high-frequency electrical muscle
stimulation (HFES) has examined muscle signaling associated with hypertrophy (Baar &
Esser, 1999; Y. W. Chen et al., 2002; B. S. Gordon, Steiner, Lang, Jefferson, & Kimball,
2014; Jacobs et al., 2013; Nader & Esser, 2001; Steiner, Fukuda, Rossetti, Hoffman, &
Gordon, 2017; Witkowski et al., 2010). Initial experiments performed by Wong & Booth
demonstrated that HFES could induce muscle hypertrophy of the eccentrically contracted
tibialis anterior (TA) muscle, while this growth response was not observed in the
concentrically contracted gastrocnemius muscle (Wong & Booth, 1988).

In this

contraction model, the maximal tension generated by the plantar flexors is greater than that
of the dorsiflexors, resulting in net plantar flexion of the ankle. This stimulation protocol
results in an initial maximal ECC of the dorsiflexor muscles (TA and EDL) due to the
greater overall force production of the simultaneously contracting plantar flexors
(gastrocnemius, plantaris, and soleus muscles). This is followed by a period of maximal
isometric contraction in a lengthened position at full plantar flexion. To date, several
research groups have utilized this model to examine the growth response to a single bout
of high-force contractions, and have used the same stimulation parameters (Baar & Esser,
1999; Y. W. Chen et al., 2002; B. S. Gordon et al., 2014; Jacobs et al., 2013; Nader &
Esser, 2001; Steiner et al., 2017; Witkowski et al., 2010). With these parameters the sciatic
nerve is stimulated at 100 Hz in 3-s pulses with a 10-s rest period between repetitions. An
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additional 50-s rest is given after the 6th repetition. This cycle of stimulation is continued
for 10 sets of 6 stimulations, resulting in 60 contractions over a 22-min period. This
protocol has been shown to induce a robust protein synthesis and mTORC1 signaling
response in rodent skeletal muscle (Baar & Esser, 1999; Y. W. Chen et al., 2002; B. S.
Gordon et al., 2014; Jacobs et al., 2013; Nader & Esser, 2001; Steiner et al., 2017;
Witkowski et al., 2010). Moreover, the initial findings revealed that electrical stimulation
could produce muscle hypertrophy without external loading (i.e., weighted resistance),
since the TA muscle contracted eccentrically against the tension generated by the
concentrically contracted gastrocnemius muscle (Baar & Esser, 1999; Wong & Booth,
1988). The major advantage of eliciting muscle contractions via electrical stimulation is
related to control of training parameters. For example, variables such as stimulation
frequency and duration, the percent of maximal muscle strength generated per contraction,
the number of contractions, and rest periods between contractions could be manipulated
based on the desired outcome. Other advantages to this model of stimulated muscle
contractions include: (a) all motor units are recruited during contraction, (b) contraction is
isolated to the muscles innervated by the nerve, (c) contraction is performed involuntary in
an unconscious animal (e.g., not dependent on animal motivation), and (d) the contralateral,
non-stimulated leg can serve as an intra-animal control. Thus, this model has several
advantages in conditions of severe cachexia or chronic disease when voluntary exercise
cannot be easily performed. Several disadvantages to this model include: (a) repeated
anesthesia, (b) size principal of recruitment pattern not followed, (c) isolated muscle
contractions versus whole-body exercise (e.g., concentric and eccentric muscle actions),
and (d) repeated bout effects are difficult to determine. Nonetheless, given that an identical
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systemic cachectic environment is present between the stimulated and non-stimulated
muscles, this can greatly enhance the interpretation of the isolated muscle contraction
response in the diseased state.
2.8.8 ECC-induced by HFES during Cancer Cachexia
While the initial synergist ablation studies provided insight into our understanding
of muscle loading with cancer, the cachectic muscle response to increased use had yet to
be fully resolved. Given that severely cachectic demonstrate reduced activity and are
unable to perform exercise training, our laboratory and others have examined this response
using electrical stimulation in the unconscious animal (al-Majid & McCarthy, 2001;
Hardee et al., 2016; Puppa, Murphy, et al., 2014). We have previously found that cachectic
muscle’s anabolic and metabolic response to a single bout of concentric muscle
contractions was disrupted in MIN mice (Puppa, Murphy, et al., 2014). Interestingly,
inhibition of systemic inflammation related to NF-κB and STAT3 signaling was sufficient
to rescue contraction induced anabolic, but not metabolic signaling in cachectic muscle
(Puppa, Murphy, et al., 2014). It is currently not known if multiple bouts of exercise or
contraction improve the metabolic response of cachectic muscle to an acute bout of
contraction. Related to muscle growth by ECC, the first study performed utilized a
preventative design and demonstrated that ECC could maintain mass and protein content
in the contracted EDL muscle of C26 tumor bearing mice. This was the first study to
demonstrate that isolated muscle contractions could preserve mass in the presence of a
systemic cachectic environment, evident by body weight loss and wasting of the nonstimulated muscle mass (al-Majid & McCarthy, 2001). Given the importance of treating
the cachectic patient, our laboratory performed a similar experiment but initiated training
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after the mice had developed cachexia to determine if the muscle was still responsive.
Despite significant wasting that occurred with cachexia progression (body weight loss,
high circulating IL-6, muscle wasting), these mice responded to training by increasing
myofiber cross-sectional area and improving oxidative capacity (Hardee et al., 2016).
These changes were accompanied by reduced AMPK activation and inflammatory
signaling (Hardee et al., 2016). It is currently unknown whether these benefits reflect
changes to improved growth or the attenuation of wasting. Moreover, whether these
contractions were sufficient to increase mTORC1 signaling and improve basal protein
synthesis has not yet been explored. Nonetheless, these results further establish that tumorbearing rodents are responsive to increased use by ECC, and that the cachectic muscle can
respond to increased loading despite the presence of a systemic cachectic environment.
2.8.9 In-vitro stretch
While increased mechanical loading can induce a potent anabolic response in vivo,
muscle’s sensitivity to chronic or intermittent stretch has also been examined in cultured
myotubes (Carson & Wei, 2000). Several in vitro stretch models have been developed to
examine the muscle’s growth response to mechanical stimuli, and the signaling response
to each type of mechanical strain are distinct (Hornberger, Armstrong, Koh, Burkholder,
& Esser, 2005). Intermittent, cyclic stretch and chronic, static stretch are two models to
study the response to repeated contractions or loading, respectively.

Many of the

biochemical and physiological responses to these paradigms are similar to that observed in
vivo, which has vastly improved our understanding of the interactions between mechanical
signaling and growth induction.
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2.8.10 In-vitro stretch and Cachectic Factors
While significant understanding of key signaling pathways regulating stretchinduced growth have been gained using cultured myotubes, much less is known about the
interaction between stretch and cachectic tumor derived factors. Therefore, recent studies
have been performed in which individual cytokines or medium containing tumor derived
factors were cultured with stretched myotubes. Our laboratory has found that C2C12
myotubes preincubated in LLC-derived media demonstrated an attenuated stretch
induction of protein synthesis (Gao & Carson, 2016). The suppressed induction of protein
synthesis by stretch was accompanied by the LLC activation of inflammatory (STAT3,
ERK1/2, P38, NFkB) and metabolic (AMPK) signaling pathways. Interestingly, the
inhibition of ERK1/2 and p38 rescued the stretch induction of protein synthesis, while
AMPK inhibition increased basal mTORC1 signaling activity and protein synthesis in
LLC-treated myotubes (Gao & Carson, 2016). We are currently examining the potential
role of individual cytokines on the basal and stretch induction of myotube protein synthesis
and mTORC1 signaling.
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CHAPTER 3
INFLAMMATORY SIGNALING REGULATES ECCENTRIC
CONTRACTION-INDUCED PROTEIN SYNTHESIS IN CACHECTIC
SKELETAL MUSCLE1

1

Hardee JP, Counts BR, Gao S, VanderVeen BN, Fix DK, Koh HJ, and JA Carson.
Inflammatory Signaling Regulates Eccentric Contraction-Induced Protein Synthesis in
Cachectic Skeletal Muscle. Submitted to J Cachexia Sarcopenia Muscle.

53

3.1 ABSTRACT
Skeletal muscle responds to eccentric contractions (ECCs) with an anabolic
response that involves the induction of protein synthesis through mTORC1. While we
have reported that repeated ECC bouts after cachexia initiation can attenuate muscle mass
loss and inflammatory signaling, cachectic muscle’s capacity to induce protein synthesis
in response to ECC has not been determined. Therefore, we examined cachectic muscle’s
ability to induce mechano-sensitive pathways and protein synthesis in response to an
anabolic stimulus involving ECC, and determined the role of muscle STAT3/NFκB
signaling on ECC-induced anabolic signaling. Mechano-sensitive pathways and anabolic
signaling were examined immediately post or 3h after a single ECC bout in cachectic male
MIN mice (N=17; 16 ± 1% body weight loss). Muscle STAT3/NFκB regulation of basal
and ECC-induced anabolic signaling was also examined in an additional cohort of MIN
mice (N=10; 16 ± 1% body weight loss) that received pyrrolidine dithiocarbamate 24h
prior to a single ECC bout. In all experiments, the stimulated tibialis anterior (TA)
performed ECC while the non-stimulated TA served as intra-animal control. Data were
analyzed by Students t-test or two-way repeated measures ANOVA with StudentNewman-Keuls post hoc when appropriate. The accepted level of significance was set at
p<0.05 for all analysis. MIN mice exhibited a cachectic muscle signature demonstrated by
perturbed proteostasis (RPS6, P70S6K, Atrogin-1, MuRF1), metabolic (AMPK, PGC-1α,
COXIV), and inflammatory (STAT3, NFκB, ERK1/2, P38) signaling pathway regulation.
Nonetheless, mechano-sensitive signaling pathways (P38, ERK1/2, AKT) were activated
immediately post-ECC irrespective of cachexia. While cachexia did not attenuate ECCinduced P70S6K activation, the protein synthesis induction remained suppressed compared
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to healthy controls. However, muscle STAT3/NFκB inhibition increased basal and ECCinduced protein synthesis in cachectic MIN mice.

Conclusions:

These studies

demonstrate that mechano-sensitive signaling is maintained in cachectic skeletal muscle,
but chronic STAT3/NFκB signaling serves to attenuate basal and ECC-induced protein
synthesis.
Keywords: MIN; Cancer Cachexia; Eccentric contractions, Interleukin-6; Muscle Protein
Synthesis

3.2 INTRODUCTION
Skeletal muscle mass depletion associated with cancer cachexia contributes to
increased patient morbidity and mortality (K. C. Fearon, 1992; Tisdale, 2009). Skeletal
muscle size is influenced by the dynamic balance between the rates of protein synthesis
and breakdown (Maddocks et al., 2011; Murton & Greenhaff, 2010), and disrupted protein
turnover accompanies cancer cachexia (Samuels et al., 2001; Smith & Tisdale, 1993;
White, Baynes, et al., 2011). While our understanding of suppressed basal protein
synthesis and activated breakdown during cachexia has increased dramatically (Bonaldo
& Sandri, 2013; Sandri, 2013; White, Baynes, et al., 2011), we have a more limited
understanding of how the cachectic environment affects skeletal muscle responsiveness to
anabolic stimuli, which is clinically relevant for the treatment of the cachectic cancer
patient.

Resistance exercise is a potent anabolic stimulus that stimulates muscle

hypertrophy through the activation of mechanistic target of rapamycin complex 1
(mTORC1) in healthy adults (Charette et al., 1991; Chesley et al., 1992; Eliasson et al.,
2006), and can attenuate skeletal muscle mass loss in several muscle wasting conditions
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(Alberga et al., 2012; Hardee, Porter, Sidossis, et al., 2014; Sharif et al., 2011). Despite
the clinical significance of maintaining or improving muscle mass during cancer, limited
information currently exists on the cachectic muscle’s anabolic response to resistance
exercise.
ECC-induced by high-frequency electrical stimulation have been used to examine
signaling associated with muscle hypertrophy in rodents (Baar & Esser, 1999; Y. W. Chen
et al., 2002; Nader & Esser, 2001; Witkowski et al., 2010), and have demonstrated great
utility for improving our mechanistic understanding of contraction-induced protein
synthesis and mTORC1 signaling (Jacobs et al., 2013; Nader & Esser, 2001; O'Neil et al.,
2009; West et al., 2016). Related to cancer cachexia, evidence suggests that increased
loading by synergist ablation or ECC can maintain muscle mass in tumor-bearing mice (alMajid & McCarthy, 2001; Hardee et al., 2016; Norton et al., 1979; Otis et al., 2007).
Indeed, we have reported that repeated ECC bouts after the initiation of cachexia can
attenuate muscle mass loss through reduced inflammatory signaling (Hardee et al., 2016);
however, cachectic muscle’s capacity to induce protein synthesis in response to ECC has
not been determined and warrants further investigation. We have found that mechanoactivation of protein synthesis in stretched myotubes can be disrupted by conditioned
media from Lewis lung carcinoma (LLC) cells (Gao & Carson, 2016), suggesting that
tumor-derived cachectic factors can interfere with mechanical signaling inducing protein
synthesis in vitro. While these studies demonstrate that skeletal muscle from tumorbearing animals may be responsive to exercise training or loading, the regulation of protein
synthesis by muscle contraction in the presence of a systemic cachectic environment
requires further investigation.
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Suppressed muscle protein synthesis and mTORC1 signaling are associated with
interleukin-6 (IL-6) induction of signal transducer and activator of transcription 3
(STAT3), nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB), and 5’adenosine monophosphate-activated protein kinase (AMPK) in tumor-bearing mice
(Narsale et al., 2016; White, Puppa, Gao, et al., 2013). Indeed, we have previously
demonstrated an inverse relationship between plasma IL-6 and muscle protein synthesis
during cachexia progression, and systemic IL-6 overexpression can suppress mTORC1
signaling in tumor-bearing mice (White, Puppa, Gao, et al., 2013). In contrast, blocking
muscle IL-6 signaling through STAT3 inhibition or glycoprotein 130 (gp130) receptor loss
attenuated wasting in tumor-bearing mice (Bonetto et al., 2012; Puppa, Gao, et al., 2014).
Additionally, acute and chronic muscle STAT3/NFκB inhibition improved mTORC1
signaling in cachectic mice (Narsale et al., 2016; Puppa, Murphy, et al., 2014). Lastly,
extracellular signal-regulated kinases 1 and 2 (ERK1/2) and P38 mitogen activated protein
kinase (MAPK) inhibition restored myotube stretch-induced protein synthesis in the
presence of LLC derived cachectic factors (Gao & Carson, 2016). Thus, there is a clear
rationale that muscle inflammatory signaling involving STAT3/NFκB can disrupt basal
and mechanical-induced regulation of protein synthesis during cancer cachexia. However,
it is currently unknown if suppressed muscle protein synthesis and mTORC1 signaling can
be activated in the cachectic environment. Therefore, we examined cachectic muscle’s
ability to induce protein synthesis in response to an anabolic stimulus involving ECC, and
determined the role of muscle STAT3/NFκB signaling on ECC-induced anabolic signaling.
Interestingly, we report that mechano-sensitive signaling is maintained in cachectic
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skeletal muscle, but STAT3/NFκB signaling attenuates basal and ECC-induced protein
synthesis.

3.3 METHODS
Animals
Male MIN mice on a B6 background were originally purchased from Jackson
Laboratories and bred at the University of South Carolina’s Animal Resource Facility.
Mice used in the current study were obtained from the investigators breeding colony in the
Center for Colon Cancer Research Mouse Core. Mice were individually housed, kept on
a 12:12-h light-dark cycle, and had access to standard rodent chow (cat#8604 Rodent Diet;
Harlan Teklad) and water ad libitum. Body weight and food measurements were taken
weekly, and the percentage body weight loss from peak body weight was calculated. Mice
lacking the Apc mutation (B6) served as controls for all experiments. The University of
South Carolina’s Institutional Animal Care and Use Committee approved all animal
experimentation in this study.
Experimental Designs
Male B6 (N=15) and MIN (N=27) mice (20 weeks of age) were used to determine
cachectic muscle’s ability to induce mechano-sensitive pathways and protein synthesis in
response to a single ECC bout. In the first experiment, B6 (N=6) and MIN (N=7) mice
were sacrificed immediately following a single ECC bout. In the second experiment, B6
(N=9) and MIN (N=10) mice were sacrificed 3h after a single ECC bout. In the third
experiment, an additional cohort of cachectic MIN mice (N=10; 16 ± 1% body weight loss)
received a single pyrrolidine dithiocarbamate (PDTC) treatment (10 mg/kg body weight;
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cat#: P8765; Sigma Aldrich) 24h prior to a single ECC bout. We have previously found
that treatment paradigm can sufficiently lower muscle inflammatory signaling prior to
muscle contraction (Puppa, Murphy, et al., 2014). In the current study, a single PDTC
treatment did not alter total tumor number (86 ± 4; p=0.91) or plasma IL-6 levels (44 ± 5;
P=0.71), as we have previously observed following short-term treatment after the initiation
of cachexia (Narsale et al., 2016). In all experiments mice were fasted 2h prior to
contraction and remained fasted until sacrifice (immediately or 3h post). Fasting was
initiated at ~0800h in each experiment. There were no differences in cachexia indices (e.g.,
body weight, muscle mass and fat loss) between MIN mice in all experiments, therefore
general animal characteristics from each cohort are summarized in Table 3.1. Additionally,
protein expression in the non-stimulated TA from MIN mice in experiments 1 and 2 were
used to determine the cachectic muscle phenotype (Figure 3.1).
Eccentric contractions
ECC of the tibialis anterior (TA) muscle was induced by high-frequency electrical
stimulation of the sciatic nerve as previously described with slight modifications (Baar &
Esser, 1999; Hardee et al., 2016). Mice were anesthetized via isoflurane (2% in O2 with
1.5% maintenance), the stimulated leg was shaved at the hip region, and two needle
electrodes were placed subcutaneously to stimulate the sciatic nerve. Tetanic muscle
contractions of one hind limb were generated using a Grass Stimulator (Grass Instruments)
for 10 sets of 6 repetitions (100 Hz, 6-12V, 1ms duration). Ten seconds of rest was given
between stimulations and 50 seconds of rest was given between sets. The stimulation
protocol recruits all motor units and results in net plantar flexion of the ankle (Wong &
Booth, 1988, 1990). The dorsiflexors (TA and EDL) undergo ECC while the plantar
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flexors (gastrocnemius, soleus, and plantaris) perform concentric muscle contractions. In
all experiments, the stimulated TA performed ECC while the non-stimulated TA served as
intra-animal control. Our laboratory and others have demonstrated repeated ECC bouts,
but not concentric contractions, can induce muscle and myofiber growth in rodents (alMajid & McCarthy, 2001; Baar & Esser, 1999; Hardee et al., 2016; Wong & Booth, 1988).
Therefore, the TA was examined in all experiments. Mice were given an intraperitoneal
injection of warm saline following the stimulation procedure and returned to cages upon
complete recovery.
Tissue Collection
Mice received an intraperitoneal injection of puromycin (0.04 umol/kg body
weight) 30 minutes prior to sacrifice (Goodman, Mabrey, et al., 2011; Narsale et al., 2016).
Mice were anesthetized with a subcutaneous injection of ketamine/xylazine/acepromazine
cocktail (1.4 ml/kg body weight) at the time of sacrifice. Muscles and organs were rapidly
excised, cleared of excess connective tissue, rinsed in phosphate-buffered saline (PBS),
dried on blotting paper, weighed, and snap frozen in liquid nitrogen. Immediately prior to
dissection blood was collected via retro-orbital sinus with heparinized capillary tubes,
placed on ice, and centrifuged (10,000 x g for 10 min at 4°C). The supernatant was
removed and stored for plasma IL-6 analysis. Plasma and tissue samples were stored at 80°C until analysis.
Western Blotting
Western blot analysis was performed as previously described (Hardee, Puppa, et
al., 2014). Briefly, frozen TA muscle was homogenized in Mueller buffer and protein
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concentration was determined by the Bradford method. Crude TA muscle homogenates
were fractionated on 7-15% sodium dodecyl sulfate (SDS)-polyacrylamide gels and
transferred to polyvinylidene difluoride (PVDF) membranes. Membranes were stained
with Ponceau red to verify equal loading and transfer. Membranes were then blocked at
room temperature (RT) for 1-2h in 5% non-fat milk Tris-buffered saline with 0.1% Tween20 (TBST).

Primary antibodies for puromycin (Millipore, cat#MABE343, 1:2000),

phospho P70S6K (T389) (cat#9205, 1:1000), total P70S6K (cat#2708, 1:1000), RPS6
(S240/244) (cat#2215, 1:500), total RPS6 (cat#2708, 1:1000), phospho Akt (S473)
(cat#4060, 1:1000), total Akt (cat#9272, 1:2000), phospho NFκB (S563) (cat#3033,
1:500), total NFκB (cat#4764, 1:2000), phospho STAT3 (Y750) (cat# 9145, 1:1000), total
STAT3 (cat#4904, 1:2000), phospho AMPK (T172) (cat#, 1:2000), total AMPK
(cat#2603, 1:1000), phospho ACC (S59) (cat#3661, 1:1000), total ACC (cat#3662),
phospho ERK1/2 (T202/Y204) (cat#4370,1:1000), total ERK1/2 (cat#4695, 1:1000), PGC1α (Abcam, cat#ab54481, 1:1000), COXIV (cat#4844, 1:1000), GAPDH (cat#2118,
1:10000), MuRF1 (ECM Biosciences, cat#MP3401, 1:2000), Atrogin-1 (ECM
Biosciences, cat#AP2041, 1:5000), and ubiquitin (cat#3933, 1:2000) were incubated
overnight in 5% TBST milk. We have previously validated the specificity of this PGC-1α
antibody in tibialis anterior skeletal muscle through somatic gene transfer of empty or
PGC-1α overexpression plasmid (data not shown). Membranes were then incubated in 5%
milk-TBST containing anti-rabbit (cat#7074, 1:5000) or anti-mouse (cat#7076, 1:5000)
IgG horseradish-peroxidase conjugated secondary antibodies for 1h at RT. Exceptions to
the aforementioned procedures were that for puromycin incorporation 1% BSA-TBST was
used for primary antibody and horseradish-peroxidase conjugated rabbit anti-mouse IgG2a
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antibody (LifeTechnologies, cat#610220, 1:5000) in 5% milk-TBST was used for
secondary antibody. All antibodies were from Cell Signaling Technology unless otherwise
stated. Tibialis anterior protein extracts from a mouse that did not receive puromycin at
sacrifice was included on all puromycin gels as a negative control.

Enhanced

chemiluminescence (ECL) (GE Healthcare Life Sciences) was used to visualize the
antibody-antigen interactions. Immunoblot images were collected using a digital imager
(SynGene GBox) and quantified by densitometry using imaging software (Image J; NIH).
Each gel contained samples from all groups and data was normalized to the respective
control group (e.g. B6 control).
Plasma Interleukin-6 Concentration
Plasma IL-6 concentrations were determined as previously described (Hetzler et
al., 2015). A commercially available IL-6 enzyme-linked immunosorbent assay kit was
obtained from BD Biosciences and the manufacturer’s protocol was followed. Briefly,
clear 96-well plates were coated and incubated overnight with an IL-6 capture antibody.
The next morning the plate was blocked with assay diluent buffer, washed, and equal
volumes of standards and plasma samples were added in duplicate. After a 2h incubation
the plate was washed and sAV-HRP reagent was added to each well. After several washes,
TMB substrate was added and the reaction was developed for 20 minutes. The reaction
was stopped with sulfuric acid and absorbance was read at 450 nm using an iMark
microplate absorbance reader (Bio-Rad Laboratories).
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Statistical Analysis
Results are reported as the means ± standard error. A repeated-measures two-way
ANOVA was performed to determine differences between cancer cachexia and ECC in B6
and MIN mice. Post-hoc analyses were performed with Student-Newman-Keuls methods
when appropriate. Students t-test was used to determined differences between two groups
when appropriate. The accepted level of significance was set at p<0.05 for all analysis.
Statistical analysis and figure generation were performed using Prism 5 for Mac OS X
(GraphPad Software Inc).

3.4 RESULTS
Systemic and muscle cachectic phenotype
In order to determine if wasting skeletal muscle could respond to a novel ECC bout
we first established the cachectic phenotype in two separate cohorts of male MIN mice.
MIN mice displayed several key features of severe cachexia which included body weight
loss, muscle atrophy, adipose tissue depletion, high tumor burden, elevated plasma IL-6
levels, and hypogonadal features (levator ani-bulbocavernosus [LABC] and seminal
vesicle atrophy) (Table 3.1). Body weights at sacrifice were lower when compared to B6
mice, and significant body weight loss from peak measurement was observed within MIN
mice. Body weight loss was accompanied by reduced TA muscle mass and epididymal fat
loss in MIN mice. Cachexia increased spleen weight and plasma IL-6 compared to B6
mice (Table 3.1). There were no differences in tibia length between B6 and MIN mice.
To further characterize the cachectic phenotype protein expression related to
protein turnover, inflammation and metabolism was examined in the non-stimulated TA
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muscle (Figure 3.1). Cachectic muscle demonstrated disrupted protein turnover regulation.
Akt/mTORC1 signaling was disrupted in cachectic muscle. While Akt was activated,
downstream mTORC1 signaling was suppressed (Figure 3.1A). Furthermore, the E3
ligases Atrogin-1 and MuRF1 were induced in cachectic muscle, which coincided with
increased expression of total ubiquitinated proteins (Figure 3.1A). We have extended our
previous observations that basal Akt activation is disconnected from mTORC1 and
FOXO3 signaling, which may be related to decreased mTORC1 formation and shift
towards mTORC2 formation. However, further investigation is needed to determine the
precise mechanisms for perturbed signaling in cachectic skeletal muscle.

Cachexia

activated inflammatory / mechanical related proteins (STAT3, NFκB, ERK1/2, and P38)
(Figure 3.1B). Lastly, cachexia altered the expression of proteins related to mitochondrial
content (PGC-1α, COXIV) and metabolic regulation (AMPK, ACC), respectively (Figure
3.1C). Overall, these findings demonstrate that severe cachexia in this cohort of mice was
associated with high circulating IL-6, enhanced muscle inflammatory signaling, and
disrupted anabolic and metabolic regulation.
Mechanical signaling response to ECC
Having established the severe cachectic phenotype in this cohort of male MIN mice,
we then examined mechano-sensitive pathways immediately following a single ECC bout
(Figure 3.2A). First, we examined two mitogen-activated protein kinases (MAPKs) which
have been shown to be activated immediately post-ECC (Nader & Esser, 2001; O'Neil et
al., 2009). While cachexia increased basal P38 and ERK1/2 phosphorylation in the nonstimulated TA muscle, ECC-induced their activation irrespective of cachexia (Figure
3.2B). While absolute P38 and ERK1/2 phosphorylation were greater following ECC
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during cachexia, there were no differences in the degree of activation from the noncontracted TA muscle. Given that ECC are a potent stimulator of Akt/mTORC1 signaling
(Nader & Esser, 2001; O'Neil et al., 2009; Thomson, Fick, & Gordon, 2008), we next
determined Akt/mTORC1 activation through phosphorylation of Akt and the downstream
mTORC1 target P70S6K. While cachexia increased basal Akt phosphorylation in the nonstimulated TA muscle, ECC-induced its activation irrespective of cachexia (Figure 3.2C).
Interestingly, while cachexia decreased basal P70S6K phosphorylation in the nonstimulated TA muscle, ECC-induced its activation irrespective of cachexia (Figure 3.2C).
While absolute P70S6K phosphorylation was decreased following ECC during cachexia,
there were no differences in the degree of activation from the non-stimulated TA muscle.
We further validated P70S6K activation through the phosphorylation of the direct P70S6K
target RPS6. Similarly, cachexia decreased basal RPS6 phosphorylation in the nonstimulated TA muscle, while ECC-induced its activation irrespective of cachexia (Figure
3.2C). Collectively, these findings demonstrate that mechano-sensitive pathways were
induced immediately post-ECC despite disrupted basal Akt/mTORC1 signaling in
cachectic MIN mice.
Proteolytic, metabolic, and inflammatory signaling response to ECC
Given that the ubiquitin-proteasome pathway has been implicated in the proteolytic
response to acute resistance exercise (Fry et al., 2013), we examined the expression of two
E3 ligases immediately following a single ECC bout. While ECC-induced Atrogin-1 and
MuRF1 protein expression in B6 mice, this was not observed in MIN mice (Figure 3.2D).
Given the potential role of metabolic stress to inhibit anabolic processes, we next examined
AMPK and its direct downstream target Acetyl-CoA carboxylase (ACC) in response to
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ECC. Interestingly, while the absolute AMPK and ACC phosphorylation were greater
immediately post-ECC during cachexia, there were no differences in the degree of
activation from the non-contracted TA muscle (Figure 3.2E). Lastly, we examined muscle
inflammatory signaling pathways which have been implicated in cachexia and muscle
contraction. Interestingly, STAT3 and NFκB were activated immediately post-ECC in B6
(Figure 3.2F). While basal STAT3 and NFκB were induced by cachexia, only NFκB was
further induced immediately post-ECC in MIN mice (Figure 3.2F). Collectively, these
findings demonstrate that mechano-sensitive pathways remained intact, and was not
associated with an exacerbated metabolic and proteolytic response immediately post-ECC
in cachectic MIN mice.
Cachectic muscle anabolic signaling response to ECC
Having established the cachectic muscle’s mechano-sensitive response to a single
ECC bout, we then determined if cachexia disrupted ECC-induced protein synthesis and
mTORC1 signaling. Therefore, anabolic signaling was examined 3h after a single ECC
bout (Figure 3.3A). While cachexia suppressed protein synthesis, ECC activated protein
synthesis irrespective of cachexia. Although the relative induction by ECC was not altered
by cachexia, the absolute protein synthesis rate remained suppressed relative to B6 mice
(Figure 3.3B). We then examined several upstream regulators and downstream targets
implicated in the mechanical activation of mTORC1 signaling.

Interestingly, while

cachexia increased basal P38 and ERK1/2 phosphorylation, these mechano-sensitive
signaling molecules were not altered 3h post-ECC irrespective of cachexia (Figure 3.3C).
We then examined Akt/mTORC1 activation in response to ECC. While Akt was not
altered by ECC regardless of cachexia, there was a strong trend (P=0.07) for ECC to
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decrease Akt phosphorylation in B6 mice (Figure 3.3D). While cachexia decreased the
phosphorylation of P70S6K, ECC-induced its activation irrespective of cachexia (Figure
3D). ECC also increased RPS6 phosphorylation irrespective of cachexia (Figure 3.3D).
Collectively, these findings demonstrate that protein synthesis and mTORC1 signaling was
induced 3h post-ECC in severely cachectic MIN mice.
Cachectic muscle proteolytic, metabolic, and inflammatory response to ECC
Muscle protein breakdown, metabolic dysfunction, and enhanced inflammatory
signaling have established roles during cancer-induced muscle wasting, and these same
signaling pathways are perturbed in response to muscle contraction (Begue et al., 2013;
Serrano et al., 2008; Washington et al., 2011; White et al., 2009). ECC did not alter the
expression of Atrogin-1 and MuRF1 irrespective of cachexia (Figure 3.4A). We have
previously shown that the sustained activation of AMPK coincided with suppressed
mTORC1 signaling 3h after a single bout of concentric muscle contractions (Puppa,
Murphy, et al., 2014). Interestingly, while AMPK and ACC were activated by cachexia,
ECC decreased their activation irrespective of cachexia (Figure 3.4B). Lastly, we found
that both STAT3 and NFκB phosphorylation were induced by cachexia, and were further
increased by ECC irrespective of cachexia (Figure 3.4C).

Collectively, these data

demonstrate that muscle metabolic and inflammatory signaling molecules were sensitive
to both cachexia and contraction.
Muscle inflammatory signaling regulation of basal and ECC-induced protein synthesis.
Given that muscle STAT3 and NFκB signaling was induced by cachexia and ECC,
we next examined its involvement in the regulation of basal and ECC-induced protein
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synthesis in cachectic MIN mice.

To accomplish this, we used an established

pharmacological approach to lower basal muscle inflammatory signaling prior to ECC
(Narsale et al., 2016; Puppa, Murphy, et al., 2014). This experimental paradigm has
previously been used by our laboratory to lower muscle STAT3/NFκB signaling prior to a
single bout of low-frequency electrical stimulation (Puppa, Murphy, et al., 2014).
Therefore, we administered PDTC 24h prior to a single ECC bout in cachectic MIN mice
(Figure 3.5A). As expected, PDTC decreased basal STAT3 and NFκB phosphorylation in
the non-stimulated TA muscle (Figure 3.5B). There was no effect of PDTC on basal P38,
ERK1/2, or Akt in cachectic skeletal muscle (data not shown). Interestingly, PDTC
induced basal protein synthesis in cachectic muscle, and was further increased 3h postECC (Figure 3.5C). While there was a trend (P=0.08) for PDTC to increase basal P70S6K
phosphorylation, there was a robust induction 3h post-ECC. Similarly, PDTC increased
basal RPS6 phosphorylation, and was further increased 3h post-ECC in cachectic skeletal
muscle (Figure 3.5D).

As previously observed, the activation of mechano-sensitive

pathways (P38, ERK1/2, Akt) were not altered 3h post-ECC (data not shown).
Collectively, these data demonstrate that acute muscle STAT3 and NFκB inhibition
improved basal and ECC-induced protein synthesis in cachectic MIN mice.
Proteolytic, metabolic, and inflammatory signaling response to PDTC and ECC.
Lastly, we examined the proteolytic, metabolic, and inflammatory signaling
response to PDTC and ECC. Neither PDTC nor ECC altered the expression of Atrogin-1
and MuRF1 in MIN mice (Figure 3.5E). While PDTC did not alter basal AMPK and ACC
activation in cachectic skeletal muscle, these molecules were further suppressed 3h postECC (Figure 3.5F). Interestingly, while PDTC suppressed basal muscle STAT3 and NFκB
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signaling, it did not block the induction 3h post-ECC (Figure 3.5G). Altogether, these data
demonstrate that improved ECC-induced protein synthesis by PDTC corresponded to
suppressed metabolic signaling, but was independent to altered proteolytic E3 ligase
expression in cachectic MIN mice.

3.5 DISCUSSION
Healthy skeletal muscle stimulates protein synthesis in response to anabolic stimuli
associated with daily living, which can include physical activity and feeding. While basal
muscle protein synthesis and mTORC1 signaling is suppressed in tumor-bearing mice and
some human cancer patients (Emery et al., 1984; White, Baynes, et al., 2011), the capacity
for cachectic muscle to respond to an anabolic stimulus is not well understood. This
knowledge could have significant ramifications for the treatment of the cachectic cancer
patient. Resistance exercise consisting of ECC is a potent stimulator of protein synthesis
and muscle growth (Chesley et al., 1992; Eliasson et al., 2006; Fry et al., 2011). We have
previously found that repeated ECC bouts after the initiation of cachexia attenuated
myofiber atrophy and was accompanied by suppressed muscle inflammatory signaling.
However, the capacity to activate mTORC1 signaling and protein synthesis by ECC has
not been investigated. Therefore, we examined if cachectic muscle maintained the ability
to induce mechano-sensitive pathways and protein synthesis in response to a single ECC
bout. We report that ECC-induced mechanical signaling was maintained in cachectic
muscle, but the capacity for increased protein synthesis was attenuated. This finding
demonstrates an unexpected uncoupling between the activation of known mechanosensitive regulators of anabolic signaling and the absolute protein synthesis induction.
Therefore, we also examined if the cachectic environment involving muscle inflammatory
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signaling could regulate ECC-induced protein synthesis. Interestingly, both cachexia and
ECC-induced muscle STAT3 and NFκB signaling. However, muscle STAT3/NFκB
inhibition by PDTC increased basal and ECC-induced protein synthesis in cachectic MIN
mice. These findings demonstrate that mechano-sensitive signaling is responsive to ECC,
and highlight muscle inflammatory signaling’s role in the altered regulation of both basal
and ECC-induced protein synthesis during cancer cachexia.
While exercise training has been discussed as a potential therapy to mitigate muscle
atrophy during cancer cachexia, there is currently a limited understanding of the acute
response and training adaptation to exercise. Whole-body treadmill exercise prevented
muscle mass loss in tumor-bearing mice (Deuster, Morrison, & Ahrens, 1985; Penna et al.,
2011; Salomao, Toneto, Silva, & Gomes-Marcondes, 2010), and blocked the disruption of
muscle oxidative metabolism regulation at the initiation of cachexia (Puppa et al., 2012;
White et al., 2012). However, the inability of severely cachectic mice to perform voluntary
exercise remains a consistent barrier and has limited our understanding of the muscle
response to exercise during refractory cachexia. To address this, we have reported that
cachexia disrupted the metabolic and anabolic signaling response to a single bout of
stimulated low-frequency concentric contractions (Puppa, Murphy, et al., 2014), which
mimics low intensity, endurance type exercise. Given that exercise involves muscle
contractions that can vary in overall intensity and metabolic demand, the molecular
responses related to growth and metabolism are distinct between contraction types.
Furthermore, the response of cachectic muscle to high force contractions is not well
established. Therefore, we first examined the mechanical and metabolic response to a
single ECC bout. We found that several contraction and mechano-sensitive kinases
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(MAPKs, Akt, P70S6K) were induced by ECC in cachectic muscle. The activation of P38,
ERK1/2, and Akt was transient, which extends previous observations in mouse skeletal
muscle (Nader & Esser, 2001). In addition, P70S6K activation by ECC remained elevated
irrespective of cachexia, which is in contrast to our previous observations using concentric
muscle contractions (Puppa, Murphy, et al., 2014). Interestingly, we also observed a
transient AMPK induction by ECC, which was not associated with mTORC1 signaling
inhibition. Collectively, we provide initial evidence that the mechanical and metabolic
plasticity of muscle to ECC is maintained despite the presence of a systemic cachectic
environment.
There is considerable interest in understanding the mechanisms that serve to repress
cachectic muscle anabolic signaling. We previously reported that repeated ECC bouts
performed after the initiation of cancer cachexia could attenuate myofiber atrophy (Hardee
et al., 2016), however this study did not determine whether these improvements were
related to the induction of muscle growth or the attenuation of muscle breakdown. While
our current study has extended these findings to demonstrate that mechano-signaling in
cachectic muscle is maintained, the ability to synthesize protein remained dramatically
suppressed. These findings further demonstrate that the capacity for either basal or
contraction-induced muscle protein synthesis is suppressed by cachexia. The chronic
activation of AMPK in cachectic skeletal muscle from tumor-bearing mice has been
implicated as a potential mechanism for mTORC1 and protein synthesis suppression
(White, Baynes, et al., 2011; White, Puppa, Gao, et al., 2013). Interestingly, our current
study demonstrates the induction of protein synthesis after ECC coincides with reduced
AMPK activation in tumor-bearing mice. Furthermore, reduced AMPK activation after a
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single ECC bout has also recently been observed in castrated mice (Steiner et al., 2017).
These findings are in contrast to our previous observations using low-frequency electrical
stimulation, and point to the differential regulation of muscle metabolic signaling by
different types of contraction.

We previously found a sustained AMPK activation

following a single bout of low-frequency, concentric contractions in cachectic skeletal
muscle (Puppa, Murphy, et al., 2014). The specificity of the responses induced by different
types of contractions may be related to metabolic stress as cachectic muscle develops
mitochondrial dysfunction (Antunes et al., 2014; Tzika et al., 2013; White, Baltgalvis, et
al., 2011). The cachectic muscle’s anabolic and metabolic response to different contraction
types will require further investigation. Nonetheless, our findings suggest ECC may be a
potential therapeutic treatment to promote muscle anabolism during cancer cachexia
progression.
Muscle signaling related to inflammation, energy status, and proteostasis are
disrupted during cachexia progression, and have been implicated in the regulation of
muscle wasting (Carson, Hardee, & VanderVeen, 2016; K. C. Fearon, Glass, & Guttridge,
2012). Interestingly, many of these same pathways are induced by muscle contraction and
exercise (B. Egan & Zierath, 2013). IL-6 and muscle STAT3 signaling through the gp130
receptor are activated during the progression of cachexia (Bonetto et al., 2012; Bonetto et
al., 2011; White, Baltgalvis, et al., 2011), and are associated with mTORC1 singaling and
protein suppression in preclinical cachexia models (White, Baynes, et al., 2011; White,
Puppa, Gao, et al., 2013). Inhibition of muscle IL-6 signaling through either direct STAT3
inhibition or gp130 loss can attenuate wasting in mouse models of cachexia (Bonetto et al.,
2012; Puppa, Gao, et al., 2014). We have previously found that short-term PDTC treatment
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attenuated the suppression of mTORC1 signaling and protein synthesis while
concomitantly reducing muscle STAT3 and NFκB activation in MIN mice (Narsale et al.,
2016; Puppa, Murphy, et al., 2014). We extend these findings by demonstrating a single
PDTC dose improved basal protein synthesis.

It has recently been suggested that

intermittent cycles of pathway inhibition / activation may be required to combat muscle
wasting during cancer cachexia (Au, Desai, Koniaris, & Zimmers, 2016). Indeed, many
cytokine-related signaling pathways have established roles in myogenesis (Costamagna,
Costelli, Sampaolesi, & Penna, 2015) and load-induced muscle growth and remodeling
(Serrano et al., 2008; Spangenburg & Booth, 2006; White et al., 2009). Therefore, we
utilized an experimental paradigm that lowered chronic muscle inflammatory signaling,
but did not block contraction-induced signaling (Puppa, Murphy, et al., 2014).
Importantly, we found that PDTC treatment increased both basal and ECC-induced protein
synthesis in cachectic muscle. These findings demonstrate that cachectic muscle retains
the anabolic capacity to increase protein synthesis, and inflammatory signaling contributes
to the suppression of these processes. Additional research is warranted to determine the
specific mechanisms related to STAT3 and NFκB that serve to diminish the capacity for
protein synthesis in cachectic muscle. Moreover, further research is also required to
determine the effect of muscle inflammatory signaling on metabolic remodeling in
response to repeated contraction bouts, which could dramatically impact health outcomes
related to exercise.
Conclusion
In summary, we examined cachectic muscle’s ability to induce mTORC1 signaling
and protein synthesis in response to ECC, and determined the role of muscle inflammatory
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signaling involving STAT3 and NFκB on ECC-induced anabolic signaling. We found that
mechano-sensitive signaling pathways related to P38, ERK1/2 and Akt were not altered by
the cachectic environment in wasting muscle. While cachexia did not attenuate the ECC
induction of mTORC1 signaling, the capacity for protein synthesis remained suppressed
compared to healthy controls. Interestingly, we found that reducing muscle STAT3/NFκB
signaling improved basal and ECC-induced protein synthesis during severe cachexia.
These studies demonstrate that mechano-sensitive signaling pathways are maintained in
skeletal muscle, but STAT3/NFκB signaling serves to attenuate basal and ECC-induced
protein synthesis. Further work is necessary to determine whether intermittent antiinflammatory therapies combined with exercise training may be useful to alleviate
suppressed muscle protein synthesis during cancer cachexia.
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Table 3.1. B6 and MIN mice that performed a single ECC bout.
B6

MIN

15

27

Peak

26.7 ± 0.7

24.7 ± 0.4

ECC

26.7 ± 0.7

20.7 ± 0.4*†

0±0

-16 ± 0.6*

Tibialis anterior, mg

49 ± 0.7

28 ± 0.9*

Epididymal fat, mg

361 ± 44

3 ± 2*

Spleen, mg

71 ± 4

506 ± 21*

Testes, mg

201 ± 7

103 ± 8*

LABC, mg

88 ± 2

31 ± 2*

Seminal vesicle, mg

261 ± 8

32 ± 3*

Plasma IL-6, pg/ml

0±0

43 ± 3*

Tumor number

0±0

87 ± 4*

16.9 ± 0.1

16.8 ± 0.1

No. of mice
Body weight, g

% Change

Tibia length, mm

Data are means ± standard error. There were no differences between control and stimulated
TA muscles, therefore the average is presented. A two-way repeated measures ANOVA
was used to determine differences between body weight at peak and immediately prior to
ECC. Post-hoc analyses were performed with Student-Knewman-Keuls methods when
appropriate. Students t-test was used to determine differences in all other variables.
Statistical significance was set at p<0.05. Abbreviations: ECC, Eccentric contractions.
No., number. g, grams. mg, milligrams. pg, picogram. ml, milliliter. mm, millimeter.
LABC, levator ani / bulbocavernosus muscle. * = significantly different from B6. † =
significantly different from difference from peak body weight.
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Figure 3.1. Cachectic muscle phenotype. A) Protein turnover regulation in B6 and MIN
mice. B) Inflammatory and mechano-sensitive pathways in B6 and MIN mice. C)
Metabolic signaling regulation in B6 and MIN mice. Tibialis anterior (TA) protein
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expression was examined in the non-stimulated muscle. The activation of signaling
molecules was determined by the phosphorylated and total ratio when appropriate. For
protein expression, values were corrected for equal protein loading using GAPDH. All
samples were run on the same gel and normalized to B6 Control values. Dotted lines
indicate images were cropped for representative purposes. Data are means ± standard error.
N = 15 B6; N=17 MIN. Students t-test was used to determine differences between B6 and
MIN mice. Statistical significance was set at p<0.05. * = significantly different from B6.
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Figure 3.2. Muscle mechanical signaling immediately post-ECC. A) Experimental
Design. B6 and MIN mice were sacrificed immediately post-ECC. Mice were fasted 2h
prior to contraction. B) Muscle mitogen activated protein kinase (MAPK) signaling
regulation by ECC in B6 and MIN mice. C) Muscle Akt/mTORC1 signaling regulation
by ECC in B6 and MIN mice. D) Muscle proteolytic regulation by ECC in B6 and MIN
mice. E) Muscle metabolic signaling regulation in B6 and MIN mice. F) Muscle
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inflammatory signaling regulation by ECC in B6 and MIN mice. The activation of
signaling molecules was determined by the phosphorylated and total ratio when
appropriate. For protein expression, values were corrected for equal protein loading using
GAPDH. All samples were run on the same gel and normalized to B6 Control values.
Dotted lines indicate images were cropped for representative purposes. Data are means ±
standard error. N = 6 B6; N=7 MIN. A two-way repeated measures ANOVA was used to
determine differences between treatment groups. Post-hoc analyses were performed with
Student-Knewman-Keuls methods when appropriate. Statistical significance was set at
p<0.05. Different letters are statistically different. & = main effect of ECC. # = main
effect of MIN.
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Figure 3.3. Muscle protein synthesis and mTORC1 signaling 3h post-ECC. A)
Experimental Design. B6 and MIN mice were sacrificed 3h post a single bout of ECC.
Mice were fasted 2h prior to contraction and remained fasted during the 3h recovery until
sacrifice. Mice were injected with puromycin 30min prior to sacrifice. B) Muscle protein
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synthesis regulation by ECC in B6 and MIN mice. C) Muscle mitogen activated protein
kinase (MAPK) signaling regulation by ECC in B6 and MIN mice. D) Muscle
Akt/mTORC1 signaling regulation by ECC in B6 and MIN mice. The activation of
signaling molecules was determined by the phosphorylated and total ratio when
appropriate. For protein expression, values were corrected for equal protein loading using
GAPDH. All samples were run on the same gel and normalized to B6 Control values.
Dotted lines indicate images were cropped for representative purposes. Data are means ±
standard error. N = 9 B6; N=10 MIN. A two-way repeated measures ANOVA was used
to determine differences between treatment groups. Post-hoc analyses were performed
with Student-Knewman-Keuls methods when appropriate. Statistical significance was set
at p<0.05. Different letters are statistically different. & = main effect of ECC. # = main
effect of MIN.
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Figure 3.4. Muscle proteolytic, metabolic, and inflammatory signaling 3h post-ECC.
A) Muscle proteolytic regulation by ECC in B6 and MIN mice. B) Muscle metabolic
signaling regulation by ECC in B6 and MIN mice. C) Muscle inflammatory signaling
regulation by ECC in B6 and MIN mice. The activation of signaling molecules was
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determined by the phosphorylated and total ratio when appropriate. For protein expression,
values were corrected for equal protein loading using GAPDH. All samples were run on
the same gel and normalized to B6 Control values. Dotted lines indicate images were
cropped for representative purposes. Data are means ± standard error. N = 9 B6; N=10
MIN. A two-way repeated measures ANOVA was used to determine differences between
treatment groups. Post-hoc analyses were performed with Student-Knewman-Keuls
methods when appropriate. Statistical significance was set at p<0.05. Different letters are
statistically different. & = main effect of ECC. # = main effect of MIN.
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Figure 3.5. Muscle inflammatory signaling regulation of ECC-induced protein
synthesis in MIN mice. A) Experimental Design. MIN mice were sacrificed 3h postECC. A cohort of MIN mice were given a single PDTC treatment (10 mg/kg body weight)
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24h prior to ECC. Mice were fasted 2h prior to ECC and remained fasted during the 3h
recovery until sacrifice. Mice were injected with puromycin 30min prior to sacrifice. B)
Muscle STAT3 and NFκB signaling in the non-stimulated muscle following a single PDTC
treatment. C) Muscle protein synthesis regulation by PDTC and ECC in MIN mice. D)
Muscle mTORC1 signaling regulation by PDTC and ECC in MIN mice. E) Muscle
proteolytic regulation by PDTC and ECC in MIN mice. F) Muscle metabolic signaling
regulation by PDTC and ECC in MIN mice. G) Muscle inflammatory signaling regulation
by PDTC and ECC in MIN mice. The activation of signaling molecules was determined
by the phosphorylated and total ratio when appropriate. For protein expression, values
were corrected for equal protein loading using GAPDH. All samples were run on the same
gel and normalized to MIN Control values. Dotted lines indicate images were cropped for
representative purposes. Data are means ± standard error. N = 10 MIN; N=10 MIN PDTC.
A two-way repeated measures ANOVA was used to determine differences between
treatment groups. Post-hoc analyses were performed with Student-Knewman-Keuls
methods when appropriate. Statistical significance was set at p<0.05. Different letters are
statistically different. & = main effect of ECC. # = main effect of PDTC.

87

CHAPTER 4
SYSTEMIC IL-6 AND MUSCLE GP130 REGULATION OF BASAL
AND ECCENTRIC CONTRACTION-INDUCED PROTEIN SYNTHESIS1

1

Hardee JP, Fix DK, Wang X, Goldsmith EC, Koh HJ, and JA Carson. Systemic IL-6 and
Muscle GP130 Regulation of Basal and Eccentric Contraction-Induced Protein Synthesis.
To be submitted to Front Physiol.
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4.1 ABSTRACT
Mechanical loading is a potent stimulator of mechanistic target of rapamycin
(mTORC1) signaling and muscle growth. While repeated ECC bouts during cachexia
progression attenuated muscle mass loss in tumor-bearing mice, we have found that tumorderived cachectic factors disrupted stretch-induced protein synthesis in cultured myotubes.
The ability of tumor-derived cachectic factors and cytokines to disrupt mechanical
signaling during muscle wasting has not been well described. Paradoxically, IL-6 signaling
through the muscle gp130 receptor has been implicated in muscle wasting with cancer
cachexia and muscle mass regulation with contraction and loading.

Therefore, we

examined long-term IL-6 regulation of mechanically induced protein synthesis in atrophic
muscle. First, we determined if long-term IL-6 (24h, 100ng/mL) treatment could disrupt
stretch-induced protein synthesis in differentiated C2C12 myotubes. Next, we determined
if 2-wks systemic IL-6 overexpression could disrupt ECC-induced protein synthesis in
tumor bearing ApcMin/+ (MIN) mice. Lastly, we examined basal and ECC-induced protein
synthesis regulation by systemic IL-6 overexpression in mice lacking muscle gp130
receptor. The stimulated tibialis anterior (TA) muscle performed ECC while the nonstimulated TA served as intra-animal control.

Long-term IL-6 exposure induced

inflammatory signaling pathways related to GP130, STAT3, and NFkB, and suppressed
myotube stretch-induction of protein synthesis and mTORC1 signaling.

Muscle

inflammatory signaling pathways related to GP130, STAT3, and NFkB were also induced
by systemic IL-6 overexpression in both healthy C57BL/6 (B6) and MIN mice. Systemic
IL-6 overexpression suppressed basal muscle protein synthesis in both B6 and MIN mice.
While systemic IL-6 overexpression disrupted ECC-induced protein synthesis in MIN
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mice, this response was maintained in B6 mice. Interestingly, ECC-induced mTORC1
signaling was not altered by systemic IL-6 overexpression regardless of cachexia mice.
Lastly, muscle gp130 receptor blocked systemic IL-6 suppression of basal protein
synthesis. However, mice lacking muscle gp130 receptor demonstrated an attenuate
protein synthesis response to ECC. These studies demonstrate that IL-6 signaling through
gp130 can regulate basal and mechanical activation of protein synthesis in skeletal muscle.
Keywords: Mechanical Signaling, Eccentric contractions, Muscle Protein Synthesis,
Cancer Cachexia

4.2 INTRODUCTION
Cancer cachexia, a wasting syndrome characterized by skeletal muscle depletion,
contributes to increased patient morbidity and mortality (K. C. Fearon, 1992; Tisdale,
2009). Additional consequences of skeletal muscle mass depletion in cancer patients can
include reduced anticancer therapy tolerance, increased susceptibility to treatment toxicity,
and decreased patient quality of life (Barret et al., 2014; Evans et al., 2008; H. W. Jung et
al., 2015). Therefore, it is recognized that the maintenance of skeletal muscle mass and
metabolic function are critically important during cancer patient treatment and survival.
Skeletal muscle mass is regulated through the balance between protein synthesis and
breakdown processes. The protein synthetic rate is controlled by translational efficiency
and capacity, which is regulated by the mechanistic target of rapamycin complex 1
(mTORC1). mTORC1 has been implicated in the regulation of cap-dependent initiation
of translation through the phosphorylation of substrates such as eukaryotic initiation factor
(eIF) 4E binding protein 1 (4E-BP1) and p70 ribosomal protein S6 kinase (P70S6K)
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(Bentzinger et al., 2013; Bentzinger et al., 2008; Kimball et al., 2002; Laplante & Sabatini,
2009). While cachexia-induced wasting is linked to disrupted mTORC1 signaling and
suppressed protein synthesis (Eley & Tisdale, 2007; Lima, Sato, Enos, Baynes, & Carson,
2013; Lopes, Black, Ashford, & Pain, 1989; White, Baynes, et al., 2011), the systemic
drivers regulating cancer-induced wasting have not been fully elucidated.
Several members of the interleukin-6 (IL-6) family of cytokines (e.g., IL-6, IL-11,
leukemia inhibitory factor [LIF]) have been implicated in muscle metabolism and growth
regulation (Pal, Febbraio, & Whitham, 2014; Serrano et al., 2008; White et al., 2009). In
general, IL-6 family of cytokines signal through gp130 by forming either heterodimer or
homodimer complexes consisting of the cytokine, ligand specific transmembrane receptor
α-subunit, and the transmembrane type I cytokine receptor β-subunit gp130 (Ernst &
Jenkins, 2004). Signal transduction through gp130 dimerization leads to the activation of
several intracellular pathways, which include JAK/STAT, Ras/ERK, and PI3K/Akt (Ernst
& Jenkins, 2004; Scheller, Chalaris, Schmidt-Arras, & Rose-John, 2011). Circulating
levels of these cytokines are elevated during wasting in patients and preclinical models
(Bonetto et al., 2011; Tazaki et al., 2011), and have been implicated in muscle wasting
through the activation of gp130/STAT3 signaling during cancer cachexia (Bonetto et al.,
2012; Bonetto et al., 2011; S. J. Lee & Kim, 2017; Puppa, Gao, et al., 2014; White, Baynes,
et al., 2011). While systemic IL-6 overexpression can disrupt mTORC1 signaling and
protein synthesis in tumor-bearing mice (White, Puppa, Gao, et al., 2013), blocking muscle
IL-6 signaling through direct STAT3 inhibition or gp130 receptor loss attenuated wasting
independent to protein synthesis activation (Bonetto et al., 2012; Puppa, Gao, et al., 2014).
Whether cachectic muscle retains the ability to induce protein synthesis in the presence of
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elevated systemic IL-6 and muscle gp130/STAT3 signaling has not been fully explored,
which could have therapeutic implications for the cachectic cancer patient.
Exercise is a non-pharmacological treatment approach that improves indices of
health related to muscle and systemic function in healthy individuals and also those with
chronic disease (Hurley, Hanson, & Sheaff, 2011; Zinna & Yarasheski, 2003). Skeletal
muscle mass is highly influenced by mechanically induced changes in protein synthesis,
and the activation of mTORC1 is required for increased protein synthesis in response to
mechanical loading (Bodine, Stitt, et al., 2001; Drummond, Fry, et al., 2009; Goodman,
Frey, et al., 2011). ECC-induced by high-frequency electrical stimulation have been used
to examine signaling associated with muscle hypertrophy in rodents (Baar & Esser, 1999;
Nader & Esser, 2001; Witkowski et al., 2010), and have demonstrated great utility for
improving our mechanistic understanding of contraction-induced protein synthesis and
mTORC1 signaling (Jacobs et al., 2013; O'Neil et al., 2009; West et al., 2016). Related to
cancer cachexia, there is evidence that repeated ECC bouts can attenuate muscle and
myofiber atrophy in tumor-bearing mice (al-Majid & McCarthy, 2001; Hardee et al., 2016).
While we have found that repeated ECC bouts could attenuate myofiber atrophy
independent to changes in plasma IL-6 levels (Hardee et al., 2016), significant gaps remain
in our understanding of protein synthesis activation by ECC during cancer cachexia.
Moreover, we have found that tumor-derived cachectic factors blocked the mechanical
activation of protein synthesis in vitro (Gao & Carson, 2016), which could have significant
ramifications on protein synthesis activation by ECC. Thus, the interaction between
mechanical signaling and systemic inflammatory cytokines on muscle protein synthesis
regulation requires further investigation.
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While the suppression of basal protein synthesis may not fully account for the
severe muscle wasting that accompanies cancer (Horstman et al., 2016), it has been
recognized that the inability to stimulate protein synthesis in response to anabolic stimuli
(e.g., anabolic resistance) can have significant long-term ramifications on skeletal muscle
homeostasis (Fry & Rasmussen, 2011; Walker et al., 2011). However, our understanding
of muscles ability to induce protein synthesis following mechanical stimuli in the presence
of a systemic cachectic environment has not been fully elucidated. Therefore, the purpose
of this study was to determine IL-6 regulation of basal and mechanically induced protein
synthesis and mTORC1 signaling during cancer cachexia. The interaction between IL-6
and mechanical stimulation was examined in C2C12 myotubes and skeletal muscle from
MIN and skeletal-muscle specific gp130 KO mice. We hypothesized that IL-6 would block
the mechanical activation of protein synthesis in atrophic muscle. To test this hypothesis,
we first examined long-term IL-6 regulation of myotube stretch-induced protein synthesis.
We then examined systemic IL-6 overexpression regulation of ECC-induced protein
synthesis in B6 and MIN mice. Lastly, we examined IL-6 overexpression regulation of
ECC-induced protein synthesis in gp130 KO mice. We provide evidence that elevated
STAT3 and AMPK activation by IL-6 disrupts mechanically induced protein synthesis in
skeletal muscle.

4.3 METHODS
Animals
Male MIN mice were originally purchased from Jackson Laboratories (Bar Harbor,
ME), bred at the University of South Carolina’s Center for Colon Cancer Research Mouse
Core, and obtained from the investigators breeding colony for the current experiments.
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Littermates lacking the Apc mutation (B6) were used as controls. In addition, male LoxPflanked (floxed) mice for IL-6ST gene (provided by Dr. Colin Stewart in collaboration with
Dr. Lothar Hennighausen) were crossed with heterozygous myosin light chain 1f (Mlc)Cre mice (provided by Dr. Steven Burden; ref (Bothe, Haspel, Smith, Wiener, & Burden,
2000)). The offspring positive for Cre were crossed with IL-6STlox/lox to obtain breeding
pairs for generation of the mice used in the current study: IL-6STlox/lox Mlc-Cre+/-, which
lack gp130 expression in muscle cells (herein referred to as gp130 KO), and IL-6STlox/lox
Mlc-Cre-/-, which express gp130 in muscle cells (herein referred to as gp130 WT). All
mice were on a B6 background and genotyped by PCR analyses using tail genomic DNA
as previously described (Mehl, Davis, Berger, & Carson, 2005; Puppa, Gao, et al., 2014).
Mice were individually housed, kept on a 12:12-h light-dark cycle, and had access to
standard rodent chow (cat#8604 Rodent Diet; Harlan Teklad) and water ad libitum. Body
weight and food measurements were taken weekly, and the percentage body weight loss
from peak body weight was calculated (B6 and MIN experiments). The University of
South Carolina’s Institutional Animal Care and Use Committee approved all animal
experimentation in this study.
Systemic IL-6 overexpression
In vivo intramuscular electroporation of an IL-6 overexpression plasmid was used
to increase circulating IL-6 levels in mice as previously described (White, Puppa, Gao, et
al., 2013). The quadriceps muscle was used as a vessel to produce IL-6 and secrete it into
circulation and was not used for any analyses in the study. The TA muscle used in the
study was not subjected to electroporation. Briefly, mice were injected with 50 ug of the
IL-6 plasmid driven by the CMV promoter, or empty control vector, into the quadriceps
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muscle. Mice were anesthetized with a 2% mixture of isoflurane and oxygen (1 L/min).
The leg was shaved and a small incision was made over the quadriceps muscle. Fat was
dissected away from the muscle, and the plasmids were injected in a 50-ul volume of
phosphate-buffered saline (PBS). A series of eight 50-ms, 100-V pulses was used to
promote uptake of the plasmid into myofibers, and then the incision was closed with a
wound clip. Both vector control (N=10/genotype) and IL-6 (N=10/genotype) groups
received the appropriate plasmid starting at 12 wks. of age, and a second electroporation
was performed at 13 wks. of age to maintain elevated plasma IL-6 levels. At 14 wks. of
age mice performed a single ECC bout and were sacrificed 3h post-ECC.
Eccentric contractions (ECC)
ECC of the TA muscle was induced by high-frequency electrical stimulation of the
sciatic nerve as previously described with slight modifications (Baar & Esser, 1999; Hardee
et al., 2016). Mice were anesthetized via isoflurane (2% in O2 with 1.5% maintenance),
the stimulated leg was shaved at the hip region, and two needle electrodes were placed
subcutaneously to stimulate the sciatic nerve. Tetanic muscle contractions of one hind limb
were generated using a Grass Stimulator (Grass Instruments) for 10 sets of 6 repetitions
(100 Hz, 6-12V, 1ms duration). Ten seconds of rest was given between stimulations and
50 seconds of rest was given between sets. The stimulation protocol recruits all motor
units and results in net plantar flexion of the ankle (Wong & Booth, 1988, 1990). The
dorsiflexors (TA and EDL) undergo ECC while the plantar flexors (gastrocnemius, soleus,
and plantaris) perform concentric muscle contractions. In all experiments, the stimulated
TA performed ECC while the non-stimulated TA served as intra-animal control. Our
laboratory and others have demonstrated repeated ECC bouts, but not concentric
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contractions, can induce muscle and myofiber growth in rodents (al-Majid & McCarthy,
2001; Baar & Esser, 1999; Hardee et al., 2016; Wong & Booth, 1988). Therefore, the TA
was examined in all experiments. Mice were given an intraperitoneal injection of warm
saline following the stimulation procedure and returned to cages upon complete recovery.
Tissue Collection
Mice received an intraperitoneal injection of puromycin (0.04 umol/kg body
weight) 30 minutes prior to sacrifice (Goodman, Mabrey, et al., 2011; Narsale et al., 2016).
Mice were anesthetized with a subcutaneous injection of ketamine / xylazine /
acepromazine cocktail (1.4 ml/kg body weight) at the time of sacrifice. Muscles and organs
were rapidly excised, cleared of excess connective tissue, rinsed in phosphate-buffered
saline (PBS), dried on blotting paper, weighed, and snap frozen in liquid nitrogen.
Immediately prior to dissection blood was collected via retro-orbital sinus with heparinized
capillary tubes, placed on ice, and centrifuged (10,000 x g for 10 min at 4°C). The
supernatant was removed and stored for plasma IL-6 analysis. Plasma and tissue samples
were stored at -80°C until analysis.
C2C12 cell culture
C2C12 myoblasts purchased from the American Type Culture Collection (Manassas,
VA) were cultured in DMEM supplemented with 10% FBS, 50 U/ml penicillin, and 50
ug/ml streptomycin. Myoblasts were then suspended (1x106 cells/mL) and plated onto
Silastic membrane mounted in a stretching device (~1.5–2x105 cells/stretching device).
The cells were grown to ~95% confluence and differentiated into myotubes. To induce
differentiation, C2C12 myoblasts were incubated in DMEM supplemented with 2% heat96

inactivated horse serum, 50 U/ml penicillin, and 50 ug/ml streptomycin. After 96 h
differentiation myotubes were treated with control (DMSO) or recombinant IL-6 (100
ng/mL, Sigma) for 24 h. To induce 5% stretch, screw nuts on both axles of the stretching
device were rotated by 1.5 cycles using sterile forceps after 20h of IL-6 exposure.
Myotubes were constantly stretched during the last 4h of IL-6 exposure. Protein was
collected as previously described (Gao & Carson, 2016; White, Puppa, Gao, et al., 2013).
Western Blotting
Western blot analysis was performed as previously described [36]. Briefly, frozen
TA muscle was homogenized in Mueller buffer and protein concentration was determined
by the Bradford method. Crude TA muscle homogenates and myotube extracts were
fractionated on 7-15% sodium dodecyl sulfate (SDS)-polyacrylamide gels and transferred
to polyvinylidene difluoride (PVDF) membranes. Membranes were stained with Ponceau
red to verify equal loading and transfer.

Membranes were then blocked at room

temperature (RT) for 1-2h in 5% non-fat milk Tris-buffered saline with 0.1% Tween-20
(TBST). Primary antibodies for puromycin (Millipore, cat#MABE343, 1:2000), phospho
P70S6K (T389) (cat#9205, 1:1000), total P70S6K (cat#2708, 1:1000), RPS6 (S240/244)
(cat#2215, 1:500), total RPS6 (cat#2708, 1:1000), phospho Akt (S473) (cat#4060, 1:1000),
total Akt (cat#9272, 1:2000), phospho NFκB (S563) (cat#3033, 1:500), total NFκB
(cat#4764, 1:2000), phospho STAT3 (Y750) (cat# 9145, 1:1000), total STAT3 (cat#4904,
1:2000), phospho AMPK (T172) (cat#, 1:2000), total AMPK (cat#2603, 1:1000), phospho
ACC (S59) (cat#3661, 1:1000), total ACC (cat#3662), and GAPDH (cat#2118, 1:10000)
were incubated overnight in 5% TBST milk. Membranes were then incubated in 5% milkTBST containing anti-rabbit (cat#7074, 1:5000) or anti-mouse (cat#7076, 1:5000) IgG
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horseradish-peroxidase conjugated secondary antibodies for 1h at RT. Exceptions to the
aforementioned procedures were that for puromycin incorporation 1% BSA-TBST was
used for primary antibody and horseradish-peroxidase conjugated rabbit anti-mouse IgG2a
antibody (LifeTechnologies, cat#610220, 1:5000) in 5% milk-TBST was used for
secondary antibody. All antibodies were from Cell Signaling Technology unless otherwise
stated. Tibialis anterior protein extracts from a mouse that did not receive puromycin at
sacrifice was included on all puromycin gels as a negative control.

Enhanced

chemiluminescence (ECL) (GE Healthcare Life Sciences) was used to visualize the
antibody-antigen interactions. Immunoblot images were collected using a digital imager
(SynGene GBox) and quantified by densitometry using imaging software (Image J; NIH).
Each gel contained samples from all groups and data was normalized to the respective
control group (e.g. B6 control).
Plasma Interleukin-6 Concentration
Plasma IL-6 concentrations were determined as previously described [37]. A
commercially available IL-6 enzyme-linked immunosorbent assay kit was obtained from
BD Biosciences and the manufacturer’s protocol was followed. Briefly, clear 96-well
plates were coated and incubated overnight with an IL-6 capture antibody. The next
morning the plate was blocked with assay diluent buffer, washed, and equal volumes of
standards and plasma samples were added in duplicate. After a 2h incubation the plate was
washed and sAV-HRP reagent was added to each well. After several washes, TMB
substrate was added and the reaction was developed for 20 minutes. The reaction was
stopped with sulfuric acid and absorbance was read at 450 nm using an iMark microplate
absorbance reader (Bio-Rad Laboratories).
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Statistical Analysis
Results are reported as the means ± standard error. Data were analyzed by twoway ANOVA with Student-Newman-Keuls methods post hoc when appropriate. The
accepted level of significance was set at p<0.05 for all analysis. Statistical analysis was
performed using GraphPad (Prism 5 for Mac OS X, La Jolla, CA).

4.4 RESULTS
IL-6 regulation of C2C12 myotube stretch-induced muscle protein synthesis
We have previously found that long-term IL-6 treatment suppressed mTORC1
signaling and recapitulated wasting mechanisms observed during cancer cachexia
progression in MIN mice (White, Puppa, Gao, et al., 2013; White et al., 2012). Moreover,
tumor-derived factors could disrupt the mechanical activation of protein synthesis in
stretched myotubes (Gao & Carson, 2016). Therefore, we sought to determine the potential
interaction between long-term IL-6 exposure and mechanical signaling in C2C12 myotubes
(Fig. 4.1A). Activation of IL-6 signaling was evident by increased total gp130 expression
and the phosphorylation of STAT3, NFkB, and AMPK (Figure 4.1B). There was no effect
of stretch alone or when combined IL-6 on total gp130 expression or the phosphorylation
of STAT3, NFkB, and AMPK (Figure 4.1B). Activation of mechanical signaling was
evident by increased Akt/mTORC1 signaling, as stretch induced the phosphorylation of
Akt, P70S6K, and RPS6 (Figure 4.1C). In contrast, IL-6 treatment suppressed basal and
blocked the stretch induction of Akt/mTORC1 signaling (Figure 4.1C). Similarly, while
stretch activated protein synthesis, IL-6 suppressed basal and blocked the stretch induction
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(Figure 4.1C). These data demonstrate that long-term IL-6 exposure was sufficient to
disrupt the mechanical activation of mTORC1 signaling and protein synthesis, and was
associated with the sustained activation of STAT3 and AMPK in myotubes.
IL-6 regulation of ECC-induced protein synthesis in tumor bearing mice
We have previously found that systemic IL-6 overexpression can induce cachexia
and suppress mTORC1 signaling in male tumor bearing MIN mice (Baltgalvis, Berger,
Pena, Davis, Muga, et al., 2008; Puppa et al., 2012). Therefore, we then examined if
systemic IL-6 was sufficient to disrupt the mechanical activation of protein synthesis. To
accomplish this, mice performed a single ECC bout following 2 wks. systemic IL-6
overexpression (Figure 4.2A). Systemic IL-6 overexpression increased plasma IL-6 levels
in both B6 and MIN mice (Figure 4.2B; Table 4.1), however IL-6-induced body weight
loss in MIN mice (Figure 4.2C; Table 4.1). Systemic IL-6 did not affect body weight,
muscle mass, or epididymal fat in WT mice (Table 4.1). In contrast, systemic IL-6
overexpression decreased tibialis anterior and epididymal fat mass in MIN mice (Table
4.1), and plasma IL-6 levels were negatively correlated with tibialis anterior muscle mass
in MIN mice (Figure 4.2D). Interestingly, both systemic IL-6 and the presence of tumors
increased spleen weight (Table 4.1). Tibia length, an index of body size, was lower in MIN
mice (Table 4.1). Collectively, these results establish systemic IL-6 overexpression was
sufficient to induce cachexia in tumor bearing MIN mice.
We then examined muscle inflammatory signaling activation by IL-6 and ECC in
B6 and MIN mice. The activation of muscle IL-6 signaling was confirmed by increased
phosphorylation of STAT3, NFkB, AMPK, and ACC in B6 and MIN mice (Figure
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4.3A,C). Muscle STAT3 and NFkB activation by IL-6 was further induced by ECC in B6
mice (Figure 4.3B) induced STAT3 and NFkB signaling while decreases AMPK and ACC
signaling. Muscle AMPK and ACC activation was decreased by ECC regardless of IL-6
activation in B6 mice (Figure 4.3B). IL-6 activation of muscle STAT3 was not affected
by ECC in MIN mice (Figure 4.3D), while NFkB activation by IL-6 was further induced
by ECC (Figure 4.3D). IL-6 activation of muscle AMPK and ACC activation was not
altered by ECC in MIN mice (Figure 4.3D).
We then examined if IL-6 was sufficient to block the mechanical activation of
protein synthesis and mTORC1 signaling in B6 and MIN mice. Mechanical activation of
protein synthesis was evident in both B6 and MIN mice (Figure 4.4A,C). While systemic
IL-6 overexpression suppressed protein synthesis regardless of tumor presence (Figure
4.4A,C), ECC-induced protein synthesis in B6 mice (Figure 4.4A). Interestingly, IL-6
overexpression blocked ECC-induced protein synthesis in MIN mice (Figure 4.4C). The
activation of mechanical signaling was evident by increased P70S6K and RPS6 signaling
in both B6 and MIN mice (Figure 4.4B,D). While systemic IL-6 overexpression reduced
P70S6K and RPS6 signaling, ECC-induced P70S6K and RPS6 signaling in both B6 and
MIN mice (Figure 4. 4B,D). These findings demonstrate that IL-6 can regulate basal
protein synthesis regardless of cancer, and disrupted the mechanical activation of protein
synthesis in MIN mice.
IL-6 regulation of ECC-induced protein synthesis in gp130 KO mice.
To elucidate possible mechanisms involved in IL-6 suppression of basal and ECCinduced mTORC1 signaling and protein synthesis, we generated mice lacking the gp130
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receptor specifically in skeletal muscle. Mice lacking gp130 (gp130 KO) and their
littermates (gp130 WT) were subjected to identical experimental procedures as previously
described, and were sacrificed 3h post a single ECC bout following 2-wks. systemic IL-6
overexpression. There was no effect of gp130 loss on several animal characteristics such
as body weight or muscle mass (Table 4.2), as we have previously observed (Puppa, Gao,
et al., 2014). Furthermore, while systemic IL-6 overexpression increased plasma IL-6
levels compared to vector controls, it did not induce body weight loss or muscle atrophy in
WT or KO mice (Table 4.2). To verify muscle gp130 loss in these mice, we examined
gp130 protein expression in the non-stimulated TA muscle. As expected, gp130 protein
was reduced in KO mice (Figure 4.5A). Interestingly, there was a trend to increase gp130
protein expression with systemic IL-6 overexpression in WT mice (Figure 4.5A). In
contrast to our previous observation, systemic IL-6 overexpression suppressed basal
protein synthesis, and blocked its induction by ECC in WT mice (Figure 4.5B). However,
muscle gp130 loss blocked basal protein synthesis suppression by IL-6, and attenuated the
ECC induction (Figure 4.5C). Collectively, these findings demonstrate that gp130 can
regulate IL-6 suppression of basal protein synthesis, and alter the protein synthesis
induction by ECC.

4.5 DISCUSSION
Tumor-derived factors and cytokines have been implicated in cancer-induced
skeletal muscle wasting through disrupted protein turnover regulation (Aversa et al., 2016;
Pettersen et al., 2017; White, Baynes, et al., 2011). While we have previously found that
tumor-derived cachectic factors blocked the mechanical activation of protein synthesis in
vitro (Gao & Carson, 2016), cachectic muscle’s ability to stimulate protein synthesis in the
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presence of systemically elevated IL-6 has not been widely examined. Therefore, the
purpose of this study was to determine IL-6 regulation of basal and mechanically induced
protein synthesis and mTORC1 signaling during cancer cachexia. The interaction between
IL-6 and mechanical activation of protein synthesis and mTORC1 signaling was examined
in C2C12 myotubes and in skeletal muscle from MIN mice. We found that the sustained
activation of inflammatory / metabolic signaling pathways (GP130, STAT3, NFkB,
AMPK) coincided with suppressed myotube stretch-induction of protein synthesis and
mTORC1 signaling. Second, we examined systemic IL-6 regulation of ECC-induced
protein synthesis in B6 and MIN mice. As observed in culture, muscle inflammatory /
metabolic signaling pathways related to STAT3, NFkB, and AMPK were activated
following systemic IL-6 overexpression, which coincided with suppressed basal protein
synthesis regardless of cancer. However, the induction of skeletal muscle wasting was
only observed in tumor bearing MIN mice, as we have previously observed. While ECCinduced protein synthesis following systemic IL-6 overexpression in B6 mice, this
response was blocked in MIN mice. Interestingly, mTORC1 signaling induction by ECC
was not altered by systemic IL-6 overexpression regardless of cachexia, which
demonstrates that the mechanical activation of mTORC1 signaling remained intact. Lastly,
muscle gp130 receptor blocked systemic IL-6 suppression of basal protein synthesis.
However, mice lacking muscle gp130 receptor demonstrated an attenuate protein synthesis
response to ECC. Collectively, these results demonstrate that systemic IL-6 can regulate
basal and mechanical activation of protein synthesis in skeletal muscle.
Disrupted muscle protein synthesis and mTORC1 signaling coincides with
increasing levels of circulating plasma IL-6 during cancer cachexia progression (White,
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Baynes, et al., 2011). Moreover, systemic IL-6 overexpression in weight stable tumor
bearing mice can induce cachexia and suppress protein synthesis, and long-term IL-6
exposure can stimulate myotube atrophy associated with disrupted mTORC1 signaling
(White, Puppa, Gao, et al., 2013). We extend these findings by demonstrating that longterm IL-6 suppression of protein synthesis and mTORC1 signaling coincides with the
activation of inflammatory / metabolic signaling pathways (STAT3, NFkB, AMPK) in
both skeletal muscle and cultured myotubes. Interestingly, muscle atrophy following
systemic IL-6 overexpression was only observed in tumor-bearing mice despite similar
plasma IL-6 levels and muscle inflammatory / metabolic signaling activation. These
findings are in agreement with previous research demonstrating preserved muscle mass
and myofiber area despite elevated IL-6 levels in healthy mice (Baltgalvis, Berger, Pena,
Davis, Muga, et al., 2008; J. L. Chen et al., 2016). While speculative, it is feasible that
other cytokines such as LIF or TNFα could work in concert with IL-6 to disrupt similar or
distinct pathways that synergize the wasting process. Furthermore, cancer can promote a
cachectic environment that may sensitize muscle to systemic inflammatory insult, however
the mechanisms involved in this cellular response have not been determined. We have
recently found that while female MIN mice are protected against IL-6-induced wasting
during the initiation of cachexia, however the loss of ovarian function was associated with
severe cachexia and increased sensitivity to muscle inflammatory signaling (Hetzler,
Hardee, LaVoie, Murphy, & Carson, 2017). While we have found that male MIN mice are
susceptible to IL-6-induced cachexia across all stages of tumor burden, there is a strong
relationship between cachexia severity and muscle STAT3/GP130 expression. Further
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research is required to determine if the link between systemic factors and intrinsic muscle
processes requires muscle GP130 signaling.
Nonetheless, we have found strong relationship between systemic IL-6 and muscle
AMPK in skeletal muscle (White, Baynes, et al., 2011). AMPK activation has been
implicated in skeletal muscle metabolism and in the suppression of mTORC1 signaling
(Bolster et al., 2002; Jorgensen, Richter, & Wojtaszewski, 2006). Short-term activation of
AMPK is associated with glucose homeostasis and the metabolic benefits of exercise,
whereas the long-term activation of AMPK can suppress mTORC1 activity (Mounier,
Theret, Lantier, Foretz, & Viollet, 2015). Indeed, AMPK inhibits mTORC1 through the
phosphorylation of TSC2 and Raptor (Gwinn et al., 2008; Inoki et al., 2003; Shaw, 2009).
The phosphorylation of TSC2 by AMPK inhibits mTORC1 and S6K1 activity (Inoki et al.,
2002; Inoki et al., 2003). Moreover, phosphorylation of the mTORC1 binding partner
Raptor by AMPK at two highly conserved serine residues (S722 and S792) leads to the
suppression of mTORC1 kinase activity (Gwinn et al., 2008). Interestingly, while systemic
IL-6 overexpression induced AMPK activation and suppressed protein synthesis, this was
not associated with muscle wasting in healthy mice. Whether the suppression of mTORC1
signaling was associated with the induction of autophagy or ubiquitin proteasome
activation should be investigated in future studies. A negative protein balance would need
to be achieved to induce wasting, however indices of these processes were not examined.
Related to cachexia, we extend previous findings and demonstrate that systemic IL-6
overexpression is associated with STAT3/AMPK activation and muscle atrophy in tumorbearing MIN mice. We then examined if cachectic muscle could respond to mechanical
stimuli after long-term IL-6 exposure in vitro and in vivo. We found that long-term IL-6
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blocked the mechanical activation of protein synthesis in atrophic myotubes and mouse
skeletal muscle.

Interestingly, while myotubes demonstrated a blunted mechanical

response, mouse skeletal muscle retained the ability to activate mTORC1 signaling. We
have also observed similar responses using LLC conditioned media in culture and in LLC
tumor bearing mice. While protein synthesis activation was blocked, we have found that
the mTORC1 signaling activation by ECC is maintained in cachectic muscle from LLC
tumor-bearing mice (unpublished observations). Further, LLC tumor derived cachectic
factors disrupted myotube stretch induced protein synthesis was blocked in culture (Gao &
Carson, 2016). Interestingly, the current study found a similar cachectic muscle response
to ECC as we have observed in LLC mice, which is in contrast to previous observations
during the natural progression of cachexia in MIN mice. This is of interest, as while the
cancer environments may be different, the rate of wasting may also be a predictive measure
of the ability to respond to mechanical stimuli. We have found that cachectic muscle during
the natural progression (e.g., 6-8 wks. of wasting) remained plastic to protein synthesis
induction by ECC, whereas the rapid induction by IL-6 overexpression blocked this
activation. While we have not mechanistically determined the differences why this occurs,
future investigations should determine if the rate of wasting determines a muscles ability
to induce anabolic processes. Given that overall mass is tightly regulated by fluctuations
between anabolic and catabolic processes, it is imperative that we define how protein
synthesis can be modulated in response to various cachectic stimuli.
Conclusion
In summary, we examined IL-6 regulation of basal and ECC-induced protein
synthesis and mTORC1 signaling during cancer cachexia. We found that IL-6 suppressed
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basal protein synthesis and mTORC1 signaling in skeletal muscle and cultured myotubes.
Furthermore, IL-6 blocked the mechanical activation of protein synthesis in atrophic
skeletal muscle and myotubes. While long-term IL-6 blocked myotube stretch-induced
mTORC1 signaling, cachectic muscle remained responsive to ECC in tumor bearing mice.
Interestingly, muscle gp130 loss blocked IL-6 suppression of basal protein synthesis, but
also attenuated the protein synthesis response to ECC.

Collectively, these studies

demonstrate that systemic IL-6 and muscle GP130 disrupt basal and ECC-induced protein
synthesis. Further work is necessary to determine if AMPK activation by IL-6/GP130
signaling is required for protein synthesis suppression.
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Table 4.1. B6 and MIN mice that performed a single ECC bout following 2 wk systemic
IL-6 overexpression.
B6
MIN

MIN
IL-6

Vector

IL-6

10

12

8

9

Pre

24.7 ± 0.3

24.9 ± 0.5

23.1 ± 0.7

22.0 ± 0.6

Post

26.2 ± 0.3†

25.8 ± 0.5†

22.9 ± 0.8

20.2 ± 0.6†

% Change from Pre

5.9 ± 1.0

3.7 ± 0.9

-0.7 ± 1.7

-8.2 ± 1.0

Tibialis anterior, mg

47 ± 1.0

46 ± 0.8

39 ± 1.9†

32 ± 2.0†

Epididymal fat, mg

298 ± 15

292 ± 16

207 ± 29†

100 ± 37†

Spleen, mg

77 ± 8

129 ± 6

299 ± 45†

428 ± 34†

Testes, mg

197 ± 5

212 ± 4

192 ± 7†

154 ± 13†

LABC, mg

82 ± 3

81 ± 2

67 ± 5†

48 ± 5†

Seminal vesicle, mg

239 ± 12

229 ± 9

154 ± 23

86 ± 20

Plasma IL-6, pg/ml

0±0

112 ± 17 &

31 ± 5*

130 ± 26 &

16.9 ± 0.1

16.9 ± 0.1

16.6 ± 0.1#

16.6 ± 0.1#

Vector
No. of mice
Body weight, g

Tibia length, mm

Data are means ± standard error. There were no differences in the non-stimulated and ECC
muscles, therefore the average tibialis anterior muscle is shown. A two-way ANOVA with
Student-Knewman-Keuls post hoc methods were performed when appropriate. Statistical
significance was set at p<0.05. Abbreviations: ECC, Eccentric contractions. No., number.
g, grams. mg, milligrams. pg, picogram. ml, milliliter. mm, millimeter. LABC, levator
ani / bulbocavernosus muscle. * = significantly different from B6. † = significantly
different to all groups. # = main effect of MIN. & = main effect of IL-6.
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Table 4.2. Muscle GP130 WT and KO mice that performed a single ECC bout following
2 wk systemic IL-6 overexpression.
WT
MIN

KO
IL-6

Vector

IL-6

7

7

6

7

Pre

24.8 ± 0.5

24.9 ± 0.4

26.3 ± 0.8

25.6 ± 0.6

Post

25.7 ± 0.4†

25.5 ± 0.2†

27.0 ± 0.8†

26.4 ± 0.5†

% Change from Pre

3.9 ± 1.9

2.8 ± 0.8

2.8 ± 0.6

2.8 ± 0.6

Tibialis anterior, mg

47 ± 0.6

47 ± 1.6

49 ± 1.4

48 ± 1.1

Epididymal fat, mg

274 ± 59

270 ± 23

295 ± 26

292 ± 26

Spleen, mg

87 ± 5

110 ± 11&

76 ± 4

129 ± 23&

Testes, mg

185 ± 9

182 ± 5

211 ± 4#

224 ± 7#

LABC, mg

91 ± 2

84 ± 4

83 ± 2

84 ± 0.9

Seminal vesicle, mg

259 ± 12

256 ± 14

257 ± 15

273 ± 16

Plasma IL-6, pg/ml

0±0

210 ± 43&

0±0

203 ± 42&

16.8 ± 0.1

16.9 ± 0.1

17.0 ± 0.1

16.9 ± 0.1

Vector
No. of mice
Body weight, g

Tibia length, mm

Data are means ± standard error. There were no differences in the non-stimulated and ECC
muscles, therefore the average tibialis anterior muscle is shown. A two-way ANOVA with
Student-Knewman-Keuls post hoc methods were performed when appropriate. Statistical
significance was set at p<0.05. Abbreviations: ECC, Eccentric contractions. No., number.
g, grams. mg, milligrams. pg, picogram. ml, milliliter. mm, millimeter. LABC, levator
ani / bulbocavernosus muscle. † = significantly different from pre body weight. # = main
effect of KO. & = main effect of IL-6.
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Figure 4.1. Long-term IL-6 regulation of myotube stretch-induced protein synthesis.
A) Experimental Design. B) Myotube inflammatory signaling regulation by IL-6 and
stretch. C) Myotube mTORC1 signaling and protein synthesis regulation by IL-6 and
stretch. The activation of signaling molecules was determined by the phosphorylated and
total ratio when appropriate. For protein expression, values were corrected for equal
protein loading using GAPDH. All samples were run on the same gel and normalized to
Control values. Dotted lines indicate images were cropped for representative purposes.
Data are means ± standard error. A two-way ANOVA was used to determine differences
between treatment groups. Post-hoc analyses were performed with Student-KnewmanKeuls methods when appropriate. Statistical significance was set at p<0.05. Different
letters are statistically different. # = main effect of IL-6.
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Figure 4.2. Systemic IL-6 regulation of cachexia initiation in tumor-bearing MIN
mice. A) Experimental Design. B) Plasma IL-6 levels following 2 wks systemic IL-6
overexpression. C) Body weight loss following 2 wks systemic IL-6 overexpression. D)
Correlation between tibialis anterior muscle mass and plasma IL-6 levels following 2 wks
systemic IL-6 overexpression. Data are means ± standard error. A two-way ANOVA was
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used to determine differences between treatment groups. Post-hoc analyses were
performed with Student-Knewman-Keuls methods when appropriate. Linear regression
was performed to determine the relationship between tibialis anterior muscle mass and
plasma IL-6 levels. Statistical significance was set at p<0.05. * = significantly different
to C57BL/6 Vector. † = significantly different to all groups. ‡ = significantly different to
all groups.
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Figure 4.3. Systemic IL-6 regulation of muscle inflammatory signaling in tumorbearing MIN mice. A) Muscle inflammatory signaling regulation by IL-6 in B6 mice.
B) Muscle inflammatory signaling regulation by IL-6 and ECC in B6 mice. C) Muscle
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inflammatory signaling regulation by IL-6 in MIN mice. D) Muscle inflammatory
signaling regulation by IL-6 and ECC in MIN mice. The activation of signaling molecules
was determined by the phosphorylated and total ratio when appropriate. For protein
expression, values were corrected for equal protein loading using GAPDH. All samples
were run on the same gel and normalized to Control values. Data are means ± standard
error. Student’s t-test or two-way ANOVA was used to determine differences between
treatment groups when appropriate. Post-hoc analyses were performed with StudentKnewman-Keuls methods when appropriate. Statistical significance was set at p<0.05. *
= significantly different to Vector within genotype. Different letters are statistically
different.
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Figure 4.4. Systemic IL-6 regulation of muscle mTORC1 signaling and protein
synthesis in tumor-bearing MIN mice. A) Muscle protein synthesis regulation by IL-6
and ECC in B6 mice. B) Muscle mTORC1 signaling regulation by IL-6 and ECC in B6
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mice. C) Muscle protein synthesis regulation by IL-6 and ECC in MIN mice. D) Muscle
mTORC1 signaling regulation by IL-6 and ECC in MIN mice. The activation of signaling
molecules was determined by the phosphorylated and total ratio when appropriate. For
protein expression, values were corrected for equal protein loading using GAPDH. All
samples were run on the same gel and normalized to Control values. Data are means ±
standard error. A repeated measures two-way ANOVA was used to determine differences
between treatment groups when appropriate. Post-hoc analyses were performed with
Student-Knewman-Keuls methods when appropriate. Statistical significance was set at
p<0.05. Different letters are statistically different. # = main effect of pIL-6. $ = main
effect of ECC.
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Figure 4.5. Systemic IL-6 and muscle gp130 regulation of muscle mTORC1 signaling
and protein synthesis in tumor free mice. A) Muscle gp130 protein synthesis in WT
and KO mice. B) Muscle mTORC1 signaling regulation by IL-6 and ECC in WT mice.
C) Muscle protein synthesis regulation by IL-6 and ECC in KO mice. The activation of
signaling molecules was determined by the phosphorylated and total ratio when
appropriate. For protein expression, values were corrected for equal protein loading using
GAPDH. All samples were run on the same gel and normalized to Control values. Data
are means ± standard error. A repeated measures two-way ANOVA was used to determine
differences between treatment groups when appropriate. Post-hoc analyses were
performed with Student-Knewman-Keuls methods when appropriate.
Statistical
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significance was set at p<0.05. Different letters are statistically different. # = main effect
of pIL-6. $ = main effect of ECC.

118

CHAPTER 5
TRAINING REGULATION OF ECCENTRIC CONTRACTIONINDUCED PROTEIN SYNTHESIS IN CACHECTIC
SKELETAL MUSCLE1

1

Hardee JP, Goldsmith EC, Wang X, Koh, HJ, and JA Carson. Training Regulation of
Eccentric Contraction-Induced Protein Synthesis in Cachectic Skeletal Muscle. To be
submitted to Journal of Cachexia, Sarcopenia and Muscle.
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5.1 ABSTRACT
Exercise training has been postulated to attenuate cancer-induced skeletal muscle
wasting, the acute responses and training adaptations to ECC in cachectic muscle have not
been fully elucidated. We have found that while a single ECC bout could stimulate
mTORC1 signaling in cachectic muscle, the protein synthesis induction remained
suppressed compared to healthy controls. Interestingly, muscle STAT3/NFκB inhibition
increased basal and ECC-induced protein synthesis in cachectic MIN mice. We have also
found that ECC training could attenuate myofiber atrophy which coincided with suppressed
muscle inflammatory / metabolic signaling and improved oxidative capacity. However,
whether training improves the regulation of basal and ECC-induced protein synthesis
during cancer cachexia has not been investigated. Therefore, the purpose of this study was
to determine if training could improve basal and ECC-induced protein synthesis and
mTORC1 signaling during cancer cachexia. Male MIN mice initiating cachexia performed
repeated ECC bouts over 2 wks. and were sacrificed either 3h (acute response) or 48
(training response) after the last bout. The stimulated tibialis anterior (TA) muscle
performed contractions while the non-stimulated TA served as the intra-animal control.
Age-matched B6 mice served as healthy controls. ECC training improved basal protein
synthesis and mTORC1 regulation in MIN mice, which coincided with improved oxidative
capacity, altered autophagy flux, and suppressed STAT3/AMPK activation. Further, the
activation of protein synthesis and mTORC1 signaling by a single ECC bout was
maintained following training in B6 and MIN mice. Collectively, these results demonstrate
that training can improve basal and ECC-induced protein synthesis and mTORC1
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regulation, which may be related to improved oxidative capacity in cachectic skeletal
muscle.
Keywords:

ApcMin/+; Cancer Cachexia; Eccentric contractions; Glycoprotein 130;

Interleukin-6; Muscle Protein Synthesis

5.2 INTRODUCTION
Cancer cachexia is a complex, metabolic wasting syndrome characterized by the
loss of skeletal muscle, and accounts for 40% of all cancer-related deaths (Bruera, 1997;
Tisdale, 2009). Adverse consequences of skeletal muscle depletion include reduced
anticancer therapy tolerance, increased susceptibility to treatment toxicity, and decreased
patient quality of life (Barret et al., 2014; Evans et al., 2008; H. W. Jung et al., 2015).
While many pharmaceutics have been proposed to treat this wasting condition, many have
failed to improve mass and metabolic quality due to the singular specificity and adverse
side effects (S. Cohen et al., 2015). Exercise is a non-pharmacological treatment approach
that improves indices of health related to muscle function and metabolism in healthy
individuals (Hurley et al., 2011; Zinna & Yarasheski, 2003), and has demonstrated benefits
on treatment and survival outcomes in cancer patients (Brown, Winters-Stone, Lee, &
Schmitz, 2012; Hardee, Porter, Sui, et al., 2014; Hojman, Gehl, Christensen, & Pedersen,
2017). However, whether these outcomes can be achieved in the cachectic cancer patient
has not yet been investigated (Grande, Silva, & Maddocks, 2015; Grande et al., 2014a).
Thus, there are significant gaps that remain in our understanding of the interactions
between exercise and the cachectic cancer environment, which hinders the use of exercise
as an effect treatment strategy.
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Despite the limitations in our mechanistic understanding of physical activity based
therapies in cachectic cancer patients, the acute responses and training adaptions to exercise
are actively being examined in preclinical cancer cachexia models. Exercise feasibility
becomes a significant barrier when studying cachectic tumor-bearing mice as they are
unable to perform vigorous exercise (e.g., treadmill exercise, ladder climbing). Therefore,
our laboratory has utilized electrical stimulation of the sciatic nerve to examine the
molecular and cellular responses to muscle contraction during severe cachexia. We have
found that cancer cachexia disrupted the metabolic and anabolic signaling response to a
single concentric muscle contraction bout induced by low-frequency electrical stimulation
(Puppa, Murphy, et al., 2014). In contrast, ECC-induced by high-frequency electrical
muscle stimulation stimulated protein synthesis in cachectic muscle, however the absolute
response remained suppressed compared to healthy skeletal muscle (Hardee et al., 2017).
Moreover, repeated ECC bouts started at the time of tumor implantation or after cachexia
development attenuated muscle and myofiber atrophy, respectively (al-Majid & McCarthy,
2001; Hardee et al., 2016). However, neither of these ECC training studies examined the
cellular processes related to growth, nor significant gaps remain in our understanding of
the regulation of protein synthesis by ECC during cancer cachexia.
Skeletal muscle mass is maintained through daily fluctuations in protein synthesis
and protein breakdown (Schiaffino & Mammucari, 2011), often referred to as protein
turnover or proteostasis. While protein breakdown has an established role in muscle
wasting, less is known related to the regulation of protein synthesis during cancer cachexia.
In healthy skeletal muscle, protein synthesis is highly responsive to nutrients, physical
activity level, and growth factors/hormones (Kimball et al., 2002; Schiaffino &
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Mammucari, 2011). Protein kinase B (PKB, also known as Akt) and the mechanistic target
of rapamycin complex 1 (mTORC1) have established roles for the integration of upstream
signaling pathways to regulate protein synthesis (Kimball et al., 2002; Laplante & Sabatini,
2009; Schiaffino & Mammucari, 2011). While growth factors such as insulin and insulinlike growth factor-1 (IGF-1) stimulate mTORC1 signaling through the activation of Akt
(Kimball et al., 2002; Schiaffino & Mammucari, 2011), muscle contraction and mechanical
loading can induce Akt/mTORC1 signaling independent of classical IGF-1 receptor and
phosphatidylinositol 3 kinase (PI3K) activation (Witkowski et al., 2010). mTORC1
activation promotes protein synthesis by phosphorylating the eukaryotic initiation factor
4E (4E-BP1) and the p70 ribosomal S6 kinase (S6K1). The hyperphosphorylation of 4EBP1 prevents binding to eukaryotic initiation factor 4E (eIF4E) and the formation of 4EBP1-eIF4E complex, resulting in the assembly of the eIF4F complex and translation
initiation (Kimball et al., 2002). In addition, S6K1 activation by mTORC1 has been
implicated in cap-dependent translation, translation elongation, and ribosomal biogenesis
(Bentzinger et al., 2013; Bentzinger et al., 2008; Laplante & Sabatini, 2009). Cancer
cachexia disrupts Akt/mTORC1 signaling leading to the suppression of basal protein
synthesis (Samuels et al., 2001; Smith & Tisdale, 1993; White, Baynes, et al., 2011).
Moreover, cachectic mice demonstrate an impaired response to nutrients and muscle
contraction (Puppa, Murphy, et al., 2014; White, Puppa, Gao, et al., 2013). Given that
ECC can induce protein synthesis and mTORC1 signaling in healthy skeletal muscle (Baar
& Esser, 1999), this may be a viable treatment approach to improve basal protein synthesis
regulation and improve the acute response to anabolic stimuli.
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While evidence suggest a single ECC bout can stimulate protein synthesis (Hardee
et al., 2017) and repeated ECC can prevent muscle and myofiber atrophy in tumor-bearing
mice (al-Majid & McCarthy, 2001; Hardee et al., 2016), it is currently unknown if ECC
training improves basal and ECC-induced protein synthesis and mTORC1 signaling during
cancer cachexia. Therefore, the purpose of this study was to determine if ECC training
could improve basal protein synthesis and mTORC1 regulation, and improve the anabolic
response to a single ECC bout. We hypothesized that ECC training would improve
suppressed basal ECC-induced protein synthesis and mTORC1 signaling during severe
cancer cachexia. To test this hypothesis, MIN mice that had initiated cachexia performed
repeated ECC bouts (8 total sessions) and were sacrificed either 48h (basal training effect)
or 3h (acute ECC effect) after the last ECC bout. Our findings demonstrate that ECC
training improved basal and ECC-induced protein synthesis and mTORC1 regulation in
MIN mice.

5.3 METHODS
Animals
Male MIN mice on a B6 (B6) background were originally purchased from Jackson
Laboratories (Bar Harbor, ME, USA) and bred at the University of South Carolina’s
Animal Resource Facility. All mice used in the current study were obtained from the
investigators breeding colony within the Center for Colon Cancer Research Mouse Core.
Mice were individually housed, kept on a 12:12-h light-dark cycle, and had access to
standard rodent chow (#8604 Rodent Diet; Harlan Teklad, Madison, WI) and water ad
libitum. Body weight measurements were taken weekly, and the percentage body weight
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loss from peak body weight (~10-14 weeks of age) was calculated. Mice lacking the Apc
allele mutation served as controls for all experiments. Body weight measurements were
taken weekly, and the percentage body weight loss from peak body weight was calculated.
The University of South Carolina’s Institutional Animal Care and Use Committee
approved all animal experimentation in this study.
Experimental Designs
Experiment 1: B6 (N=8) and MIN (N=8) mice were subjected to repeated ECC
bouts (8 total sessions) after the initiation of cachexia. Each ECC bout was separated by
at least 48h (e.g., Monday, Wednesday, Friday) and each stimulation session was
performed as previously described (Hardee et al., 2016). Mice were sacrificed 48h after
the last ECC bout. We have found no effect of a single ECC bout on protein synthesis at
this time point (data not shown), and thus any alteration would represent the muscles
adaptation to training.
Experiment 2: B6 (N=8) and MIN (N=9) mice were subjected to repeated ECC
bouts (8 total sessions) after the initiation of cachexia. Each ECC bout was separated by
at least 48h (e.g., Monday, Wednesday, Friday) and each stimulation session was
performed as previously described (Hardee et al., 2016). Mice were sacrificed 3h after the
last ECC bout. We have previously found that a novel single ECC bout induced protein
synthesis in both B6 and MIN mice at this time point (Hardee et al., 2017).
Eccentric contractions (ECC)
ECC of the tibialis anterior (TA) muscle was induced by high-frequency electrical
stimulation of the sciatic nerve as previously described with slight modifications (Baar &
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Esser, 1999; Hardee et al., 2016). Mice were anesthetized via isoflurane (2% in O2 with
1.5% maintenance), the stimulated leg was shaved at the hip region, and two needle
electrodes were placed subcutaneously to stimulate the sciatic nerve. Tetanic muscle
contractions of one hind limb were generated using a Grass Stimulator (Grass Instruments)
for 10 sets of 6 repetitions (100 Hz, 6-12V, 1ms duration). Ten seconds of rest was given
between stimulations and 50 seconds of rest was given between sets. The stimulation
protocol recruits all motor units and results in net plantar flexion of the ankle (Wong &
Booth, 1988, 1990). The dorsiflexors (TA and EDL) undergo ECC while the plantar
flexors (gastrocnemius, soleus, and plantaris) perform concentric muscle contractions. In
all experiments, the stimulated TA performed ECC while the non-stimulated TA served as
intra-animal control. Our laboratory and others have demonstrated repeated ECC bouts,
but not concentric contractions, can induce muscle and myofiber growth in rodents (alMajid & McCarthy, 2001; Baar & Esser, 1999; Hardee et al., 2016; Wong & Booth, 1988).
Therefore, the TA was examined in all experiments. Mice were given an intraperitoneal
injection of warm saline following the stimulation procedure and returned to cages upon
complete recovery.
Tissue Collection
Mice were anesthetized by a subcutaneous injection of ketamine / xylazine /
acepromazine cocktail (1.4 ml/kg body weight) at the time of sacrifice. The TA muscles
were rapidly excised, cleared of excess connective tissue, rinsed in PBS, weighed, and snap
frozen in liquid nitrogen. The TA muscle was cut at the mid-belly, and frozen in liquid
nitrogen. Blood was collected prior to muscle collection via retro-orbital eye bleed with
heparinized capillary tubes, placed on ice, and centrifuged (10,000 x g for 10 min at 4°C).
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The supernatant was removed and stored for plasma IL-6 analysis. Plasma and tissue
samples were stored at -80°C until further analysis.
Western Blotting
Western blot analysis was performed as previously described (Hetzler et al., 2014).
Frozen TA muscle was homogenized in ice-cold Mueller buffer and protein concentration
was determined by the Bradford method. Non-stimulated and stimulated TA muscles from
B6 and MIN mice were run on the same gels. Crude muscle homogenates were fractionated
on 6-5% SDS-polyacrylamide gels and transferred to PVDF membranes overnight.
Membranes were stained with Ponceau red to verify equal loading and transfer for each
gel. Membranes were blocked at room temperature for 1-2 h in 5% Tris-buffered saline
with 0.1% Tween-20 (TBST) milk.

Primary antibodies for puromycin (Millipore,

cat#MABE343, 1:2000), phospho P70S6K (T389) (cat#9205, 1:1000), total P70S6K
(cat#2708, 1:1000), RPS6 (S240/244) (cat#2215, 1:500), total RPS6 (cat#2708, 1:1000),
phospho Akt (S473) (cat#4060, 1:1000), total Akt (cat#9272, 1:2000), phospho NFκB
(S563) (cat#3033, 1:500), total NFκB (cat#4764, 1:2000), phospho STAT3 (Y750) (cat#
9145, 1:1000), total STAT3 (cat#4904, 1:2000), phospho AMPK (T172) (cat#, 1:2000),
total AMPK (cat#2603, 1:1000), PGC-1α (Abcam, cat#ab54481, 1:1000), COXIV
(cat#4844, 1:1000), and GAPDH (cat#2118, 1:10000) were incubated overnight in 5%
TBST milk. Membranes were then incubated in 5% milk-TBST containing anti-rabbit
(cat#7074, 1:5000) or anti-mouse (cat#7076, 1:5000) IgG horseradish-peroxidase
conjugated secondary antibodies for 1h at RT.

Exceptions to the aforementioned

procedures were that for puromycin incorporation 1% BSA-TBST was used for primary
antibody and horseradish-peroxidase conjugated rabbit anti-mouse IgG2a antibody
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(LifeTechnologies, cat#610220, 1:5000) in 5% milk-TBST was used for secondary
antibody. All antibodies were from Cell Signaling Technology unless otherwise stated.
Tibialis anterior protein extracts from a mouse that did not receive puromycin at sacrifice
was included on all puromycin gels as a negative control. Enhanced chemiluminescence
(ECL) (GE Healthcare Life Sciences) was used to visualize the antibody-antigen
interactions. Immunoblot images were collected using a digital imager (SynGene GBox)
and quantified by densitometry using imaging software (Image J; NIH).

Each gel

contained samples from all groups and data was normalized to the respective control group
(e.g. B6 control).
Succinate dehydrogenase activity
Succinate dehydrogenase (SDH) enzyme activity was performed as previously
described to determine muscle oxidative capacity (Hardee, Puppa, et al., 2014). Briefly,
frozen cross-sections were air-dried for 10 minutes, followed by incubation in a solution
containing 0.2M phosphate buffer (pH 7.4), 0.1M MgCl2, 2.4 mM nitroblue tetrazolium
(NBT), and 0.2M succinic acid for 45 minutes at 37°C. Sections were then washed in
dH2O for 3 minutes, dehydrated in 50% ethanol for 2 minutes, and mounted for viewing
with mounting media.

Digital photographs were taken from each section at X25

magnification, and fibers were manually traced with imaging software (Image J; NIH).
Whole TA muscle cross-sections were examined since fibers with high oxidative capacity
are more abundant in the deep region of the muscle compared to the superficial region
(Pullen, 1977). The images were converted to 8-bit gray scale (range of gray levels 0-255)
images, and an integrated optical density was created by subtracting the background
intensity from each myofiber. Thresholds corresponding to high SDH enzyme activity
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were set manually and uniformly across all images, and myofibers were classified as
having high or low SDH enzyme activities. The whole muscle containing glycolytic and
oxidative regions were included in analysis. The cross-sectional area of high and low SDH
enzyme activity myofibers were quantified.

The analyses were performed by an

investigator blinded to the treatment groups.
Plasma Interleukin-6 Concentration
Plasma IL-6 concentrations were determined as previously described (Hetzler et
al., 2015). A commercially available IL-6 enzyme-linked immunosorbent assay kit was
obtained from BD Biosciences and the manufacturer’s protocol was followed. Briefly,
clear 96-well plates were coated and incubated overnight with an IL-6 capture antibody.
The next morning the plate was blocked with assay diluent buffer, washed, and equal
volumes of standards and plasma samples were added in duplicate. After a 2h incubation
the plate was washed and sAV-HRP reagent was added to each well. After several washes,
TMB substrate was added and the reaction was developed for 20 minutes. The reaction
was stopped with sulfuric acid and absorbance was read at 450 nm using an iMark
microplate absorbance reader (Bio-Rad Laboratories).
Statistical Analysis
Results are reported as the means ± standard error. Either a Students t-test or twoway repeated measures ANOVA with Student-Knewman-Keuls post hoc methods were
performed when appropriate. The accepted level of significance was set at p<0.05 for all
analysis. Statistical analysis and figure generation were performed using Prism 5 for Mac
OS X (GraphPad Software Inc).
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5.4 RESULTS
Animal characteristics (Experiment 1)
Male B6 and MIN mice performed repeated ECC bouts over ~2 wks. and were
sacrificed 48 h the last bout. MIN mice had initiated cachexia prior to the first ECC bout
and continued to lose body weight during the training period (Table 5.1). MIN mice
displayed several key features of severe cachexia which included body weight loss, adipose
tissue depletion, muscle atrophy, elevated plasma IL-6 levels, and hypogonadal features
(levator ani-bulbocavernosus [LABC] and seminal vesicle atrophy) (Table 5.1). MIN mice
had smaller TA and gastrocnemius muscle mass (-33% and -37%, respectively) at sacrifice
compared to B6 mice. ECC increased TA muscle mass regardless of cachexia, however
there was no effect of concentric contractions on gastrocnemius muscle mass (Table 5.1).
Plasma IL-6 and tumor number was elevated in MIN mice at sacrificed (Table 5.1). There
were no differences in tibia length, a measure of body size, between B6 and MIN mice.
Cachexia and ECC on TA muscle cachectic signature in MIN mice (Experiment 1)
Cachectic signaling related to muscle wasting was examined in the non-stimulated
TA muscle of B6 and MIN mice.

Cachectic MIN muscle demonstrated enhanced

inflammatory / metabolic (STAT3, AMPK) signaling; however, ECC training reduced
STAT3 and AMPK activation regardless of cancer (Figure 5.1). Indices of mitochondrial
content and autophagy / mitophagy were disrupted in cachectic MIN muscle (Figure 5.1B).
PGC-1α and COXIV protein were reduced in MIN mice, however ECC training increased
COXIV protein expression in MIN mice (Figure 5.1B). Interestingly, cachectic MIN
muscle demonstrated enhanced autophagy / mitophagy (LC3-II, P62) regulation, however
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ECC training reduced LC3-II and P62 protein expression regardless of cancer (Figure
5.1B). While cytochrome c oxidase (COX) enzyme activity was reduced in cachectic MIN
muscle, ECC training increased COX enzyme activity regardless of cancer (Figure 5.1C).
These findings demonstrate that ECC training improved muscle inflammatory / metabolic
signaling regulation, which coincided with improved muscle oxidative capacity and
autophagy / mitophagy regulation.
In a separate cohort of cachectic MIN mice, we have previously demonstrated that
repeated ECC attenuated myofiber atrophy that coincided with improved succinate
dehydrogenase enzyme activity (Hardee et al., 2016). Therefore, we examined post hoc if
these alterations were related to improved cross-sectional area of myofibers containing
high and low succinate dehydrogenase enzyme activity. We found that while cachexia
decreased myofiber area of both high and low succinate dehydrogenase enzyme activity
myofibers, ECC increased both high and low succinate dehydrogenase enzyme activity
myofiber area regardless of cancer (Figure 5.2A). While cachexia resulted in a leftward
shift in the disruption of high and low succinate dehydrogenase enzyme activity myofiber
area, ECC-induced a rightward shift in the disruption of high and low succinate
dehydrogenase enzyme activity myofiber area (Figure 5.2B,C).

These findings

demonstrate that ECC training attenuated atrophy of both myofibers containing high and
low succinate dehydrogenase enzyme activity.
Given that a single ECC bout is a potent stimulator of protein synthesis and
Akt/mTORC1 signaling (Nader & Esser, 2001; O'Neil et al., 2009; Thomson et al., 2008),
we next determined if ECC training could improve basal protein synthesis and
Akt/mTORC1 signaling in cachectic muscle. There was no effect of ECC training on Akt
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regardless of cancer (Figure 5.3A). Interestingly, while cachexia decreased basal P70S6K
phosphorylation, ECC training improved P70S6K activation in cachectic MIN muscle
(Figure 5.3A). We further validated P70S6K activation through the phosphorylation of the
direct P70S6K target RPS6. Similarly, cachexia decreased basal RPS6 phosphorylation,
whereas ECC training increased RPS6 activation in cachectic MIN mice (Figure 5.3A).
Interestingly, ECC training increased basal protein synthesis regardless of cancer (Figure
5.3B). Collectively, these findings demonstrate ECC training improved basal mTORC1
signaling and protein synthesis in cachectic MIN muscle.
Animal characteristics (Experiment 2)
Similar to the previous experiment, male B6 and MIN mice performed repeated
ECC bouts over 2 wks. and were sacrificed 3h after the last bout. MIN mice had initiated
cachexia prior to the first ECC bout and continued to lose body weight during the training
period (Table 5.2). MIN mice displayed several key features of severe cachexia which
included body weight loss, adipose tissue depletion, muscle atrophy, elevated plasma IL-6
levels, and hypogonadal features (levator ani-bulbocavernosus [LABC] and seminal
vesicle atrophy) (Table 5.2). MIN mice had smaller TA and gastrocnemius muscle mass
(-38% and -41%, respectively) at sacrifice compared to B6 mice. ECC increased TA
muscle mass regardless of cachexia, however there was no effect of concentric contractions
on gastrocnemius muscle mass (Table 5.2). Plasma IL-6 and tumor number was elevated
in MIN mice at sacrificed (Table 5.2). There were no differences in tibia length, a measure
of body size, between B6 and MIN mice.
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Training regulation of ECC-induced mTORC1 signaling and protein synthesis
(Experiment 2)
Having established the cachectic muscle’s response to repeated ECC bouts, we then
determined if training improved ECC-induced protein synthesis and mTORC1 signaling.
Therefore, anabolic signaling was examined 3h after a single ECC bout following training.
ECC activated protein synthesis after training regardless of cancer. Although the relative
induction by ECC was not altered by cachexia, the absolute protein synthesis rate remained
suppressed relative to healthy B6 mice (Figure 5.4A). While Akt was increased by
cachexia in MIN muscle, there was no effect of ECC regardless of cancer (Figure 5.4B).
While cachexia decreased the phosphorylation of P70S6K, ECC-induced its activation
regardless of cancer cachexia (Figure 5.4B). ECC also increased RPS6 phosphorylation
regardless of cancer cachexia (Figure 5.4B). Collectively, these findings demonstrate that
protein synthesis and mTORC1 signaling was induced 3h after a single ECC bout following
training in cachectic MIN mice.

5.5 DISCUSSION
Physical activity and exercise interventions have clear therapeutic implications for
treating and preventing muscle wasting associated with cancer cachexia. Whole-body
treadmill exercise can prevent muscle mass loss in tumor bearing mice (Deuster et al.,
1985; Penna et al., 2011; Salomao et al., 2010), and is sufficient to rescue suppressed
muscle oxidative metabolism at the initiation of cachexia (Puppa et al., 2012; White et al.,
2012). While evidence suggest a single ECC bout can stimulate protein synthesis (Hardee
et al., 2017) and repeated ECC can prevent muscle and myofiber atrophy in tumor-bearing
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mice (al-Majid & McCarthy, 2001; Hardee et al., 2016), it is currently unknown if ECC
training improves basal and ECC-induced protein synthesis and mTORC1 signaling during
cancer cachexia. Therefore, the purpose of this study was to determine if ECC training
improved basal protein synthesis and mTORC1 regulation, and improved the anabolic
response to a single ECC bout. We hypothesized that ECC training would improve
suppressed basal ECC-induced protein synthesis and mTORC1 signaling during severe
cancer cachexia. To test this hypothesis, MIN mice that had initiated cachexia performed
repeated ECC bouts (8 total sessions) and were sacrificed either 48h (basal training effect)
or 3h (acute ECC effect) after the last ECC bout. We found that ECC training improved
protein synthesis which coincided with the enhanced oxidative metabolism and reduced
inflammatory / metabolic activation. In addition, the acute ECC induction of protein
synthesis and mTORC1 signaling was maintained after training in cachectic muscle. Our
findings demonstrate that ECC training improved basal and ECC-induced protein synthesis
and mTORC1 regulation in cachectic MIN muscle.
While the effects of exercise in the cachectic cancer patient have not been
investigated, preclinical models have examined the interaction between muscle contraction
and the cachectic environment. We have previously demonstrated that the cachectic
environment disrupted concentric contraction induced anabolic and metabolic signaling in
MIN mice (Puppa, Murphy, et al., 2014). In contrast, we found that a single ECC bout
could induce protein synthesis, however the absolute induction remained suppressed
compared to healthy skeletal muscle (Hardee et al., 2017). Interestingly, repeated ECC
(e.g., training) attenuated myofiber atrophy that coincided with reduced inflammatory
signaling and improved succinate dehydrogenase enzyme activity (Hardee et al., 2016).
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We extend these findings demonstrating that ECC training improved basal protein
synthesis regulation, which was linked to improved oxidative capacity and indices of
autophagy / mitophagy control. Interestingly, hypertrophic growth induced by resistance
exercise was accompanied by improved mitochondrial function and content (Porter et al.,
2015), which is in contrast to commonly discussed training adaptations (e.g., hypertrophy,
strength) associated with growth (B. Egan & Zierath, 2013). However, emerging evidence
suggests that oxidative metabolism is linked to muscle protein synthesis via mTORC1
signaling. Indeed, a reciprocal relationship between mTORC1 and oxidative metabolism
regulation has been observed across multiple cell types (Cunningham et al., 2007; Polak et
al., 2008; Schieke et al., 2006). Inhibition of mTORC1 signaling reduces mitochondrial
respiration (coupled and uncoupled), impairs TCA cycle activity, and lowers ATP
production capacity (Morita et al., 2013).

Related to skeletal muscle, reduced

mitochondrial content and function has been observed in muscle-specific mTOR or Raptor
knockout mice (Bentzinger et al., 2008; Risson et al., 2009). Interestingly, mTORC1
inactivation has also been associated with altered systemic metabolic homeostasis and a
muscle atrophy/dystrophic phenotype (Bentzinger et al., 2008; Risson et al., 2009). While
protein synthesis may be suppressed prior to disrupted mitochondrial function during
cancer cachexia (White, Baynes, et al., 2011; White et al., 2012), future research is needed
to determine the precise interactions between these cellular processes during cachexia
progression. Nonetheless, the current findings demonstrate that ECC improved basal
protein synthesis regulation that coincided with enhanced oxidative capacity.
Anabolic resistance, which is defined as an attenuated response to anabolic stimuli
such as nutrition and exercise (Burd, Gorissen, & van Loon, 2013; Fry & Rasmussen,
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2011), has been implicated in muscle wasting associated with cancer (Horstman et al.,
2016). We have found an attenuated response to glucose injection and contraction during
severe cachexia (Puppa, Murphy, et al., 2014; White, Puppa, Gao, et al., 2013). While
evidence suggest exercise training may be beneficial for improvements in basal protein
synthesis regulation, the response to anabolic stimuli after training has not been well
described. We are the first to demonstrate that the acute anabolic response to ECC was
maintained after training in cachectic muscle. Interestingly, it has been postulated that the
protein synthesis induction following a novel exercise bout is related to skeletal muscle
remodeling rather than hypertrophic growth, whereas the response favors growth in the
trained state (Damas et al., 2016). This would suggest that the protein synthesis induction
by ECC following training would be partitioned towards skeletal muscle growth in
cachectic muscle. While the acute anabolic response to resistance exercise is diminished
in the trained state (Damas, Phillips, Vechin, & Ugrinowitsch, 2015), we did not observe
this in cachectic muscle. Moreover, we have not observed indices of muscle damage
following an acute bout (SS and JAC unpublished) or training in cachectic muscle (Hardee
et al., 2016). Therefore, the protein synthesis and mTORC1 signaling response to ECC
appears to be related to growth, however future investigations are needed to determine the
precise mechanisms associated with this growth response. It is also possible that the
protein synthesis induction following exercise could be replacing damaged or
dysfunctional proteins, which is a positive exercise adaptive response. Nonetheless, our
results collectively demonstrate that the activation of protein synthesis following training
was associated with improved muscle oxidative metabolism and reduced inflammatory
signaling in cachectic muscle.
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In summary, we demonstrate that cachectic skeletal muscle retains the anabolic and
metabolic plasticity to improve basal and ECC-induced protein synthesis in response to
training. We report that ECC training improved protein synthesis which coincided with
enhanced oxidative metabolism and reduced STAT3 / AMPK activation. In addition, we
also found that the acute ECC induction of protein synthesis and mTORC1 signaling was
maintained after training in cachectic muscle.

Interestingly, these data suggest that

cachectic skeletal muscle remains plastic to exercise despite the presence of a systemic
cachectic environment. While further research is needed to determine whether these initial
improvements can be sustained over time, it appears cachectic skeletal muscle retains the
capacity to adapt to ECC throughout the progression of cancer cachexia. Whether exercise
training is also associated with an enhanced anabolic response to feeding or anabolic
stimuli will improve our efforts for treating the cachectic cancer patient.
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Table 5.1. B6 and MIN mice that performed ECC training.
B6

MIN

8

8

Peak

27.5 ± 0.7

25.5 ± 0.5

Pre

27.6 ± 0.3

23.5 ± 0.5*†

Post

27.7 ± 0.3

22.6 ± 0.6*†‡

% change from peak

1.1 ± 0.5

-11 ± 1.0*

47.7 ± 1.0

32.6 ± 1.3#

49.8 ± 1.0&

36.4 ± 1.0#&

309 ± 27

68 ± 17*

Spleen, mg

72 ± 2

593 ± 30*

Testes, mg

198 ± 3

136 ± 14*

LABC, mg

90 ± 2

46 ± 4*

Seminal vesicle, mg

234 ± 18

53 ± 7*

Plasma IL-6, pg/ml

0±0

35 ± 5*

Tumor number

0±0

68 ± 8*

16.9 ± 0.1

16.8 ± 0.1

No. of mice
Body weight, g

Tibialis anterior, mg
Control
ECC
Epididymal fat, mg

Tibia length, mm

Data are means ± standard error. Either a Students t-test or two-way repeated measures
ANOVA with Student-Knewman-Keuls post hoc methods were performed when
appropriate. Statistical significance was set at p<0.05. Abbreviations: ECC, Eccentric
contractions. No., number. g, grams. mg, milligrams. pg, picogram. ml, milliliter. mm,
millimeter. LABC, levator ani / bulbocavernosus muscle. * = significantly different from
B6. † = significantly different from peak body weight. ‡ = significantly different from pre
body weight. # = main effect of MIN. & = main effect of ECC.
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Table 5.2. B6 and MIN mice that performed a single ECC bout after training.
B6

MIN

8

9

Peak

26.5 ± 0.9

25.3 ± 0.4

Pre

26.5± 0.9

22.4 ± 0.6*†

Post

27.7 ± 0.3

21.3 ± 0.5*†‡

% change from peak

0.8 ± 0.9

-16 ± 1.4*

45.4 ± 1.5

28.0 ± 1.1#

49.4 ± 1.0&

30.6 ± 1.2#&

293 ± 39

15 ± 6*

Spleen, mg

66 ± 2

598 ± 42*

Testes, mg

187 ± 4

87 ± 10*

LABC, mg

90 ± 3

30 ± 1*

Seminal vesicle, mg

261 ± 19

28 ± 2*

Plasma IL-6, pg/ml

0±0

51 ± 6*

Tumor number

0±0

80 ± 9*

16.9 ± 0.1

16.8 ± 0.1

No. of mice
Body weight, g

Tibialis anterior, mg
Control
ECC
Epididymal fat, mg

Tibia length, mm

Data are means ± standard error. Either a Students t-test or two-way repeated measures
ANOVA with Student-Knewman-Keuls post hoc methods were performed when
appropriate. Statistical significance was set at p<0.05. Abbreviations: ECC, Eccentric
contractions. No., number. g, grams. mg, milligrams. pg, picogram. ml, milliliter. mm,
millimeter. LABC, levator ani / bulbocavernosus muscle. * = significantly different from
B6. † = significantly different from peak body weight. ‡ = significantly different from pre
body weight. # = main effect of MIN. & = main effect of ECC.
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Figure 5.1. ECC training regulation of muscle STAT3 and AMPK signaling. A)
Muscle STAT3 and AMPK regulation by ECC training and cancer cachexia. B) Muscle
oxidative capacity regulation by ECC training and cancer cachexia. C) Muscle
cytochrome c oxidase (COX) enzyme activity regulation by ECC training and cancer
cachexia. The activation of signaling molecules was determined by the phosphorylated
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and total ratio when appropriate. For protein expression, values were corrected for equal
protein loading using GAPDH. All samples were run on the same gel and normalized to
Control values. Data are means ± standard error. A two-way ANOVA was used to
determine differences between treatment groups when appropriate. Post-hoc analyses were
performed with Student-Knewman-Keuls methods when appropriate.
Statistical
significance was set at p<0.05. Different letters are statistically different. & = main effect
of ECC training. # = main effect of MIN.
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Figure 5.2. ECC training regulation of succinate dehydrogenase enzyme activity
myofiber area. A) High and low succinate dehydrogenase enzyme activity myofiber area.
B) High succinate dehydrogenase enzyme activity myofiber area distribution. C) Low
succinate dehydrogenase enzyme activity myofiber area distribution. High and low
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succinate dehydrogenase enzyme activity myofiber area was examined post hoc on a
separate cohort of B6 and MIN previously described (Hardee et al., 2016). Data are means
± standard error. A two-way ANOVA was used to determine differences between
treatment groups when appropriate. Post-hoc analyses were performed with StudentKnewman-Keuls methods when appropriate. Statistical significance was set at p<0.05. &
= main effect of ECC training. # = main effect of MIN.
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Figure 5.3. ECC training regulation of muscle mTORC1 signaling and protein
synthesis. A) Muscle Akt/mTORC1 signaling regulation by ECC training and cancer
cachexia. B) Muscle protein synthesis regulation by ECC training and cancer cachexia.
The activation of signaling molecules was determined by the phosphorylated and total ratio
when appropriate. For protein expression, values were corrected for equal protein loading
using GAPDH. All samples were run on the same gel and normalized to Control values.
Data are means ± standard error. A two-way ANOVA was used to determine differences
between treatment groups when appropriate. Post-hoc analyses were performed with
Student-Knewman-Keuls methods when appropriate. Statistical significance was set at
p<0.05. Different letters are statistically different. & = main effect of ECC training. # =
main effect of MIN.
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Figure 5.4. ECC-induced protein synthesis and mTORC1 signaling following
training. A) Muscle protein synthesis activation by ECC following training. B) Muscle
Akt/mTORC1 signaling activation by ECC following training. The activation of signaling
molecules was determined by the phosphorylated and total ratio when appropriate. For
protein expression, values were corrected for equal protein loading using GAPDH. All
samples were run on the same gel and normalized to Control values. Data are means ±
standard error. A two-way ANOVA was used to determine differences between treatment
groups when appropriate. Post-hoc analyses were performed with Student-KnewmanKeuls methods when appropriate. Statistical significance was set at p<0.05. Different
letters are statistically different. & = main effect of ECC training. # = main effect of MIN.
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CHAPTER 6
DISCUSSION

146

Cachexia, a complex metabolic syndrome that involves the unintentional loss of
bodyweight which cannot be reversed by nutritional intervention, directly impacts patient
survival and life quality (K. Fearon et al., 2011).

Cancer cachexia accounts for

approximately 20% of all cancer related deaths, and approximately 40% of deaths related
to colon cancer (Bruera, 1997; Tisdale, 2002). Human cancer patients and preclinical
models share several key features of cachexia which include body weight loss, muscle
atrophy, adipose tissue depletion, elevated plasma IL-6 levels, and hypogonadism (Evans
et al., 2008; K. Fearon et al., 2011; White, Puppa, Narsale, et al., 2013). Skeletal muscle
mass depletion associated with cancer cachexia directly contributes to increased patient
morbidity and mortality (K. C. Fearon, 1992; Tisdale, 2009). Tumor-derived factors and
cytokines have been implicated in muscle wasting associated with cancer, and high levels
of circulating IL-6 have been reported in both cachectic cancer patients (Argiles, Busquets,
& Lopez-Soriano, 2003; Burney et al., 2012; Kuroda et al., 2005; Kuroda et al., 2007;
Scott, McMillan, Crilly, McArdle, & Milroy, 1996) and preclinical models (Bonetto et al.,
2011; Strassmann et al., 1993; Strassmann, Fong, Kenney, & Jacob, 1992).

While

significant progress has been made in our understanding of disrupted protein regulation by
circulating factors such as IL-6 during cancer, it is currently unknown if suppressed muscle
protein synthesis and mTORC1 signaling can be activated in the presence of the cachectic
environment. The overall purpose of this dissertation was to determine how cancerinduced inflammation affects wasting muscles ability to respond to ECC. We hypothesized
that chronic muscle inflammatory signaling would attenuate the anabolic response to ECC.
Key findings from the experiments accompanying this dissertation demonstrate: (1)
cachexia did not disrupt the ECC induction of mechano-sensitive pathways and mTORC1
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signaling, (2) cachexia did not disrupt ECC-induced protein synthesis, but the capacity for
protein synthesis remained suppressed; (3) short-term muscle STAT3/NFkB inhibition
prior to contraction improved basal and ECC-induced protein synthesis; (4) elevated IL-6
levels could disrupt mechanical activation of protein synthesis in atrophic myotubes and
MIN skeletal muscle; (5) muscle gp130 regulated IL-6 suppression of basal protein
synthesis and ECC-induced protein synthesis, (6) ECC training improved basal mTORC1
regulation which was related to improved oxidative capacity and suppressed AMPK
activity; and (7) exercise training maintained ECC-induced protein synthesis and mTORC1
signaling in cachectic MIN muscle. These findings provide preliminary mechanistic
insight to the use of ECC as a potential therapeutic to combat skeletal muscle wasting
during cancer cachexia.
Cachectic muscle response to a single ECC bout in male MIN mice
Disrupted muscle protein synthesis and mTORC1 signaling parallel increased
plasma IL-6 levels during cancer cachexia progression (White, Baynes, et al., 2011).
Moreover, we have previously found that systemic IL-6 overexpression can suppress
protein synthesis in tumor-bearing mice, and long-term IL-6 exposure can stimulate
myotube atrophy associated with disrupted mTORC1 signaling (White, Puppa, Gao, et al.,
2013). The present study extends these findings establishing severe wasting coincided with
a cachectic muscle signature exhibiting enhanced inflammatory signaling, disrupted
proteostasis regulation, and perturbed metabolic signaling regulation. Indeed, we found
that basal Akt/mTORC1 signaling was disrupted in MIN mice. In healthy skeletal muscle,
binding of insulin/IGF1 to its respective cell surface receptor initiates tyrosine kinase
activity and PI3K-dependent activation of Akt Thr308 through PDK1. The rapamycin-
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insensitive mTORC2 has also been implicated in growth factor signaling through the
phosphorylation of Akt Ser473 (Fayard et al., 2005), and this site is required for full Akt
activation. Subsequent downstream targets of Akt which can control muscle protein
synthesis include TSC2, GSK3B, and PRAS40 (Laplante & Sabatini, 2009; Schiaffino &
Mammucari, 2011). While Akt stimulates protein synthesis by activating mTORC1 in
healthy skeletal muscle, male MIN mice demonstrated elevated Akt Ser473
phosphorylation despite reduced mTORC1 signaling and protein synthesis. It has been
suggested that this robust Akt activation in cachectic muscle may be related to the
redistribution of mTOR to mTORC2 formation when mTORC1 signaling is suppressed.
Indeed, our data demonstrate Akt activation coincided with reduced phosphorylation of
downstream mTORC1 targets P70S6K and RPS6, which has previously been observed by
our laboratory (White, Puppa, Gao, et al., 2013). Interestingly, the activation of mTORC1
signaling by ECC was not sufficient to relieve the robust activation of Akt in cachectic
skeletal muscle. Future research is warranted to determine the precise role of mTOR
complex formation in cancer-induced skeletal muscle wasting.
While our understanding of disrupted proteostasis during cachexia has increased
dramatically (Bonaldo & Sandri, 2013; Sandri, 2013; White, Baynes, et al., 2011), we have
a more limited understanding of how the cachectic environment affects muscle’s ability to
stimulate protein synthesis in response to an anabolic stimulus. Resistance exercise is a
potent stimulator of mechano-sensitive pathways that interact with mTORC1 signaling to
induce protein synthesis in healthy adults (Fry et al., 2011; Walker et al., 2011). However,
no studies to date have examined the cachectic muscle response to exercise in cancer
patients (Grande et al., 2014b; Granger, McDonald, Parry, Oliveira, & Denehy, 2013), and
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the cachectic muscle’s acute response and training adaptations to exercise has only recently
been examined in preclinical models. While there is evidence that repeated ECC bouts
after the initiation of cachexia attenuated muscle and myofiber atrophy in tumor-bearing
mice (al-Majid & McCarthy, 2001; Hardee et al., 2016), the capacity to activate mechanosensitive pathways, mTORC1 signaling, and protein synthesis by ECC has not been
investigated. The present study found that cachexia did not disrupt ECC-induced mechanosensitive pathways and mTORC1 signaling when examined immediately or 3h post-ECC.
In fact, the induction of mechano-sensitive and mTORC1 signaling pathways were either
induced to a similar or greater extent than healthy skeletal muscle. While the stimulation
model used in the current studies provides maximal activation of motor units and
subsequent muscle contraction, these data would suggest increased sensitivity to
contraction in cachectic MIN mice. Given that severe cachexia is associated with profound
reductions in voluntary physical activity (Narsale et al., 2016; Puppa, Murphy, et al., 2014),
this may serve to increase cachectic muscle’s sensitivity to contraction. Therefore, the
induction of mechano-sensitive pathways in cachectic muscle to this stimulation paradigm
may be more related to reduced physical activity levels prior to contraction, rather than an
enhanced activation of mechano-sensitive pathways and mTORC1 signaling. However,
force production during each stimulation session was not examined, and would provide
clearer insight to the degree of activation, total work produced, and fatigue accumulation
during each contraction bout. There is also the potential that cachexia would increase the
susceptibility to muscle damage during high-force contractions. We and others have not
observed evidence of muscle damage at the acute time points utilized in the current study
or following repeated ECC bouts (Hardee et al., 2016; McLoughlin, Mylona, Hornberger,
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Esser, & Pizza, 2003). Nonetheless, it appears that cachectic muscle retains the capacity
to induce mechano-sensitive and mTORC1 signaling pathways in response to a single ECC
bout.
We found that cachectic muscle could induce protein synthesis, however the overall
capacity for this induction remained suppressed to healthy skeletal muscle.

While

cachectic muscle can initiate an anabolic response to a single ECC bout, whether these
repeated bouts are sufficient to account for the improved myofiber area following ECC
training will require future investigation. While a similar protein synthesis response was
observed 3h post-ECC, we have not determined the time course for the magnitude and
duration of this protein synthesis induction by ECC. This stimulation paradigm has been
shown to induce protein synthesis for up to 18-24h in healthy, rodent skeletal muscle (West
et al., 2016). However, it is plausible that either the magnitude or duration of protein
synthesis induction by ECC may be altered by the cachectic environment during cancer
cachexia. Indeed, an attenuated mTORC1 signaling response has been observed 6h postECC in aged skeletal muscle (Funai, Parkington, Carambula, & Fielding, 2006).
Furthermore, both the magnitude and duration of mTORC1 activation by ECC was
disrupted in obese Zucker rats compared to lean counterparts (Katta et al., 2009). While
these studies did not directly measure protein synthesis rates per se, they demonstrate
conditions associated with muscle metabolic dysfunction can alter the response to a single
ECC bout. Future studies are warranted to determine if cachexia disrupts either the
magnitude or duration of the protein synthesis induction by ECC. Similarly, nutrient
availability can interact with muscle contraction to augment the duration and absolute
protein synthesis induction in human and rodent skeletal muscle (Drummond, Dreyer, Fry,
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Glynn, & Rasmussen, 2009), the fed response should be examined in future studies.
Recently, resistance exercise has been shown to improve the anabolic response to feeding
in cancer patients received androgen deprivation therapy (Hanson et al., 2017). It has been
suggested that resistance exercise may also enhance the nutrient sensitivity of muscle for
up to 24h post-contraction (Burd, Tang, Moore, & Phillips, 2009). Whether single and
repeated exercise bouts improve muscle’s sensitivity to nutrients has yet to be examined
with cancer cachexia, which could have significant ramifications on muscle mass
regulation during cancer. Collectively, future studies are warranted to determine the extent
and duration of the anabolic response to ECC in both the fasted and fed state.
We have previously found that systemic IL-6 overexpression can suppress protein
synthesis in tumor-bearing mice, and long-term IL-6 exposure can stimulate myotube
atrophy associated with disrupted mTORC1 signaling (White, Puppa, Gao, et al., 2013).
Interestingly, muscle STAT3/NFkB inhibition increased basal and ECC-induced protein
synthesis in cachectic MIN muscle. Interestingly, while these findings are consistent with
the anabolic properties of PDTC treatment in male MIN mice (Narsale et al., 2016; Puppa,
Murphy, et al., 2014), they are in contrast to previous studies which have not observed
improved protein synthesis regulation by inflammatory signaling inhibition (Puppa, Gao,
et al., 2014; White, Baynes, et al., 2011). Given that PDTC has both anti-inflammatory
and anti-oxidant properties (Shi, Leonard, Wang, & Ding, 2000), additional studies are
needed to determine the precise molecular mechanisms associated with improve anabolism
by PDTC treatment.

Nonetheless, the current findings highlight a role for muscle

inflammatory signaling in the regulation of basal and ECC-induced protein synthesis
during cancer cachexia.

152

Systemic IL-6 regulation of ECC-induced protein synthesis in MIN mice
The male MIN mouse is an IL-6-dependent model of cancer cachexia that develops
a slow onset of cachexia (Baltgalvis, Berger, Pena, Davis, & Carson, 2008; Carson &
Baltgalvis, 2010). During the natural progression of cachexia plasma IL-6 is associated
with tumor burden (polyp number and polyp size), body weight and muscle loss, and
suppressed protein synthesis and mTORC1 signaling (Baltgalvis, Berger, Pena, Davis, &
Carson, 2008; McClellan et al., 2012; White, Baynes, et al., 2011). Furthermore, systemic
IL-6 overexpression can induce cachexia (e.g., body weight and muscle mass loss,
disrupted protein turnover) in weight stable MIN mice (Baltgalvis, Berger, Pena, Davis,
Muga, et al., 2008; Baltgalvis et al., 2009; Puppa et al., 2012; White, Puppa, Gao, et al.,
2013; White et al., 2012). Interestingly, the rapid induction of cachexia by IL-6 in weight
stable MIN mice recapitulates the cachectic phenotype observed during the natural
progression of cancer cachexia. Whole-body treadmill exercise prevented systemic IL-6induced muscle wasting and disrupted mTORC1 signaling in MIN mice (Puppa et al.,
2012; White, Puppa, Gao, et al., 2013), which occurred independent to alterations in
inflammatory signaling. Therefore, we examined the protein synthesis and mTORC1
signaling response to a single ECC bout after 2 wks. systemic IL-6 overexpression. In
contrast to our previous observations, systemic IL-6 overexpression blocked the
mechanical activation of protein synthesis in MIN mice. We also found that long-term IL6 disrupted myotube stretch-induced protein synthesis and mTORC1 signaling. These
findings extend our previous observations in stretched myotubes exposed to LLC
conditioned media (Gao & Carson, 2016). Interestingly, the discrepancy between the
activation of protein synthesis responses by ECC between studies may be related to the rate
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and duration of cachexia development (2 wks. vs 6 wks.). We have previously observed
the cachectic environment blocked ECC-induced protein synthesis in LLC tumor-bearing
mice, despite a robust activation of mTORC1 signaling (unpublished observations). Thus,
the ability to induce protein synthesis in response to anabolic stimuli may be related to rate
of wasting induced by the cachectic environment. We also observed systemic IL-6
overexpression suppressed basal protein synthesis in healthy B6 mice independent to
alterations in muscle mass, which provides evidence of a role for systemic IL-6 in protein
synthesis suppression. Collectively, these studies demonstrate that circulating cachectic
factors such as IL-6 can regulate basal and mechanical activation of protein synthesis in
atrophic myotubes and muscle.
Exercise training regulation of protein synthesis and mTORC1 regulation in MIN
mice
While preliminary evidence suggest that cachectic muscle retains the plasticity to
adapt to mechanical loading and muscle contraction (al-Majid & McCarthy, 2001; Hardee
et al., 2016; Norton et al., 1979; Otis et al., 2007), it is unclear whether these training
adaptations improve metabolic regulation and function. Related to the cachectic muscle
phenotype, muscle STAT3 and AMPK activation coincides with suppressed protein
synthesis and disrupted mitochondrial quality control in preclinical models (White,
Baltgalvis, et al., 2011; White, Baynes, et al., 2011; White, Puppa, Gao, et al., 2013; White
et al., 2012). Moreover, severe cachexia is associated disrupted metabolic homeostasis and
functional deficits (Baltgalvis, Berger, Pena, Davis, Muga, et al., 2008; Puppa et al., 2011).
Several lines of evidence suggest an intricate relationship between protein synthesis,
mitochondrial function, and metabolic plasticity in skeletal muscle (Bentzinger et al., 2008;
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Cunningham et al., 2007; Risson et al., 2009). While not commonly appreciated as an
adaptation to high-force muscle contractions, recent evidence suggest that resistance
exercise can improve mitochondrial function in healthy skeletal muscle (Porter et al.,
2015). Related to cancer cachexia, we have previously found that repeated ECC bouts after
the initiation of cachexia attenuated myofiber atrophy that coincided with improved
oxidative capacity (e.g., percent fibers with high succinate dehydrogenase enzyme activity)
and suppressed chronic AMPK activation in MIN mice (Hardee et al., 2016). In the current
study, we found the ECC training improved whole muscle cytochrome c oxidative (COX)
enzyme activity, suppressed chronic AMPK activation, and improved basal protein
synthesis. Furthermore, we demonstrate that improved oxidative capacity coincided with
the induction of autophagy / mitophagy processes. Unfortunately, it is currently unknown
if these changes were associated with improved muscle function. Critical to the treatment
of the cachectic cancer patient is improvements in muscle function. Indeed, several clinical
trials have been terminated due to lack of functional improvements (S. Cohen et al., 2015).
We have recently found that several functional deficits that occur with cancer cachexia are
associated with increased muscle inflammatory signaling, and muscle fatigability is
elevated prior to cachexia development in male MIN mice (VanderVeen, Hardee, Fix, &
Carson, 2017). Future studies are warranted to determine if the observed changes related
to muscle inflammatory signaling, oxidative capacity, and mitochondrial quality control in
the current study are associated with improved muscle function.
While the current studies were isolated to a single eccentrically contracted muscle,
we provide initial mechanistic insight into the potential role of muscle contraction during
cancer. Interestingly, we found that ECC training improved basal protein synthesis and

155

mTORC1 regulation, and found that the protein synthesis induction by ECC was
maintained in trained skeletal muscle. Experimental evidence in humans suggests that the
protein synthesis induction following a novel resistance exercise bout may be highly
influenced by the resolution of acute muscle damage, whereas the acute protein synthesis
response in the trained state may be more related to growth (Damas et al., 2016). Given
that we have not previously observed indices of muscle damage following the completion
of ECC training (Hardee et al., 2016), these data collectively suggest that the acute protein
synthesis induction by ECC following training is partitioned towards growth. However, a
significant barrier to our fundamental understanding of muscle proteostasis in both basal
and stimulated conditions is a precise measurement of protein breakdown in rodent skeletal
muscle. While accelerated protein breakdown has established roles in skeletal muscle
atrophy, this process is also stimulated by exercise and muscle contraction. It has been
suggested that targeting aberrant protein degradation processes may be a potential
treatment for cachexia (S. Cohen et al., 2015), however it is conceivable that inhibiting
protein degradation processes may be detrimental to systemic metabolism and muscle
function. Indeed, inhibition of ER stress and unfolding protein response pathways has been
shown to exacerbate skeletal muscle wasting during cancer cachexia (Bohnert et al., 2016).
Muscle protein breakdown processes (e.g., autophagy, mitophagy, proteasome activity) are
also stimulated by both acute endurance and resistance exercise (C. He et al., 2012;
Vainshtein, Tryon, Pauly, & Hood, 2015; Wolfe, 2006a), and it has been suggested that the
positive benefits of exercise may be related to the clearance of damaged or dysfunctional
proteins and organelles. Mostly driven by methodology issues, whether acute exercise can
favorably accelerate protein turnover in cachectic skeletal muscle has not been
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investigated. Furthermore, additional studies are required to determine if the anabolic
responses observed in the current study promote a positive net protein balance in cachectic
muscle.
Summary
In summary, cachectic muscle maintained the ability to induce mechano-sensitive
pathways and mTORC1 signaling in response to a single ECC bout, however the capacity
to induce protein synthesis remained suppressed.

Interestingly, short-term muscle

STAT3/NFkB inhibition prior to contraction improved basal and ECC-induced protein
synthesis. Elevated IL-6 levels could disrupt mechanical activation of protein synthesis in
cultured myotubes and MIN skeletal muscle. IL-6 suppression of basal protein synthesis
required muscle gp130 signaling. ECC training improved basal mTORC1 regulation
which coincided with improved oxidative capacity and suppressed AMPK activity. Lastly,
ECC training maintained ECC-induced protein synthesis and mTORC1 signaling in
cachectic muscle.
Table 6.1. Summary of findings.
Outcome
Cancer cachexia
Muscle mass
Decreased
Protein synthesis
Decreased
mTORC1 signaling
Decreased
Inflammatory
Increased
signaling
Metabolic signaling
Increased
Mitochondrial
Decreased
quality control

Acute ECC
No change
Increased
Increased
Increased

ECC training
Increased
Increased
Increased
Decreased

Decreased
Not measured

Decreased
Increased
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